• Diagnosis, Management, and Surveillance for Patients with PALB2, CHEK2, and ATM Gene Mutations.
    • Fencer MG, Krupa KA, Bleich GC, Grumet S, Eladoumikdachi FG, Kumar S, Kowzun MJ, Potdevin LB.
    • Clin Breast Cancer. 2023 Feb 15:S1526-8209(23)00034-4. doi: 10.1016/j.clbc.2023.02.004. Epub ahead of print.
    • Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk.
    • Allman R, Mu Y, Dite GS, Spaeth E, Hopper JL, Rosner BA.
    • Breast Cancer Res Treat. 2023 Feb 7. doi: 10.1007/s10549-022-06834-7. Epub ahead of print.
    • Oncogenetic pedigrees: Relation between design and ability to predict mutation.
    • Kwiatkowski F, Serlet L, Stos A.
    • Biosystems. 2023 Feb 4:104841. doi: 10.1016/j.biosystems.2023.104841. Epub ahead of print.
    • Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
    • Lee SS, Karpel HC, Oh C, Smith J, Pothuri B.
    • Gynecol Oncol. 2023 Jan 30;170:234-240. doi: 10.1016/j.ygyno.2022.12.012. Epub ahead of print.
    • Performance of INHERET® risk assessment tool for identifying pathogenic germline variants among individuals referred for cancer genetics evaluation. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Henry ML, Pialtos K, Fry S, Koeppe E, Osborne J, Cook A, Hulswitt B, Milliron KJ, Merajver S, Stoffel E.
    • Fam Cancer. [P-21: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Histopathological results of radical prostatectomy specimen of men younger than 50 years of age at the time of surgery: possible implications for prostate cancer screening programs?
    • Mehring G, Tilki D, Heinzer H, Steuber T, Pose RM, Thederan I, Budäus L, Salomon G, Haese A, Michl U, Maurer T, Huland H, Graefen M, Isbarn H.
    • World J Urol. 2023 Jan 19. doi: 10.1007/s00345-023-04287-1. Epub ahead of print.
    • Long-term risk of cancer among the first-degree relatives of epithelial ovarian cancer patients: A cohort study with 48 years of follow up.
    • Kotaniemi-Talonen L, Pukkala E, Aittomäki K, Auranen A.
    • Acta Obstet Gynecol Scand. 2023 Jan 16. doi: 10.1111/aogs.14504. Epub ahead of print.
    • Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer.
    • Abdel-Razeq H, Abujamous L, Al-Azzam K, Abu-Fares H, Bani Hani H, Alkyam M, Sharaf B, Elemian S, Tamimi F, Abuhijla F, Edaily S, Salama O, Abdulelah H, Daoud R, Abubaker M, Al-Atary A.
    • Breast Cancer (Dove Med Press). 2023 Jan 13;15:1-10. doi: 10.2147/BCTT.S394092.
    • Molecular characteristics of Asian male BRCA-related cancers.
    • Kwong A, Ho CYS, Shin VY, Ng ATL, Chan TL, Ma ESK.
    • Breast Cancer Res Treat. 2023 Jan 13. doi: 10.1007/s10549-022-06651-y. Epub ahead of print.
    • Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.
    • Pederson HJ, Batur P.
    • Menopause. 2023 Jan 10. doi: 10.1097/GME.0000000000002136. Epub ahead of print.
    • Review
    • January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey.
    • Mechanic L, Helzlsouer K.
    • Genet Med. GenePOD. 2023 Jan 9.

    •• Original research:

    Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020.

    • Missed opportunities in the real-world genetic testing in BRCA gene variant carriers with cancers meeting NCCN criteria.
    • Lee SS, Rajeev P, Finning S, Oh C, Pothuri B.
    • Gynecol Oncol. 2023 Jan 5;170:32-37. doi: 10.1016/j.ygyno.2022.12.015. Epub ahead of print.
    • Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
    • Jiao Y, Truong T, Eon-Marchais S, Mebirouk N, Caputo SM, Dondon MG, Karimi M, Le Gal D, Beauvallet J, Le Floch É, Dandine-Roulland C, Bacq-Daian D, Olaso R, Albuisson J, Audebert-Bellanger S, Berthet P, Bonadona V, Buecher B, Caron O, Cavaillé M, Chiesa J, Colas C, Collonge-Rame MA, Coupier I, Delnatte C, De Pauw A, Dreyfus H, Fert-Ferrer S, Gauthier-Villars M, Gesta P, Giraud S, Gladieff L, Golmard L, Lasset C, Lejeune-Dumoulin S, Léoné M, Limacher JM, Lortholary A, Luporsi É, Mari V, Maugard CM, Mortemousque I, Mouret-Fourme E, Nambot S, Noguès C, Popovici C, Prieur F, Pujol P, Sevenet N, Sobol H, Toulas C, Uhrhammer N, Vaur D, Venat L, Boland-Augé A, Guénel P, Deleuze JF, Stoppa-Lyonnet D, Andrieu N, Lesueur F.
    • Eur J Cancer. 2022 Nov 13 [2023 Jan 1];179:76-86. doi: 10.1016/j.ejca.2022.11.007. Epub ahead of print.
    • Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study.
    • Taji T, Odan N, Kataoka Y, Ikeda M, Yamaguchi A, Suzuki E, Suwa H.
    • Breast Cancer. 2022 Dec 22. doi: 10.1007/s12282-022-01424-3. Epub ahead of print.
    • Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?
    • Metcalfe KA, Narod SA, Eisen A, Poll A, Zamani N, McCready D, Cil TD, Wright FC, Lerner-Ellis J, McCuaig J, Graham T, Sun P, Akbari MR.
    • Cancer Med. 2022 Dec 21. doi: 10.1002/cam4.5515. Epub ahead of print.
    • Performance of risk prediction models in breast cancer screening among women in Cyprus.
    • Danladi C, Serakinci N.
    • East Mediterr Health J. 2022 Dec 21;28(12):888-895. doi: 10.26719/emhj.22.089.
    • Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
    • Abdel-Razeq H, Al-Azzam K, Elemian S, Abu-Fares H, Abu Sheikha A, Bani Hani H, Bater R, Sharaf B, Heald B, Esplin ED, Nielsen SM, Alkyam M, Abujamous L, Al-Attary A.
    • Mol Genet Genomic Med. 2022 Dec 19:e2125. doi: 10.1002/mgg3.2125. Epub ahead of print.
    • Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
    • Brook MN, Ní Raghallaigh H, Govindasami K, Dadaev T, Rageevakumar R, Keating D, Hussain N, Osborne A, Lophatananon A; UKGPCS Collaborators; Muir KR, Kote-Jarai Z, Eeles RA.
    • Eur Urol. 2022 Dec 15:S0302-2838(22)02838-X. doi: 10.1016/j.eururo.2022.11.019. Epub ahead of print.
    • CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.
    • Nyberg T, Brook MN, Ficorella L, Lee A, Dennis J, Yang X, Wilcox N, Dadaev T, Govindasami K, Lush M, Leslie G, Lophatananon A, Muir K, Bancroft E, Easton DF, Tischkowitz M, Kote-Jarai Z, Eeles R, Antoniou AC.
    • J Clin Oncol. 2022 Dec 9:JCO2201453. doi: 10.1200/JCO.22.01453. Epub ahead of print.

    •• Press: Tool Accurately Predicts Risk of Developing Prostate Cancer. (Inside Precision Medicine)

    • BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers.
    • Sun J, Chu F, Pan J, Zhang Y, Yao L, Chen J, Hu L, Zhang J, Xu Y, Wang X, Cao W, Xie Y.
    • J Clin Oncol. 2022 Dec 8:JCO2200833. doi: 10.1200/JCO.22.00833. Epub ahead of print.
    • Sociodemographic, Clinical, and Variation Outcomes for Breast Cancer and Breast Cancer-Related Mutations in a Ten-Year Cohort From Neiva, Huila, Colombia.
    • Olaya J, Sanjuan J, Torres-Lopez D, Olaya L, Gutierrez-Vargas M, Olaya G, Olaya JD.
    • Cureus. 2022 Dec 6;14(12):e32257. doi: 10.7759/cureus.32257.
    • Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.
    • Cassani C, Rossi C, Camnasio CA, Urtis M, Fiandrino G, Grasso M, Zanellini F, Lucioni M, D’Ambrosio G, Di Toro A, Rossi M, Roccio M, Ferrari A, Secondino S, Nappi RE, Arbustini E, Paulli M, Spinillo A, Cesari S.
    • Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054.
    • Insurance Coverage of Prophylactic Mastectomies: A National Review of the United States.
    • Ha M, Ngaage LM, Finkelstein ER, Klein M, Yang A, Colohan SM, Nurudeen SM, Terhune JH, Slezak S, Rasko YM.
    • Clin Breast Cancer. 2022 Dec 5:S1526-8209(22)00269-5. doi: 10.1016/j.clbc.2022.12.001. Epub ahead of print.
    • Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020.
    • Tiner JC, Mechanic LE, Gallicchio L, Gillanders EM, Helzlsouer KJ.
    • Genet Med. 2022 Dec;24(12):2526-2534. doi: 10.1016/j.gim.2022.08.023. Epub 2022 Sep 22.

    •• Podcast: January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey. (Genetics in Medicine GenePOD)

    • Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019.
    • Winchar K, Lambert P, McManus KJ, Chodirker B, Kean S, Serfas K, Decker K, Nachtigal MW, Altman AD.
    • Curr Oncol. 2022 Nov 30;29(12):9365-9376. doi: 10.3390/curroncol29120735.
    • Germline Variants in DNA Damage Repair Genes and HOXB13 Among Black Patients With Early-Onset Prostate Cancer.
    • Trendowski MR, Sample C, Baird T, Sadeghpour A, Moon D, Ruterbusch JJ, Beebe-Dimmer JL, Cooney KA.
    • JCO Precis Oncol. 2022 Nov [2022 Nov 29];6:e2200460. doi: 10.1200/PO.22.00460.

    •• Research news: Genetic Variants Linked to Prostate Cancer in Black Men Identified. (Inside Precision Medicine)

    •• Research news: Genetic Variants Could Predict Prostate Cancer Risk in Black Men. (Inside Precision Medicine)

    • Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers.
    • Evans DG, Sithambaram S, van Veen EM, Burghel GJ, Schlecht H, Harkness EF, Byers H, Ellingford JM, Gandhi A, Howell SJ, Howell A, Forde C, Lalloo F, Newman WG, Smith MJ, Woodward ER.
    • J Med Genet. 2022 Nov 28:jmg-2022-108790. doi: 10.1136/jmg-2022-108790. Epub ahead of print.
    • UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
    • Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees, Lalloo F.
    • J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. Epub ahead of print.
    • Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru.
    • Zavaleta E, Solis N, Palacios MI, Zevallos-Escobar LE, Vasquez Corales E, Bazo-Alvarez JC, Dominguez-Barrera C, Campos A, Wernhoff P, Ekstrøm PO, Møller P, Visnovska T, Hovig E, Balazar-Palacios J, Alvarez-Valenzuela K, Nakken S, Dominguez-Valentin M.
    • Cancers (Basel). 2022 Nov 15;14(22):5603. doi: 10.3390/cancers14225603.
    • Rare MYC-N11S germline mutation indicative of inherited breast cancer in a multigeneration family.
    • Budurlean L, Baker M, Broach J.
    • BMJ Case Rep. 2022 Nov 11;15(11):e251336. doi: 10.1136/bcr-2022-251336.
    • Case report
    • Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service.
    • Matta BP, Gomes R, Mattos D, Olicio R, Nascimento CM, Ferreira GM, Brant AC, Boroni M, Furtado C, Lima V, Moreira MÂM, Dos Santos ACE.
    • Sci Rep. 2022 Nov 3;12(1):18629. doi: 10.1038/s41598-022-23012-3.
    • BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP.
    • Cancers (Basel). 2022 Nov 2;14(21):5399. doi: 10.3390/cancers14215399.
    • Reducing the risk of breast cancer.
    • Pederson HJ, Al-Hilli Z, Kurian AW.
    • Cleve Clin J Med. 2022 Nov 1;89(11):643-652. doi: 10.3949/ccjm.89a.21113.
    • Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP.
    • Adv Ther. 2022 Oct 28. doi: 10.1007/s12325-022-02302-2. Epub ahead of print.
    • Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    • Zang B, Helms M, Besch L, Kalmbach N, Stegen S, Blohmer JU, Speiser D.
    • Arch Gynecol Obstet. 2022 Oct 28. doi: 10.1007/s00404-022-06819-3. Epub ahead of print.
    • Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
    • Negri S, De Ponti E, Sina FP, Sala E, Dell'Oro C, Roversi G, Lazzarin S, Delle Marchette M, Inzoli A, Toso C, Fumagalli S, Campanella M, Kotsopoulos J, Fruscio R.
    • Mol Genet Genomic Med. 2022 Oct 28:e2071. doi: 10.1002/mgg3.2071. Epub ahead of print.
    • Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer.
    • Lobanova O, Medvedieva N, Fishchuk L, Dubitska O, Cheshuk V, Vereshchako R, Zakhartseva L, Rossokha Z, Gorovenko N.
    • Breast Cancer Res Treat. 2022 Oct 25. doi: 10.1007/s10549-022-06774-2. Epub ahead of print.
    • Breast cancer incidence among women with a family history of breast cancer by relative's age at diagnosis.
    • Durham DD, Abraham LA, Roberts MC, Khan CP, Smith RA, Kerlikowske K, Miglioretti DL.
    • Cancer. 2022 Oct 19. doi: 10.1002/cncr.34365. Epub ahead of print.

    •• Commentary:

    What if the age at which a woman started regular mammographic screening depended on her risk, not age?

    •• Press release: Study finds earlier mammograms for women with family history of breast cancer may not be needed. (UC Davis Health | News)

    •• Research news: Earlier mammograms for women with family history of breast cancer may not be needed. (ScienceDaily)

    •• Research news: Earlier Mammograms Based on Family Breast Cancer History May Not Be Necessary. (Inside Precision Medicine)

    • Association of Treatment Response with Clinicopathological Characteristics in Female Breast Cancer Patients: Genomic Insights for Future Implementation of Personalized Medicine in Egypt.
    • Nakhla S, Elhameed AA, Ali IM, Elnaggar M, Hassan R, Yousef M, Adel K, Saleh W, Gaber M, Kotze MJ, El-Sharkawy RM.
    • Front Genet. 2022 Oct 12;12:990669. doi: 10.3389/fgene.2022.990669.
    • Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
    • Harper JB, Greenberg SE, Hunt TC, Cooney KA, O'Neil BB.
    • Prostate. 2022 Oct 7. doi: 10.1002/pros.24447. Epub ahead of print.
    • Segregation analysis of 17,425 population-based breast cancer families: Evidence for genetic susceptibility and risk prediction.
    • Li S, MacInnis RJ, Lee A, Nguyen-Dumont T, Dorling L, Carvalho S, Dite GS, Shah M, Luccarini C, Wang Q, Milne RL, Jenkins MA, Giles GG, Dunning AM, Pharoah PDP, Southey MC, Easton DF, Hopper JL, Antoniou AC.
    • Am J Hum Genet. 2022 Oct 6;109(10):1777-1788. doi: 10.1016/j.ajhg.2022.09.006.

    Research news: Breast Cancer Risk Contributors, Remaining Gaps Found With Familial Analyses. (GenomeWeb)

    • Family history of breast cancer, mammographic breast density and breast cancer risk: Findings from a cohort study of Korean women.
    • Mai Tran TX, Kim S, Song H, Park B.
    • Breast. 2022 Oct;65:180-186. doi: 10.1016/j.breast.2022.08.008. Epub 2022 Aug 23.
    • Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.
    • Zang F, Ding X, Chen J, Hu L, Sun J, Zhang J, Xu Y, Yao L, Xie Y.
    • Breast Cancer Res Treat. 2022 Oct;195(3):431-439. doi: 10.1007/s10549-022-06702-4. Epub 2022 Aug 16.
    • Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.
    • Comeaux JG, Culver JO, Lee JE, Dondanville D, McArthur HL, Quinn E, Gorman N, Ricker C, Li M, Lerman C.
    • Mol Genet Genomic Med. 2022 Oct;10(10):e2031. doi: 10.1002/mgg3.2031. Epub 2022 Aug 25.
    • Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence.
    • Lee A, Mavaddat N, Cunningham A, Carver T, Ficorella L, Archer S, Walter FM, Tischkowitz M, Roberts J, Usher-Smith J, Simard J, Schmidt MK, Devilee P, Zadnik V, Jürgens H, Mouret-Fourme E, De Pauw A, Rookus M, Mooij TM, Pharoah PP, Easton DF, Antoniou AC.
    • J Med Genet. 2022 Sep 26:jmedgenet-2022-108471. doi: 10.1136/jmedgenet-2022-108471. Epub ahead of print.
    • Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
    • Yang X, Eriksson M, Czene K, Lee A, Leslie G, Lush M, Wang J, Dennis J, Dorling L, Carvalho S, Mavaddat N, Simard J, Schmidt MK, Easton DF, Hall P, Antoniou AC.
    • J Med Genet. 2022 Sep 26:jmg-2022-108806. doi: 10.1136/jmg-2022-108806. Epub ahead of print.
    • Germline Variants in 32 Cancer-Related Genes among 700 Chinese Breast Cancer Patients by Next-Generation Sequencing: A Clinic-Based, Observational Study.
    • Yang L, Xie F, Liu C, Zhao J, Hu T, Wu J, Zhao X, Wang S.
    • Int J Mol Sci. 2022 Sep 24;23(19):11266. doi: 10.3390/ijms231911266.
    • Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
    • Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, Sanchez E, Rallis KS, Boussios S.
    • Int J Environ Res Public Health. 2022 Sep 23;19(19):12057. doi: 10.3390/ijerph191912057.
    • Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases.
    • Lakeman IMM, Rodríguez-Girondo MDM, Lee A, Celosse N, Braspenning ME, van Engelen K, van de Beek I, van der Hout AH, Gómez García EB, Mensenkamp AR, Ausems MGEM, Hooning MJ, Adank MA, Hollestelle A, Schmidt MK, van Asperen CJ, Devilee P.
    • J Med Genet. 2022 Sep 22:jmedgenet-2022-108502. doi: 10.1136/jmg-2022-108502. Epub ahead of print.

    Research news: Polygenic Risk Scores Could Refine Breast Cancer Screening Recommendations. (Precision Oncology News)

    • Family history of prostate and breast cancer integrated with a polygenic risk score identifies men at highest risk of dying from prostate cancer before age 75 years.
    • Plym A, Zhang Y, Stopsack KH, Jee YH, Wiklund F, Kibel AS, Kraft P, Giovannucci E, Penney KL, Mucci LA.
    • Clin Cancer Res. 2022 Sep 14:CCR-22-1723. doi: 10.1158/1078-0432.CCR-22-1723. Epub ahead of print.
    • Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis.
    • Liu X, Yue J, Pervaiz R, Zhang H, Wang L.
    • Front Endocrinol (Lausanne). 2022 Sep 13;13:986477. doi: 10.3389/fendo.2022.986477.

    Review registration number: CRD42021281336: The incidence of breast cancer in high risk population after fertility treatment: a systematic review and meta-analysis. (PROSPERO register)

    • Association between epidemiological and clinico-pathological features of breast cancer with prognosis, family history, Ki-67 proliferation index and survival in Tunisian breast cancer patients.
    • Mighri N, Mejri N, Boujemaa M, Berrazega Y, Rachdi H, El Benna H, Labidi S, Benna F, Boubaker S, Boussen H, Abdelhak S, Hamdi Y.
    • PLoS One. 2022 Sep 12;17(9):e0269732. doi: 10.1371/journal.pone.0269732.
    • Ethnic predisposition, risk factors and breast cancer presentation; a 10-year data. Single centered prospective cohort study from Karachi.
    • Sultan N, Memon SA, Mooghal M, Wali S, Khan W, Tahseen H, Khan M, Monis D.
    • Ann Med Surg (Lond). 2022 Sep 9;82:104612. doi: 10.1016/j.amsu.2022.104612.
    • Risk-reducing mastectomy for unaffected women with a strong family history of breast cancer.
    • Willson ML, Srinivasa S, Fatema K, Lostumbo L, Carbine NE, Egger SJ, Goodwin A.
    • Cochrane Database Syst Rev. 2022 Sep 6;9(9):CD015020. doi: 10.1002/14651858.CD015020.pub2.
    • Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
    • Minoura Y, Takahashi M, Maeda H, Kuwahara S, Tachikawa H, Yamamoto M, Tomioka N, Watanabe K, Sakurai A.
    • Breast Cancer. 2022 Sep;29(5):808-813. doi: 10.1007/s12282-022-01360-2. Epub 2022 May 31.
    • Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
    • Peters MLB, Eckel A, Lietz A, Seguin C, Mueller P, Hur C, Pandharipande PV.
    • Pancreatology. 2022 Sep;22(6):760-769. doi: 10.1016/j.pan.2022.05.003. Epub 2022 May 31.
    • Background Parenchymal Enhancement at Postoperative Surveillance Breast MRI: Association with Future Second Breast Cancer Risk.
    • Lee SH, Jang MJ, Yoen H, Lee Y, Kim YS, Park AR, Ha SM, Kim SY, Chang JM, Cho N, Moon WK.
    • Radiology. 2022 Aug 30:220440. doi: 10.1148/radiol.220440. Epub ahead of print.

    Commentary:

    Background Parenchymal Enhancement at Breast MRI: More Is Not Better.

    • Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.
    • Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De La Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F.
    • Cancers (Basel). 2022 Aug 21;14(16):4040. doi: 10.3390/cancers14164040.
    • Impact of BRCA1/2 cascade testing on anxiety, depression, and cancer worry levels among unaffected relatives in a multiethnic Asian cohort.
    • Padmanabhan H, Mariapun S, Lee SY, Hassan NT, Lee DS, Meiser B, Wong SW, Lee YQ, Yip CH, Teo SH, Thong MK, Taib NAM, Yoon SY.
    • J Genet Couns. 2022 Aug 1. doi: 10.1002/jgc4.1619. Epub ahead of print.
    • Association Between Family History and Risk of Pancreatic Cancer in Patients With BRCA1 and BRCA2 Pathogenic Variants.
    • Shah I, Silva-Santisteban A, Germansky KA, Kandasamy C, Mlabasati J, Huang DC, Wadhwa V, Bilal M, Sawhney MS.
    • Pancreas. 2022 Aug 1;51(7):733-738. doi: 10.1097/MPA.0000000000002104.
    • Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC.
    • Ohsumi S, Nakamura S, Miyata H, Watanabe C, Den H, Arai M.
    • Jpn J Clin Oncol. 2022 Jul 30:hyac120. doi: 10.1093/jjco/hyac120. Epub ahead of print.
    • Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
    • Hurwitz LM, Townsend MK, Jordan SJ, Patel AV, Teras LR, Lacey JV Jr, Doherty JA, Harris HR, Goodman MT, Shvetsov YB, Modugno F, Moysich KB, Robien K, Prizment A, Schildkraut JM, Berchuck A, Fortner RT, Chan AT, Wentzensen N, Hartge P, Sandler DP, O'Brien KM, Anton-Culver H, Ziogas A, Menon U, Ramus SJ, Pearce CL, Wu AH, White E, Peters U, Webb PM, Tworoger SS, Trabert B.
    • J Clin Oncol. 2022 Jul 22:JCO2101900. doi: 10.1200/JCO.21.01900. Epub ahead of print.
    • Meta-Analysis
    • Study Confirms BRCA1 and BRCA2 Linked to Seven Cancers.
    • Alexander W.
    • Medscape Oncology. 2022 Jul 12.

    Original research:

    Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.

    • Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.
    • Rolfes M, Borde J, Möllenhoff K, Kayali M, Ernst C, Gehrig A, Sutter C, Ramser J, Niederacher D, Horváth J, Arnold N, Meindl A, Auber B, Rump A, Wang-Gohrke S, Ritter J, Hentschel J, Thiele H, Altmüller J, Nürnberg P, Rhiem K, Engel C, Wappenschmidt B, Schmutzler RK, Hahnen E, Hauke J.
    • Cancers (Basel). 2022 Jul 5;14(13):3292. doi: 10.3390/cancers14133292.
    • Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers.
    • Kim SR, Tone A, Kim R, Cesari M, Clarke B, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE, Eiriksson L.
    • Int J Gynecol Cancer. 2022 Jul 4;32(7):891-898. doi: 10.1136/ijgc-2021-003082.
    • Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol consumption recommendations.
    • Geczik AM, Ferris JS, Terry MB, Andrulis IL, Buys SS, Daly MB, Hopper JL, John EM, Kurian AW, Southey MC, Liao Y, Genkinger JM.
    • Breast Cancer Res Treat. 2022 Jul 2. doi: 10.1007/s10549-022-06656-7. Epub ahead of print.
    • Understanding Cancer Genetic Risk Assessment Intentions in a Tailored Risk Communication Intervention Randomized Controlled Trial.
    • LeCompte CG, McDougall J, Walters ST, Toppmeyer D, Boyce TW, Lu S, Stroup A, Paddock L, Grumet S, Lin Y, Ani J, Heidt E, Kinney AY.
    • Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1513-1514. doi: 10.1158/1055-9965.EPI-22-0482.
    • Conference abstract
    • Autres approches en dépistage du cancer du sein [Other approaches in breast cancer screening].
    • Veron L, Wehrer D, Caron O, Balleyguier C, Delaloge S.
    • Bull Cancer. 2022 Jul-Aug;109(7-8):786-794. French. doi: 10.1016/j.bulcan.2022.02.006. Epub 2022 May 5.
    • Review. [Article in French]
    • Genetic medicine is accelerating in Japan.
    • Hayashi S, Kubo M, Kaneshiro K, Kai M, Yamada M, Morisaki T, Takao Y, Shimazaki A, Shikada S, Nakamura M.
    • Breast Cancer. 2022 Jul;29(4):659-665. doi: 10.1007/s12282-022-01342-4. Epub 2022 Feb 21.
    • BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, Hasan J, Mitchell CL, Salih Z, Woodward ER, Lalloo F, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR.
    • Br J Cancer. 2022 Jul;127(1):163-167. doi: 10.1038/s41416-022-01773-y. Epub 2022 Mar 8.
    • Review
    • Identification of women at risk of hereditary breast-ovarian cancer among participants in a population-based breast cancer screening.
    • Bonelli L, Valle I, Rebora I, Ricci P, Biocchi L, Bruschi G, Parodi S, Bruzzone C, Varesco L.
    • Fam Cancer. 2022 Jul;21(3):309-318. doi: 10.1007/s10689-021-00281-x. Epub 2021 Oct 20.
    • Polygenic risk score as a possible tool for identifying familial monogenic causes of complex diseases.
    • Lu T, Forgetta V, Richards JB, Greenwood CMT.
    • Genet Med. 2022 Jul;24(7):1545-1555. doi: 10.1016/j.gim.2022.03.022. Epub 2022 Apr 23.
    • Worldwide review with meta-analysis of women's awareness about breast cancer.
    • Wang YJ, Wang F, Yu LX, Xiang YJ, Zhou F, Huang SY, Zheng C, Fu QY, Li L, Gao DZ, Zhang Q, Ma ZB, Yu ZG, Liu LY.
    • Patient Educ Couns. 2022 Jul;105(7):1818-1827. doi: 10.1016/j.pec.2021.12.012. Epub 2021 Dec 18.
    • Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, Hasan J, Mitchell C, Salih Z, Woodward ER, Lalloo F, Shaw J, Desai S, Crosbie EJ, Edmondson RJ, Schlecht H, Wallace AJ, Jayson GC, Evans DGR.
    • J Clin Pathol. 2022 Jun 23:jclinpath-2022-208369. doi: 10.1136/jcp-2022-208369. Epub ahead of print.
    • Prevalence of Pathogenic Germline BRCA1/2 Variants and Their Association with Clinical Characteristics in Patients with Epithelial Ovarian Cancer in a Rural Area of Japan.
    • Abe A, Imoto I, Tange S, Nishimura M, Iwasa T.
    • Genes (Basel). 2022 Jun 18;13(6):1085. doi: 10.3390/genes13061085.
    • Spectrum of germline pathogenic variants using a targeted next generation sequencing panel and genotype-phenotype correlations in patients with suspected hereditary breast cancer at an academic medical centre in Pakistan.
    • Akbar F, Siddiqui Z, Waheed MT, Ehsan L, Ali SI, Wiquar H, Valimohammed AT, Khan S, Vohra L, Zeeshan S, Rashid Y, Moosajee M, Jabbar AA, Zahir MN, Zahid N, Soomro R, Ullah NN, Ahmad I, Haider G, Ansari U, Rizvi A, Mehboobali A, Sattar A, Kirmani S.
    • Hered Cancer Clin Pract. 2022 Jun 16;20(1):24. doi: 10.1186/s13053-022-00232-2.
    • Nine Myths About Men and Hereditary Cancer.
    • [No author given]
    • My Gene Counsel. Genetic Journal blog. 2022 Jun 15.
    • Literacy-adapted, electronic family history assessment for genetics referral in primary care: patient user insights from qualitative interviews.
    • Mittendorf KF, Lewis HS, Duenas DM, Eubanks DJ, Gilmore MJ, Goddard KAB, Joseph G, Kauffman TL, Kraft SA, Lindberg NM, Reyes AA, Shuster E, Syngal S, Ukaegbu C, Zepp JM, Wilfond BS, Porter KM.
    • Hered Cancer Clin Pract. 2022 Jun 10;20(1):22. doi: 10.1186/s13053-022-00231-3.

    Identifier: NCT03426878: Cancer Health Assessments Reaching Many (CHARM). (ClinicalTrials.gov)

    • ASGE Expands BRCA Screening for Pancreatic Cancer.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Jun 9.

    Guideline summary:

    ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations.

    Guideline:

    American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence.

    • Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study.
    • Tiller JM, Cousens NE, Kaur R, Rowley S, Ko YA, Mahale S, Bankier A, Meiser B, Barlow-Stewart K, Burnett L, Jacobs C, James P, Trainer A, Neil S, Campbell IG, Andrews L, Delatycki M.
    • J Med Genet. 2022 Jun 3:jmedgenet-2022-108519. doi: 10.1136/jmedgenet-2022-108519. Epub ahead of print.
    • Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.
    • Momozawa Y, Sasai R, Usui Y, Shiraishi K, Iwasaki Y, Taniyama Y, Parsons MT, Mizukami K, Sekine Y, Hirata M, Kamatani Y, Endo M, Inai C, Takata S, Ito H, Kohno T, Matsuda K, Nakamura S, Sugano K, Yoshida T, Nakagawa H, Matsuo K, Murakami Y, Spurdle AB, Kubo M.
    • JAMA Oncol. 2022 Jun 1;8(6):871-878. doi: 10.1001/jamaoncol.2022.0476.

    Research news: Study Confirms BRCA1 and BRCA2 Linked to Seven Cancers. (Medscape Oncology)

    • Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
    • Bajpai J, Kashyap L, Vallathol DH, Das A, Singh M, Pathak R, Rath S, Sekar A, Mohanta S, Reddy A, Joshi S, Nandhana R, Ravind R, Wadasadawala T, Nair N, Ghosh J, Parmar V, Gulia S, Desai S, Shet T, Thakur M, Patil A, Sarin R, Gupta S, Badwe R.
    • Breast. 2022 Jun;63:77-84. doi: 10.1016/j.breast.2022.03.011. Epub 2022 Mar 19.
    • Prevalence of Americans reporting a family history of cancer indicative of increased cancer risk: Estimates from the 2015 National Health Interview Survey.
    • Kumerow MT, Rodriguez JL, Dai S, Kolor K, Rotunno M, Peipins LA.
    • Prev Med. 2022 Jun;159:107062. doi: 10.1016/j.ypmed.2022.107062. Epub 2022 Apr 20.
    • Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: a population-based study.
    • Barnard ME, Meeks H, Jarboe EA, Albro J, Camp NJ, Doherty JA.
    • J Med Genet. 2022 May 9:jmedgenet-2021-108402. doi: 10.1136/jmedgenet-2021-108402. Epub ahead of print.
    • Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population.
    • Kerlikowske K, Chen S, Golmakani MK, Sprague BL, Tice JA, Tosteson ANA, Rauscher GH, Henderson LM, Buist DSM, Lee JM, Gard CC, Miglioretti DL.
    • J Natl Cancer Inst. 2022 May 9;114(5):676-685. doi: 10.1093/jnci/djac008.

    Commentary:

    Toward Using Breast Cancer Risk Prediction Models for Guiding Screening Decisions.

    • Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman Study™.
    • Tone A, Boghosian T, Ross A, Baugh E, Altman AD, Dawson L, Reid F, Crawford C.
    • Curr Oncol. 2022 May 5;29(5):3318-3340. doi: 10.3390/curroncol29050271.
    • Molecular phenotypes and clinical characterization of familial hereditary breast cancer among half and full sisters.
    • Xu Y, He J, Qian C, Yang C.
    • BMC Womens Health. 2022 May 2;22(1):145. doi: 10.1186/s12905-022-01732-y.
    • Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.
    • Sekine M, Enomoto T, Arai M, Yokoyama S, Nomura H, Nishino K, Ikeuchi T, Kuriyama Y, Nakamura S; Registration Committee of the Japanese Organization of Hereditary Breast and Ovarian Cancer.
    • J Hum Genet. 2022 May;67(5):267-272. doi: 10.1038/s10038-021-01002-z. Epub 2022 Jan 4.
    • Whole-Exome Sequencing of Germline Variants in Non-BRCA Families with Hereditary Breast Cancer.
    • Liu Y, Helgadottir HT, Kharaziha P, Choi J, López-Giráldez F, Mane SM, Höiom V, Juhlin CC, Larsson C, Bajalica-Lagercrantz S.
    • Biomedicines. 2022 Apr 26;10(5):1004. doi: 10.3390/biomedicines10051004.
    • Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification.
    • Ho PJ, Ho WK, Khng AJ, Yeoh YS, Tan BK, Tan EY, Lim GH, Tan SM, Tan VKM, Yip CH, Mohd-Taib NA, Wong FY, Lim EH, Ngeow J, Chay WY, Leong LCH, Yong WS, Seah CM, Tang SW, Ng CWQ, Yan Z, Lee JA, Rahmat K, Islam T, Hassan T, Tai MC, Khor CC, Yuan JM, Koh WP, Sim X, Dunning AM, Bolla MK, Antoniou AC, Teo SH, Li J, Hartman M.
    • BMC Med. 2022 Apr 26;20(1):150. doi: 10.1186/s12916-022-02334-z.
    • Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review.
    • Kaubryte J, Lai AG.
    • NPJ Precis Oncol. 2022 Apr 20;6(1):27. doi: 10.1038/s41698-022-00269-5.
    • Male Breast Cancer: From Molecular Genetics to Clinical Management.
    • Pensabene M, Von Arx C, De Laurentiis M.
    • Cancers (Basel). 2022 Apr 15;14(8):2006. doi: 10.3390/cancers14082006.
    • Effective Surveillance of High-Risk Women.
    • Lotz M, Ghebremichael M, Chervinsky K, Zorc T, Brenner C, Bousvaros G, Pories SE.
    • Clin Breast Cancer. 2022 Apr;22(3):e263-e269. doi: 10.1016/j.clbc.2021.07.014. Epub 2021 Jul 27.
    • Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice.
    • Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, Gomella LG, Fischer C, Loeb S.
    • Clin Genitourin Cancer. 2022 Apr;20(2):e104-e113. doi: 10.1016/j.clgc.2021.11.009. Epub 2021 Nov 27.
    • Room for improvement in capturing cancer family history in a gynecologic oncology outpatient setting.
    • Lin J, Wolfe I, Ahsan MD, Krinsky H, Lackner AI, Pelt J, Bolouvi K, Gamble C, Thomas C, Christos PJ, Cantillo E, Holcomb K, Chapman-Davis E, Sharaf R, Lipkin SM, Blank SV, Frey MK.
    • Gynecol Oncol Rep. 2022 Feb 14 [eCollection 2022 Apr];40:100941. doi: 10.1016/j.gore.2022.100941.
    • Importance of multigene panel test in patients with consanguineous marriage and family history of breast cancer.
    • Ozmen V, Caglayan AO, Yararbas K, Ordu C, Aktepe F, Ozmen T, Ilgun AS, Soybir G, Alco G, Tsaousis GN, Papadopoulou E, Agiannitopoulos K, Pepe G, Kampouri S, Nasioulas G, Sezgin E, Soran A.
    • Oncol Lett. 2022 Apr;23(4):118. doi: 10.3892/ol.2022.13238. Epub 2022 Feb 9.
    • The Significant Predictors for Breast, Cervical, Colorectal, or Oral Cancer Screening Intention and Behavior in Taiwan.
    • Huang HC, Chang PC, Li SF, Wang CY, Huang WT, Chen W, Fan SY.
    • Cancer Nurs. 2022 Mar 29. doi: 10.1097/NCC.0000000000001107. Epub ahead of print.
    • Do current family history-based genetic testing guidelines contribute to breast cancer health inequities?
    • Jakuboski SH, McDonald JA, Terry MB.
    • NPJ Breast Cancer. 2022 Mar 22;8(1):36. doi: 10.1038/s41523-022-00391-4.
    • Familial Aspects of Mammographic Density Measures Associated with Breast Cancer Risk.
    • Nguyen TL, Li S, Dowty JG, Dite GS, Ye Z, Nguyen-Dumont T, Trinh HN, Evans CF, Tan M, Sung J, Jenkins MA, Giles GG, Southey MC, Hopper JL.
    • Cancers (Basel). 2022 Mar 14;14(6):1483. doi: 10.3390/cancers14061483.
    • Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC).
    • Ye Z, Li S, Dite GS, Nguyen TL, MacInnis RJ, Andrulis IL, Buys SS, Daly MB, John EM, Kurian AW, Genkinger JM, Chung WK, Phillips KA, Thorne H, Winship IM, Milne RL, Dugué PA, Southey MC, Giles GG, Terry MB, Hopper JL.
    • Cancer Prev Res (Phila). 2022 Mar 1;15(3):185-191. doi: 0.1158/1940-6207.CAPR-21-0164.
    • Breast cancer risk evaluation for the primary care physician.
    • Klassen CL, Gilman E, Kaur A, Lester SP, Pruthi S.
    • Cleve Clin J Med. 2022 Mar 1;89(3):139-146. doi: 10.3949/ccjm.89a.21023.
    • Transforming the 2-week wait (2WW) pathway: management of breast pain in primary care.
    • Jahan M, Bartholomeuz T, Milburn N, Rogers V, Sibbering M, Robertson J.
    • BMJ Open Qual. 2022 Mar;11(1):e001634. doi: 10.1136/bmjoq-2021-001634.
    • Epidemiologic evidence of exposure to polycyclic aromatic hydrocarbons and breast cancer: A systematic review and meta-analysis.
    • Gamboa-Loira B, López-Carrillo L, Mar-Sánchez Y, Stern D, Cebrián ME.
    • Chemosphere. 2022 Mar;290:133237. doi: 10.1016/j.chemosphere.2021.133237. Epub 2021 Dec 17.
    • Meta-Analysis
    • Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.
    • Lux MP, Lewis K, Rider A, Niyazov A.
    • Future Oncol. 2022 Mar;18(9):1089-1101. doi: 10.2217/fon-2021-1387. Epub 2022 Jan 31.
    • Breast and prostate cancer risk: The interplay of polygenic risk, rare pathogenic germline variants, and family history.
    • Hassanin E, May P, Aldisi R, Spier I, Forstner AJ, Nöthen MM, Aretz S, Krawitz P, Bobbili DR, Maj C.
    • Genet Med. 2022 Mar;24(3):576-585. doi: 10.1016/j.gim.2021.11.009. Epub 2021 Nov 18.
    • Mutations in exon region of BRCA1-related RING domain 1 gene and risk of breast cancer.
    • Wu J, Aini A, Ma B.
    • Mol Genet Genomic Med. 2022 Mar;10(3):e1847. doi: 10.1002/mgg3.1847. Epub 2022 Jan 27.
    • Family History of Breast Cancer and Mammographic Breast Density in Premenopausal Women.
    • Han Y, Moore JX, Colditz GA, Toriola AT.
    • JAMA Netw Open. 2022 Feb 1;5(2):e2148983. doi: 10.1001/jamanetworkopen.2021.48983.

    Research news: Breast Density Linked to Familial Breast Cancer Risk. (Medscape)

    • Air Pollution and Breast Cancer: An Examination of Modification By Underlying Familial Breast Cancer Risk.
    • Niehoff NM, Terry MB, Bookwalter DB, Kaufman JD, O'Brien KM, Sandler DP, White AJ.
    • Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):422-429. doi: 10.1158/1055-9965.EPI-21-1140. Epub 2021 Dec 14.
    • Indications des mastectomies de réduction de risque en dehors du risque avéré de prédisposition héréditaire : recommandations du Collège national des gynécologues et obstétriciens français (CNGOF) [Non-genetic indications for risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)].
    • Mathelin C, Barranger E, Boisserie-Lacroix M, Boutet G, Brousse S, Chabbert-Buffet N, Coutant C, Daraï E, Delpech Y, Duraes M, Espié M, Fornecker L, Golfier F, Grosclaude P, Hamy AS, Kermarrec E, Lavoué V, Lodi M, Luporsi É, Maugard CM, Molière S, Seror JY, Taris N, Uzan C, Vaysse C, Fritel X.
    • Gynecol Obstet Fertil Senol. 2022 Feb;50(2):107-120. French. doi: 10.1016/j.gofs.2021.12.005. Epub 2021 Dec 14.
    • Guideline, [Article in French]
    • BRCA1/2 Mutations in Vietnamese Patients with Hereditary Breast and Ovarian Cancer Syndrome.
    • Le TN, Tran VK, Nguyen TT, Vo NS, Hoang TH, Vo HL, Nguyen TT, Nguyen PD, Nguyen VT, Ta TV, Tran HT.
    • Genes (Basel). 2022 Jan 29;13(2):268. doi: 10.3390/genes13020268.
    • The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study.
    • Bouferraa Y, Haibe Y, Chedid A, Jabra E, Charafeddine M, Temraz S, Mukherji D, El Saghir N, Shamseddine A.
    • BMC Cancer. 2022 Jan 3;22(1):27. doi: 10.1186/s12885-021-09100-z.
    • Tubal histopathological abnormalities in BRCA1/2 mutation carriers undergoing prophylactic salpingo-oophorectomy: a case-control study.
    • Sina F, Cassani C, Comerio C, De Ponti E, Zanellini F, Delle Marchette M, Roversi G, Jaconi M, Arbustini E, Urtis M, Dell'Oro C, Zambetti B, Paniga C, Acampora E, Negri S, Lazzarin S, Cesari S, Spinillo A, Kotsopoulos J, Fruscio R.
    • Int J Gynecol Cancer. 2022 Jan;32(1):41-47. doi: 10.1136/ijgc-2021-003153. Epub 2021 Nov 29.
    • Evaluating the Effect of Health Education Intervention on the Health Beliefs and Behaviors of First-Degree Female Relatives of Breast Cancer Patients.
    • Olgun S, Dizer B.
    • South Asian J Cancer. 2021 Nov 24 [eCollection 2022 Jan];11(1):14-18. doi: 10.1055/s-0041-1733318.
    • Validation of Breast Cancer Risk Models by Race/Ethnicity, Family History and Molecular Subtypes.
    • McCarthy AM, Liu Y, Ehsan S, Guan Z, Liang J, Huang T, Hughes K, Semine A, Kontos D, Conant E, Lehman C, Armstrong K, Braun D, Parmigiani G, Chen J.
    • Cancers (Basel). 2021 Dec 23;14(1):45. doi: 10.3390/cancers14010045.
    • Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes.
    • Kurian AW, Abrahamse P, Ward KC, Hamilton AS, Deapen D, Berek JS, Hoang L, Yussuf A, Dolinsky J, Brown K, Slavin T, Hofer TP, Katz SJ.
    • JCO Precis Oncol. 2021 Dec 22;5:PO.21.00261. doi: 10.1200/PO.21.00261.
    • Underutilisation of breast cancer prevention medication in Australia.
    • Macdonald C, Chamberlain JA, Mazza D, Milne RL; kConFab investigators, Phillips KA.
    • Breast. 2021 Dec;60:35-37. doi: 10.1016/j.breast.2021.08.013. Epub 2021 Aug 23.
    • Comparison of a Cancer Family History Collection and Risk Assessment Tool - ItRunsInMyFamily - with Risk Assessment by Health-Care Professionals.
    • Ritchie JB, Welch BM, Allen CG, Frey LJ, Morrison H, Schiffman JD, Alekseyenko AV, Dean B, Hughes Halbert C, Bellcross C.
    • Public Health Genomics. 2021 Dec 6:1-9. doi: 10.1159/000520001. Epub ahead of print.
    • Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population.
    • Shen L, Zhang S, Wang K, Wang X.
    • Front Oncol. 2021 Dec 1;11:740227. doi: 10.3389/fonc.2021.740227.

    Commentary:

    Editorial: Familial Cancer in China: From Detection to Screening and Management.

    • Epidemiology of Ductal Carcinoma In Situ.
    • Iatrakis G, Zervoudis S.
    • Chirurgia (Bucur). 2021 Dec;116(500):S15-S21. doi: 10.21614/chirurgia.116.5.suppl.S15.
    • Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk.
    • Kehm RD, MacInnis RJ, John EM, Liao Y, Kurian AW, Genkinger JM, Knight JA, Colonna SV, Chung WK, Milne R, Zeinomar N, Dite GS, Southey MC, Giles GG, McLachlan SA, Whitaker KD, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators, Phillips KA, Andrulis IL, Buys SS, Daly MB, Hopper JL, Terry MB.
    • JNCI Cancer Spectr. 2021 Dec;5(6):pkab090. doi: 10.1093/jncics/pkab090.
    • Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    • Su Y, Yao Q, Xu Y, Yu C, Zhang J, Wang Q, Li J, Shi D, Yu B, Zeng Y, Zhu X, Bai Q, Zhou X.
    • Front Genet. 2021 Nov 30;12:674094. doi: 10.3389/fgene.2021.674094.
    • Family history of breast cancer is associated with elevated risk of prostate cancer: evidence for shared genetic risks.
    • Calvo Chozas A, Mahjani B, Rönnegård L.
    • Hum Hered. 2021 Nov 30. doi: 10.1159/000521215. Epub ahead of print.
    • The DAMA25 Study: Feasibility of a Lifestyle Intervention Programme for Cancer Risk Reduction in Young Italian Women with Breast Cancer Family History.
    • Masala G, Palli D, Ermini I, Occhini D, Facchini L, Sequi L, Castaldo M, Caini S, Bendinelli B, Saieva C, Assedi M, Zanna I.
    • Int J Environ Res Public Health. 2021 Nov 23;18(23):12287. doi: 10.3390/ijerph182312287.
    • Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study.
    • Zheng G, Sundquist J, Sundquist K, Ji J.
    • BMC Cancer. 2021 Nov 12;21(1):1210. doi: 10.1186/s12885-021-08925-y.
    • Oral Contraceptive Use and Breast Cancer Risk Assessment: A Systematic Review and Meta-Analysis of Case-Control Studies, 2009-2020.
    • Baranska A, Blaszczuk A, Kanadys W, Malm M, Drop K, Polz-Dacewicz M.
    • Cancers (Basel). 2021 Nov 12;13(22):5654. doi: 10.3390/cancers13225654.
    • Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks.
    • Wolfson M, Gribble S, Pashayan N, Easton DF, Antoniou AC, Lee A, van Katwyk S, Simard J.
    • Genet Med. 2021 Nov;23(11):2114-2121. doi: 10.1038/s41436-021-01258-y. Epub 2021 Jul 6.
    • Changing Patterns in Clinicopathological Characteristics of Breast Cancer and Prevalence of BRCA Mutations: Analysis in a Rural Area of Southern China.
    • Wang Q, Wu H, Lan Y, Zhang J, Wu J, Zhang Y, Li L, Liu D, Zhang J.
    • Int J Gen Med. 2021 Oct 29;14:7371-7380. doi: 10.2147/IJGM.S333858.
    • Experience and Perceptions of a Family Health History Risk Assessment Tool among Multi-Ethnic Asian Breast Cancer Patients.
    • Yoon S, Goh H, Fung SM, Tang S, Matchar D, Ginsburg GS, Orlando LA, Ngeow J, Wu RR.
    • J Pers Med. 2021 Oct 19;11(10):1046. doi: 10.3390/jpm11101046.
    • Care of men with cancer-predisposing BRCA variants.
    • Horton R, Pharoah P, Hayward J, Lucassen A.
    • BMJ. 2021 Oct 14;375:n2376. doi: 10.1136/bmj.n2376.
    • Review
    • Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.
    • Bernstein-Molho R, Galmor L, Laitman Y, Segev S, Friedman E.
    • Cancer. 2021 Oct 1;127(19):3599-3604. doi: 10.1002/cncr.33560. Epub 2021 Jun 22.
    • Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
    • Ji G, Bao L, Yao Q, Zhang J, Zhu X, Bai Q, Shao Z, Yang W, Zhou X.
    • J Cancer Res Clin Oncol. 2021 Oct;147(10):2935-2944. doi: 10.1007/s00432-021-03696-2. Epub 2021 Jul 13.
    • "The Continuous Shadow of My Mother's Breast Cancer": exploring the voice of daughters.
    • Fang SY, Wang YM, Lee KT.
    • Support Care Cancer. 2021 Sep 16. doi: 10.1007/s00520-021-06551-9. Epub ahead of print.
    • Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations.
    • Reichl F, Muhr D, Rebhan K, Kramer G, Shariat SF, Singer CF, Tan YY.
    • J Pers Med. 2021 Sep 15;11(9):917. doi: 10.3390/jpm11090917.
    • Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer.
    • Huang KL, Liu YL, Hsu YY, Kuo WL.
    • Healthcare (Basel). 2021 Sep 13;9(9):1203. doi: 10.3390/healthcare9091203.
    • Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk.
    • Gamble LA, Rossi A, Fasaye GA, Kesserwan C, Hernandez JM, Blakely AM, Davis JL.
    • JAMA Surg. 2021 Oct 13. doi: 10.1001/jamasurg.2021.5118. Epub ahead of print.
    • Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.
    • Tung N, Desai N.
    • J Clin Oncol. 2021 Sep 7:JCO2101761. doi: 10.1200/JCO.21.01761. Epub ahead of print.

    Original research:

    Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.

    Original research:

    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.

    • Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families.
    • Matis TS, Zayed N, Labraki B, de Ladurantaye M, Matis TA, Camacho Valenzuela J, Hamel N, Atayan A, Rivera B, Tabach Y, Tonin PN, Orthwein A, Mes-Masson AM, El Haffaf Z, Foulkes WD, Polak P.
    • NPJ Breast Cancer. 2021 Aug 25;7(1):109. doi: 10.1038/s41523-021-00315-8.
    • Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    • Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady A, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo MA, Campbell I, Cassingham H, Lotte Christensen L, Cini G, Claes KBM; GEMO Study Collaborators; EMBRACE Collaborators, Cook J, Coppa A, Cortesi L, Damante G, Darder E, Davidson R, de la Hoya M, De Leeneer K, de Putter R, Del Valle J, Diez O, Chun Ding Y, Domchek SM, Donaldson A, Eason J, Eeles R, Engel C, Gareth Evans D, Feliubadaló L, Fostira F, Frone M, Frost D, Gallagher D, Gehrig A, Giraud S, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gregory H, Gross E, Hahnen E, Hamann U, Hansen TVO, Hanson H, Hentschel J, Horvath J; KConFab Investigators; HEBON Investigators, Izatt L, Izquierdo A, James PA, Janavicius R, Birk Jensen U, Johannsson OT, John EM, Kramer G, Kroeldrup L, Kruse TA, Lautrup C, Lazaro C, Lesueur F, Lopez-Fernández A, Mai PL, Manoukian S, Matrai Z, Matricardi L, Maxwell KN, Mebirouk N, Meindl A, Montagna M, Monteiro AN, Morrison PJ, Muranen TA, Murray A, Nathanson KL, Neuhausen SL, Nevanlinna H, Nguyen-Dumont T, Niederacher D, Olah E, Olopade OI, Palli D, Parsons MT, Sokilde Pedersen I, Peissel B, Perez-Segura P, Peterlongo P, Petersen AH, Pinto P, Porteous ME, Pottinger C, Angel Pujana M, Radice P, Ramser J, Rantala J, Robson M, Rogers MT, Rønlund K, Rump A, María Sánchez de Abajo A, Shah PD, Sharif S, Side LE, Singer CF, Stadler Z, Steele L, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira MR, Teulé A, Thull DL, Tischkowitz M, Toland AE, Tommasi S, Toss A, Trainer AH, Tripathi V, Valentini V, van Asperen CJ, Venturelli M, Viel A, Vijai J, Walker L, Wang-Gohrke S, Wappenschmidt B, Whaite A, Zanna I, Offit K, Thomassen M, Couch FJ, Schmutzler RK, Simard J, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L; Consortium of Investigators of Modifiers of BRCA1 and BRCA2.
    • J Natl Cancer Inst. 2021 Jul 28:djab147. doi: 10.1093/jnci/djab147. Epub ahead of print.
    • Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
    • Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, Barr L, Wallace A, Lalloo F, Wilson M, Hurley E, Lim Y, Maxwell AJ, Harkness EF, Howell A.
    • Breast Cancer Res Treat. 2021 Jul 26. doi: 10.1007/s10549-021-06333-1. Epub ahead of print.
    • Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    • Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE, Na J, Huang H, Gnanaolivu RD, Larson N, Yussuf A, Yao S, Vachon CM, Trentham-Dietz A, Teras L, Taylor JA, Scott CE, Sandler DP, Pesaran T, Patel AV, Palmer JR, Ong IM, Olson JE, O'Brien K, Neuhausen S, Martinez E, Ma H, Lindstrom S, Le Marchand L, Kooperberg C, Karam R, Hunter DJ, Hodge JM, Haiman C, Gaudet MM, Gao C, LaDuca H, Lacey JV, Dolinsky JS, Chao E, Carter BD, Burnside ES, Bertrand KA, Bernstein L, Auer PW, Ambrosone C, Yadav S, Hart SN, Polley EC, Domchek SM, Couch FJ.
    • J Clin Oncol. 2021 Jul 22:JCO2100531. doi: 10.1200/JCO.21.00531. Epub ahead of print.

    Commentary, Research report:

    Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.

    Press: Older Women with Breast Cancer May Benefit from Genetic Testing (Clinical OMICs)

    • No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
    • Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kogut Kubiak T, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Maalouf A, Daures JP, Pujol P.
    • Genes (Basel). 2021 Jul 20;12(7):1100. doi: 10.3390/genes12071100.
    • A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.
    • Wendt C, Muranen TA, Mielikäinen L, Thutkawkorapin J, Blomqvist C, Jiao X, Ehrencrona H, Tham E, Arver B, Melin B, Kuchinskaya E, Stenmark Askmalm M, Paulsson-Karlsson Y, Einbeigi Z, von Wachenfeldt Väppling A, Kalso E, Tasmuth T, Kallioniemi A, Aittomäki K, Nevanlinna H, Borg Å, Lindblom A.
    • Sci Rep. 2021 Jul 20;11(1):14763. doi: 10.1038/s41598-021-93926-x.
    • Results from London Regional Clinical Genetics services over a 5-year period on germline TP53 testing in women diagnosed with breast cancer at <30 years.
    • Garrett A, Talukdar S, Izatt L, Brady AF, Whyte S, Josephs KS, Shanmugasundaram M, Guillemot LS, Vakili D, Ey S, Ahmed M.
    • J Med Genet. 2021 Jul 15:jmedgenet-2021-107742. doi: 10.1136/jmedgenet-2021-107742. Epub ahead of print.
    • The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients With Germline Pathogenic Variants in Cancer Predisposition Genes.
    • Liu J, Wang X, Dong L, Huang X, Zhao H, Li J, Huang S, Yuan P, Wang W, Wang J, Xing Z, Jia Z, Ming Y, Li X, Qin L, Liu G, Wu J, Li Y, Zhang M, Feng K, Ying J, Wang X.
    • Front Oncol. 2021 Jul 13;11:710156. doi: 10.3389/fonc.2021.710156.
    • Clinical and pathological features and risk factors for primary breast cancer patients.
    • Lei YY, Bai S, Chen QQ, Luo XJ, Li DM.
    • World J Clin Cases. 2021 Jul 6;9(19):5046-5053. doi: 10.12998/wjcc.v9.i19.5046.
    • Psychological consequences of MRI-based screening among women with strong family histories of breast cancer.
    • Castelo M, Brown Z, D'Abbondanza JA, Wasilewski NV, Eisen A, Muradali D, Hansen BE, Grunfeld E, Scheer AS.
    • Breast Cancer Res Treat. 2021 Jul 2. doi: 10.1007/s10549-021-06300-w. Epub ahead of print.
    • Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
    • Ren M, Orozco A, Shao K, Albanez A, Ortiz J, Cao B, Wang L, Barreda L, Alvarez CS, Garland L, Wu D, Chung CC, Wang J, Frone M, Ralon S, Argueta V, Orozco R, Gharzouzi E, Dean M.
    • Breast Cancer Res Treat. 2021 Jul 1. doi: 10.1007/s10549-021-06305-5. Epub ahead of print.
    • Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer.
    • Gonda K, Horita S, Maejima Y, Takenoshita S, Shimomura K.
    • Sci Prog. 2021 Jul-Sep;104(3):368504211039590. doi: 10.1177/00368504211039590.
    • The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
    • Escudeiro C, Pinto C, Vieira J, Peixoto A, Pinto P, Pinheiro M, Santos C, Guerra J, Lisboa S, Santos R, Silva J, Leal C, Coimbra N, Lopes P, Ferreira M, Sousa AB, Teixeira MR.
    • Fam Cancer. 2021 Jul;20(3):173-180. doi: 10.1007/s10689-020-00212-2. Epub 2020 Oct 14.
    • Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
    • Abubakar M, Guo C, Koka H, Zhu B, Deng J, Hu N, Zhou B, Garcia-Closas M, Lu N, Yang XR.
    • Breast Cancer Res Treat. 2021 Jun 29. doi: 10.1007/s10549-021-06294-5. Epub ahead of print.
    • Ten years follow-up of histologically benign calcifications in the breast after vacuum-assisted stereotactic biopsy (VASB): Is additional mammographic follow-up warranted?
    • van Bekkum S, Dams FEM, Westenend PJ, van Rosmalen J, Menke-Pluijmers MBE, Kock MCJM.
    • Breast. 2021 Jun 26;59:135-143. doi: 10.1016/j.breast.2021.06.008. Epub ahead of print.
    • Examining the etiology of early-onset breast cancer in the Canadian Partnership for Tomorrow's Health (CanPath).
    • Pader J, Basmadjian RB, O'Sullivan DE, Mealey NE, Ruan Y, Friedenreich C, Murphy R, Wang E, Quan ML, Brenner DR.
    • Cancer Causes Control. 2021 Jun 25. doi: 10.1007/s10552-021-01460-y. Epub ahead of print.
    • Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    • Safra T, Waissengrin B, Gerber D, Bernstein-Molho R, Klorin G, Salman L, Josephy D, Chen-Shtoyerman R, Bruchim I, Frey MK, Pothuri B, Muggia F.
    • Gynecol Oncol. 2021 Jun 22:S0090-8258(21)00489-3. doi: 10.1016/j.ygyno.2021.06.009. Epub ahead of print.
    • Risk-adapted starting age of breast cancer screening in women with a family history of ovarian or other cancers: A nationwide cohort study.
    • Mukama T, Kharazmi E, Sundquist K, Sundquist J, Fallah M.
    • Cancer. 2021 Jun 15;127(12):2091-2098. doi: 10.1002/cncr.33456. Epub 2021 Feb 23.
    • Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer.
    • Wang A, Everett JN, Chun J, Cen C, Simeone DM, Schnabel F.
    • Sci Rep. 2021 Jun 14;11(1):12491. doi: 10.1038/s41598-021-91971-0.
    • Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden.
    • Johansson A, Christakou AE, Iftimi A, Eriksson M, Tapia J, Skoog L, Benz CC, Rodriguez-Wallberg KA, Hall P, Czene K, Lindström LS.
    • JAMA Netw Open. 2021 Jun 1;4(6):e2114716. doi: 10.1001/jamanetworkopen.2021.14716.
    • Micronuclei and upper body cancers (head, neck, breast cancers) a systematic review and meta-analysis.
    • Bolognesi C, Bruzzone M, Ceppi M, Marcon F.
    • Mutat Res. 2021 Jan-Jun;787:108358. doi: 10.1016/j.mrrev.2020.108358. Epub 2020 Nov 28.
    • Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Wunderle M, Häberle L, Hein A, Jud SM, Lux MP, Hack CC, Emons J, Heindl F, Nabieva N, Loehberg CR, Schulz-Wendtland R, Hartmann A, Beckmann MW, Fasching PA, Gass P.
    • Breast Care (Basel). 2021 Jun;16(3):254-262. doi: 10.1159/000507475. Epub 2020 Jul 1.
    • Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.
    • Gupta S, Rajappa S, Advani S, Agarwal A, Aggarwal S, Goswami C, Palanki SD, Arya D, Patil S, Kodagali R.
    • JCO Glob Oncol. 2021 Jun;7:849-861. doi: 10.1200/GO.21.00051.
    • Ethical, legal, and sociocultural challenges of genomic research in Jordan: a mixed methods study in patients with breast cancer with Jordanian-Palestinian heritage.
    • Al-Omari A, Al-Hussaini M, Zahran F, Abdel-Razeq H.
    • Lancet. 2022 Jun;399 Suppl 1:S26. doi: 10.1016/S0140-6736(22)01161-8.
    • Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer.
    • Rapposelli IG, Zampiga V, Cangini I, Arcangeli V, Ravegnani M, Valgiusti M, Pini S, Tamberi S, Bartolini G, Passardi A, Martinelli G, Calistri D, Frassineti GL, Falcini F, Danesi R.
    • BMC Cancer. 2021 May 26;21(1):611. doi: 10.1186/s12885-021-08368-5.
    • Screening High-Risk Women Veterans for Breast Cancer.
    • Park YA, Keller A, Hsu TM, Bidassie B, Venne V, Hawley D, Hoffman-Högg L, Heron B, Colonna S, Aggarwal A.
    • Fed Pract. 2021 May;38(Suppl 2):S35-S41. doi: 10.12788/fp.0122.
    • Prevalence of BRCA1 and BRCA2 mutations in Japanese patients with triple-negative breast cancer: A single institute retrospective study.
    • Fujisawa F, Tamaki Y, Inoue T, Nakayama T, Yagi T, Kittaka N, Yoshinami T, Nishio M, Matsui S, Kusama H, Kamiura S.
    • Mol Clin Oncol. 2021 May;14(5):96. doi: 10.3892/mco.2021.2258. Epub 2021 Mar 12.
    • Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    • Leon P, Cancel-Tassin G, Bourdon V, Buecher B, Oudard S, Brureau L, Jouffe L, Blanchet P, Stoppa-Lyonnet D, Coulet F, Sobol H, Cussenot O.
    • Prostate. 2021 May;81(6):318-325. doi: 10.1002/pros.24109. Epub 2021 Feb 18.
    • Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    • Sabol RA, Ledet EM, Jaeger E, Hatton W, Moses M, Lankford A, Zaheria A, Barata P, Layton JL, Lewis BE, Sartor O.
    • Prostate. 2021 May;81(7):427-432. doi: 10.1002/pros.24120. Epub 2021 Mar 24.
    • Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
    • Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, Lewis BE, Nakazawa M, Zhu J, Dellinger B, Elrefai S, Nafissi NN, Egan JB, Shore N, McKay RR, Bryce AH, Cheng HH, Antonarakis ES, Sartor O.
    • Prostate. 2021 May;81(7):433-439. doi: 10.1002/pros.24123. Epub 2021 Apr 1.
    • Family Cancer Stories
    • Genetic Support Foundation.
    • YouTube. Genetic Support Foundation. 2021 Apr 24.

    Resource: Genetic Support Foundation

    Blog post: Behind the Scenes of an Awareness Video: How a Genetic Support Foundation and BRCA Patients are Making a Difference. (FORCE Blog)

    • Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer.
    • Singareeka Raghavendra A, Alameddine HF, Andersen CR, Selber JC, Brewster AM, Barcenas CH, Caudle AS, Arun BK, Tripathy D, Ibrahim NK.
    • Cancers (Basel). 2021 Apr 23;13(9):2050. doi: 10.3390/cancers13092050.
    • Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
    • Toss A, Tenedini E, Piombino C, Venturelli M, Marchi I, Gasparini E, Barbieri E, Razzaboni E, Domati F, Caggia F, Grandi G, Combi F, Tazzioli G, Dominici M, Tagliafico E, Cortesi L.
    • Genes (Basel). 2021 Apr 21;12(5):616. doi: 10.3390/genes12050616.
    • Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility.
    • Lonjou C, Eon-Marchais S, Truong T, Dondon MG, Karimi M, Jiao Y, Damiola F, Barjhoux L, Le Gal D, Beauvallet J, Mebirouk N, Cavaciuti E, Chiesa J, Floquet A, Audebert-Bellanger S, Giraud S, Frebourg T, Limacher JM, Gladieff L, Mortemousque I, Dreyfus H, Lejeune-Dumoulin S, Lasset C, Venat-Bouvet L, Bignon YJ, Pujol P, Maugard CM, Luporsi E, Bonadona V, Noguès C, Berthet P, Delnatte C, Gesta P, Lortholary A, Faivre L, Buecher B, Caron O, Gauthier-Villars M, Coupier I, Mazoyer S, Monraz LC, Kondratova M, Kuperstein I, Guénel P, Barillot E, Stoppa-Lyonnet D, Andrieu N, Lesueur F.
    • Int J Cancer. 2021 Apr 15;148(8):1895-1909. doi: 10.1002/ijc.33457. Epub 2021 Jan 9.
    • The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    • Tone AA, McCuaig JM, Ricker N, Boghosian T, Romagnuolo T, Stickle N, Virtanen C, Zhang T, Kim RH, Ferguson SE, May T, Laframboise S, Armel S, Demsky R, Volenik A, Stuart-McEwan T, Shaw P, Oza A, Kamel-Reid S, Stockley T, Bernardini MQ.
    • Gynecol Oncol. 2021 Apr 13:S0090-8258(21)00321-8. doi: 10.1016/j.ygyno.2021.04.011. Epub ahead of print.
    • Prevalence of Known Risk Factors in Uruguayan Women Treated for Breast Cancer at a University Hospital.
    • Castillo C, Camejo N, Hernandez AL, Artagaveytia N, Alonso R, Delgado L.
    • Breast Cancer (Auckl). 2021 Apr 12;15:11782234211006667. doi: 10.1177/11782234211006667.
    • Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort.
    • Aristarco V, Johansson H, Gandini S, Macis D, Zanzottera C, Tolva G, Feroce I, Accornero C, Bonanni B, Guerrieri-Gonzaga A, Serrano D.
    • Nutrients. 2021 Apr 6;13(4):1208. doi: 10.3390/nu13041208.
    • The Relationship of Mutation Carriage of BRCA1/2 and Family History in Triple-Negative Breast Cancer: Experience from a Diagnostic Center in Turkey.
    • Duzkale N, Kandemir O.
    • Eur J Breast Health. 2021 Mar 31;17(2):137-144. doi: 10.4274/ejbh.galenos.2020.5909.
    • Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.
    • Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, O'Neil BB, Tward JD.
    • JCO Precis Oncol. 2021 Mar 23;5:PO.20.00432. doi: 10.1200/PO.20.00432.
    • Contralateral Prophylactic Mastectomy in Patients with Breast Cancer.
    • Noditi A, Caragheorghe G, Stoleru S, Blidaru A, Bordea CI.
    • Chirurgia (Bucur). 2021 Mar-Apr;116(2 Suppl):73-83.
    • Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
    • Sunar V, Korkmaz V, Topcu V, Cavdarli B, Arik Z, Ozdal B, Ustun YE.
    • Asia Pac J Clin Oncol. 2021 Feb 25. doi: 10.1111/ajco.13520. Epub ahead of print.
    • Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer.
    • Lukomska A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Jasiówka M, Blecharz P, Kluz T, Stawicka-Nielacna M, Madry R, Bialkowska K, Prajzendanc K, Kluzniak W, Cybulski C, Debniak T, Huzarski T, Toloczko-Grabarek A, Byrski T, Baszuk P, Narod SA, Lubinski J, Jakubowska A.
    • Cancers (Basel). 2021 Feb 18;13(4):849. doi: 10.3390/cancers13040849.
    • Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    • Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE.
    • Eur J Cancer. 2021 Feb 9;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub ahead of print.
    • Abnormal screens among nonmutation carriers in the High Risk Ontario Breast Screening Program.
    • Castelo M, Brown Z, Schellenberg AE, Mills JK, Eisen A, Muradali D, Grunfeld E, Scheer AS.
    • Breast J. 2021 Feb 7. doi: 10.1111/tbj.14185. Epub ahead of print.
    • First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and White women.
    • Bethea TN, Ochs-Balcom HM, Bandera EV, Beeghly-Fadiel A, Camacho F, Chyn D, Cloyd EK, Harris HR, Joslin CE, Myers E, Moorman PG, Peres LC, Rosenow W, Setiawan VW, Wu AH, Rosenberg L, Schildkraut JM.
    • Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33493. Epub ahead of print.
    • Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk.
    • Geuzinge HA, Heijnsdijk EAM, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.
    • Breast. 2021 Jan 18;56:1-6. doi: 10.1016/j.breast.2021.01.002. Epub ahead of print.
    • Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.
    • Jung Y, Hur S, Liu J, Lee S, Kang BS, Kim M, Choi YJ.
    • J Gynecol Oncol. 2021 Jan 7. doi: 10.3802/jgo.2021.32.e23. Epub ahead of print.

    Editorial, Research review:

    Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.

    • Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey.
    • Jones S, Hogan B, Patel K, Ooi S, Turton P, Achuthan R, Kim B.
    • Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06046-x. Epub ahead of print.
    • Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
    • Calip GS, Kidd J, Bernhisel R, Cox HC, Saam J, Rauscher GH, Lancaster JM, Hoskins KF.
    • Breast Cancer Res Treat. 2021 Jan;185(1):195-204. doi: 10.1007/s10549-020-05922-w. Epub 2020 Sep 11.
    • The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.
    • You C, Xiao Q, Zhu X, Sun Y, Di G, Liu G, Hou Y, Chen C, Wu J, Shao Z, Gu Y, Hu Z.
    • Gland Surg. 2021 Jan;10(1):262-272. doi: 10.21037/gs-20-596.
    • Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England.
    • Lee SI, Curtis H, Qureshi S, Dutton B, Qureshi N.
    • J Community Genet. 2021 Jan;12(1):111-120. doi: 10.1007/s12687-020-00490-4. Epub 2020 Oct 28.
    • The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study.
    • Seiffert K, Thoene K, Eulenburg CZ, Behrens S, Schmalfeldt B, Becher H, Chang-Claude J, Witzel I.
    • Breast. 2020 Dec 24;55:98-104. doi: 10.1016/j.breast.2020.12.008. Epub ahead of print.
    • Trends in screening breast magnetic resonance imaging use among US women, 2006 to 2016.
    • Wernli KJ, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK.
    • Cancer. 2020 Dec 15;126(24):5293-5302. doi: 10.1002/cncr.33140. Epub 2020 Sep 28.
    • The role of polygenic risk and susceptibility genes in breast cancer over the course of life.
    • Mars N, Widén E, Kerminen S, Meretoja T, Pirinen M, Della Briotta Parolo P, Palta P; FinnGen, Palotie A, Kaprio J, Joensuu H, Daly M, Ripatti S.
    • Nat Commun. 2020 Dec 14;11(1):6383. doi: 10.1038/s41467-020-19966-5.
    • DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
    • Armstrong N, Quek RG, Ryder S, Ross J, Titas Buksnys, Forbes C, Fox KM, Castro E.
    • Future Oncol. 2020 Dec 2. doi: 10.2217/fon-2020-0569. Epub ahead of print.
    • Review
    • Evidence for familial clustering in breast cancer age of onset.
    • Von Holle A, O'Brien KM, Sandler DP, Weinberg CR.
    • Int J Epidemiol. 2020 Nov 28:dyaa201. doi: 10.1093/ije/dyaa201. Epub ahead of print.
    • Beyond the AJR: "Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk".
    • Lowry KP, Sippo DA.
    • AJR Am J Roentgenol. 2020 Nov 25. doi: 10.2214/AJR.20.25138. Epub ahead of print.
    • Commentary

    Original research:

    Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.

    • Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness.
    • Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Mil Med. 2020 Nov 18:usaa485. doi: 10.1093/milmed/usaa485. Epub ahead of print.
    • Previvor at 25 - The Beginning has just Begun.
    • Wilson L.
    • FORCE. Blog. 2020 Nov 10.
    • Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study.
    • Mukama T, Fallah M, Brenner H, Xu X, Sundquist K, Sundquist J, Kharazmi E.
    • BMC Med. 2020 Nov 5;18(1):295. doi: 10.1186/s12916-020-01772-x.
    • BRCA-Related Cancer Genetic Counseling is Indicated in Many Women Seeking Primary Care.
    • Parente DJ.
    • J Am Board Fam Med. 2020 Nov-Dec;33(6):885-893. doi: 10.3122/jabfm.2020.06.190461.
    • Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer.
    • Sim EJ, Ko KP, Ahn C, Park SM, Surh YJ, An S, Kim SW, Lee MH, Lee JW, Lee JE, Kim KS, Yom CK, Kim HA, Park SK.
    • Breast Cancer Res Treat. 2020 Nov;184(2):615-626. doi: 10.1007/s10549-020-05875-0. Epub 2020 Oct 17.
    • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    • O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, Ohsumi S.
    • Breast Cancer Res. 2020 Oct 27;22(1):114. doi: 10.1186/s13058-020-01349-9.
    • Prevalence of Germline Pathogenic and Likely Pathogenic Variants in Patients With Second Breast Cancers.
    • Yao K KA, Clifford J, Li S, LaDuca H, Hulick P, Gutierrez S, Black MH.
    • JNCI Cancer Spectr. 2020 Oct 26;4(6):pkaa094. doi: 10.1093/jncics/pkaa094.
    • Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort.
    • Monson KR, Goldberg M, Wu HC, Santella RM, Chung WK, Terry MB.
    • Breast Cancer Res. 2020 Oct 22;22(1):109. doi: 10.1186/s13058-020-01352-0.
    • Comparison of interval breast cancers with 2D digital mammography versus 3D digital breast tomosynthesis in a large community-based practice.
    • Winter AM, Kazmi S, Hardy AK, Bennett DL.
    • Breast J. 2020 Oct 16. doi: 10.1111/tbj.14047. Epub ahead of print.
    • Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer.
    • Dülgar Ö, Ilvan S, Turna ZH.
    • Eur J Breast Health. 2020 Apr 17 [eCollection 2020 Oct];16(4):276-281. doi: 10.5152/ejbh.2020.5305.
    • The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
    • Matsumoto T, Shiota M.
    • Transl Androl Urol. 2020 Oct;9(5):2289-2291. doi: 10.21037/tau-20-866.

    Original research:

    Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

    • Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.
    • Kramer I, Hooning MJ, Mavaddat N, Hauptmann M, Keeman R, Steyerberg EW, Giardiello D, Antoniou AC, Pharoah PDP, Canisius S, Abu-Ful Z, Andrulis IL, Anton-Culver H, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Bremer M, Brucker SY, Burwinkel B, Castelao JE, Chan TL, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Choi JY, Clarke CL; NBCS Collaborators, Collée JM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Giles GG, Goldgar DE, González-Neira A, Haiman CA, Håkansson N, Hamann U, Hartman M, Heemskerk-Gerritsen BAM, Hollestelle A, Hopper JL, Hou MF, Howell A; ABCTB Investigators; kConFab Investigators, Ito H, Jakimovska M, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kets CM, Khusnutdinova E, Ko YD, Kristensen VN, Kurian AW, Kwong A, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubinski J, Mannermaa A, Manoochehri M, Margolin S, Matsuo K, Mavroudis D, Meindl A, Milne RL, Mulligan AM, Muranen TA, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Park-Simon TW, Peto J, Petridis C, Plaseska-Karanfilska D, Presneau N, Pylkäs K, Radice P, Rennert G, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, See MH, Shah M, Shen CY, Shu XO, Siesling S, Slager S, Sohn C, Southey MC, Spinelli JJ, Stone J, Tapper WJ, Tengström M, Teo SH, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Vachon CM, van Ongeval C, van Veen EM, Winqvist R, Wolk A, Zheng W, Ziogas A, Easton DF, Hall P, Schmidt MK.
    • Am J Hum Genet. 2020 Sep 28:S0002-9297(20)30321-9. doi: 10.1016/j.ajhg.2020.09.001. Epub ahead of print.
    • Cancer Predisposition Genes in Cancer-Free Families.
    • Zheng G, Catalano C, Bandapalli OR, Paramasivam N, Chattopadhyay S, Schlesner M, Sijmons R, Hemminki A, Dymerska D, Lubinski J, Hemminki K, Försti A.
    • Cancers (Basel). 2020 Sep 27;12(10):2770. doi: 10.3390/cancers12102770.
    • Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer.
    • Carr CE, Chambers L, Jernigan AM, Freeman L, Escobar PF, Michener CM.
    • Int J Gynecol Cancer. 2020 Sep 18:ijgc-2020-001405. doi: 10.1136/ijgc-2020-001405. Epub ahead of print.
    • Concordance of tumour characteristics and survival clustering among pairs of first-degree relatives with breast cancer.
    • Rapiti E, Tille JC, Fournier E, Saiji E, Weintraub D, Bouzourene H, Viassolo V, Bouchardy C, Chappuis PO, Benhamou S.
    • Swiss Med Wkly. 2020 Sep 14;150:w20327. doi: 10.4414/smw.2020.20327.
    • Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?
    • Alberty-Oller JJ, Weltz S, Santos A, Pisapati K, Ru M, Weltz C, Schmidt H, Port E.
    • Ann Surg Oncol. 2020 Sep 11. doi: 10.1245/s10434-020-09123-z. Epub ahead of print.
    • NCCN Updates Guidelines Advising Against Using Polygenic Risk Scores Outside of Clinical Trials.
    • [No author given]
    • GenomeWeb. Diagnostics. 2020 Sep 10.
    • Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: a series from north of Morocco.
    • Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, El Fahime E, Barakat A, Ghailani Nourouti N, Martinez De Villarreal J, Cortijo Bringas C, Bennani Mechita M.
    • BMC Cancer. 2020 Sep 7;20(1):859. doi: 10.1186/s12885-020-07352-9.
    • Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.
    • Schairer C, Hablas A, Eldein IAS, Gaafar R, Rais H, Mezlini A, Ayed FB, Ayoub WB, Benider A, Tahri A, Khouchani M, Aboulazm D, Karkouri M, Eissa S, Bastawisy AE, Yehia M, Gadalla SM, Swain SM, Merajver SD, Brown LM, Pfeiffer RM, Soliman AS.
    • Breast Cancer Res Treat. 2020 Sep 2. doi: 10.1007/s10549-020-05864-3. Epub ahead of print.
    • Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program.
    • White RE, Warren L, Nakhlis F, Rosenbluth J, Bellon J, Block C, Overmoyer B.
    • Breast J. 2020 Sep 1. doi: 10.1111/tbj.14030. Epub ahead of print.
    • Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    • Geuzinge HA, Obdeijn IM, Rutgers EJT, Saadatmand S, Mann RM, Oosterwijk JC, Tollenaar RAEM, de Roy van Zuidewijn DBW, Lobbes MBI, van 't Riet M, Hooning MJ, Ausems MGEM, Loo CE, Wesseling J, Luiten EJT, Zonderland HM, Verhoef C, Heijnsdijk EAM, Tilanus-Linthorst MMA, de Koning HJ; Familial MRI Screening (FaMRIsc) Study group.
    • JAMA Oncol. 2020 Sep 1;6(9):1381-1389. doi: 10.1001/jamaoncol.2020.2922.

    Commentary:

    Beyond the AJR: "Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk".

    • Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example.
    • Hemminki K, Srivastava A, Rachakonda S, Bandapalli O, Nagore E, Hemminki A, Kumar R.
    • Hered Cancer Clin Pract. 2020 Jul 31;18:15. doi: 10.1186/s13053-020-00146-x.
    • Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
    • van den Broek JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, Wolfson MC, Trentham-Dietz A, Simard J, Easton DF, Mandelblatt JS, Kraft P, de Koning HJ.
    • J Natl Cancer Inst. 2020 Aug 27. pii: djaa127. doi: 10.1093/jnci/djaa127. [Epub ahead of print]
    • Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland.
    • Rogoza-Janiszewska E, Malinska K, Cybulski C, Jakubowska A, Gronwald J, Huzarski T, Lener M, Górski B, Kluzniak W, Rudnicka H, Akbari MR, Kashyap A, Narod SA, Lubinski J, Debniak T, On Behalf Of The Polish Hereditary Breast Cancer Consortium.
    • Cancers (Basel). 2020 Aug 17;12(8):2321. doi: 10.3390/cancers12082321.
    • Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.
    • Jeong GW, Shin W, Lee DO, Seo SS, Kang S, Park SY, Lim MC.
    • Cancer Res Treat. 2020 Aug 11. doi: 10.4143/crt.2020.364. Epub ahead of print.
    • Patterns of cancer family history and genetic counseling eligibility among African Americans with breast, prostate, lung, and colorectal cancers: A Detroit Research on Cancer Survivors cohort study.
    • Purrington KS, Schwartz AG, Ruterbusch JJ, Manning MA, Nair M, Wenzlaff AS, Pandolfi SS, Simon MS, Beebe-Dimmer J.
    • Cancer. 2020 Aug 4. doi: 10.1002/cncr.33126. Epub ahead of print.
    • Management of women at increased risk for breast cancer secondary to high-risk proliferative lesions and family history of the disease.
    • Cen C, Chun J, Schnabel F.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13964. Online ahead of print.
    • Review
    • Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
    • Wood ME, McKinnon W, Garber J.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13969. Epub ahead of print.
    • Review
    • Evidence for Increased Susceptibility for Breast Cancer from Exposure to Ionizing Radiation Due to Familial Breast Cancer History: Results from the Swedish Hemangioma Cohort.
    • Eidemüller M, Holmberg E, Lundell M, Karlsson P.
    • Am J Epidemiol. 2020 Jul 31:kwaa163. doi: 10.1093/aje/kwaa163. Epub ahead of print.
    • Breast MRI texture analysis for prediction of BRCA-associated genetic risk.
    • Vasileiou G, Costa MJ, Long C, Wetzler IR, Hoyer J, Kraus C, Popp B, Emons J, Wunderle M, Wenkel E, Uder M, Beckmann MW, Jud SM, Fasching PA, Cavallaro A, Reis A, Hammon M.
    • BMC Med Imaging. 2020 Jul 29;20(1):86. doi: 10.1186/s12880-020-00483-2.
    • Clinicopathological characteristics of gene-positive breast cancer in the United Arab Emirates.
    • Altinoz A, Al Ameri M, Qureshi W, Boush N, Nair SC, Abdel-Aziz A.
    • Breast. 2020 Jul 27;53:119-124. doi: 10.1016/j.breast.2020.07.005. Epub ahead of print.
    • Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.
    • Chapman-Davis E, Zhou ZN, Fields JC, Frey MK, Jordan B, Sapra KJ, Chatterjee-Paer S, Carlson AD, Holcomb KM.
    • J Gen Intern Med. 2020 Jul 27. doi: 10.1007/s11606-020-06064-x. Epub ahead of print.
    • Population genetic screening efficiently identifies carriers of autosomal dominant diseases.
    • Grzymski JJ, Elhanan G, Morales Rosado JA, Smith E, Schlauch KA, Read R, Rowan C, Slotnick N, Dabe S, Metcalf WJ, Lipp B, Reed H, Sharma L, Levin E, Kao J, Rashkin M, Bowes J, Dunaway K, Slonim A, Washington N, Ferber M, Bolze A, Lu JT.
    • Nat Med. 2020 Jul 27. doi: 10.1038/s41591-020-0982-5. Epub ahead of print.
    • Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?
    • Whitaker KD, Sheth D, Olopade OI.
    • Breast Cancer Res Treat. 2020 Jul 3. doi: 10.1007/s10549-020-05759-3. Epub ahead of print.
    • Review
    • Hereditary and breastfeeding factors are positively associated with the aetiology of mammary gland hyperplasia: a case-control study.
    • Gao H, Yang C, Fan J, Lan L, Pang D.
    • Int Health. 2020 Jun 18:ihaa028. doi: 10.1093/inthealth/ihaa028. Epub ahead of print.
    • Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
    • Okano N, Morizane C, Nomura S, Takahashi H, Tsumura H, Satake H, Mizuno N, Tsuji K, Shioji K, Asagi A, Yasui K, Kitagawa S, Kashiwada T, Ishiguro A, Kanai M, Ueno M, Ogura T, Shimizu S, Tobimatsu K, Motoya M, Nakashima K, Ikeda M, Okusaka T, Furuse J.
    • Int J Clin Oncol. 2020 Jun 13. doi: 10.1007/s10147-020-01721-x. Epub ahead of print.
    • Secondary Angiosarcoma With C-MYC Amplification Following Prophylactic Bilateral Mastectomy and Autologous Breast Reconstruction: Report of a Case and Review of the Literature.
    • Webb C, Partain N, Koduru P, Hwang H, Sarode VR.
    • Int J Surg Pathol. 2020 Jun 18:1066896920930100. doi: 10.1177/1066896920930100. Epub ahead of print.
    • Case report
    • Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.
    • Qureshi N, Dutton B, Weng S, Sheehan C, Chorley W, Robertson JFR, Kendrick D, Kai J.
    • Fam Cancer. 2020 Jun 11. doi: 10.1007/s10689-020-00188-z. Epub ahead of print.
    • Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.
    • Rosenberger LH, Thomas SM, Nimbkar SN, Hieken TJ, Ludwig KK, Jacobs LK, Miller ME, Gallagher KK, Wong J, Neuman HB, Tseng J, Hassinger TE, Jakub JW.
    • Ann Surg Oncol. 2020 Jun 5. doi: 10.1245/s10434-020-08480-z. Epub ahead of print.
    • Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.
    • Yoshihara K, Enomoto T, Aoki D, Watanabe Y, Kigawa J, Takeshima N, Inomata H, Hattori K, Jinushi M, Tsuda H, Sugiyama T.
    • Cancer Sci. 2020 Jun 3. doi: 10.1111/cas.14513. Epub ahead of print.
    • Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
    • Armel SR, Volenik A, Demsky R, Malcolmson J, Maganti M, McCuaig J.
    • Gynecol Oncol. 2020 Jun 3:S0090-8258(20)31082-9. doi: 10.1016/j.ygyno.2020.05.014. Epub ahead of print.
    • Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.
    • Chelmow D, Pearlman MD, Young A, Bozzuto L, Dayaratna S, Jeudy M, Kremer ME, Scott DM, O'Hara JS.
    • Obstet Gynecol. 2020 Jun;135(6):1457-1478. doi: 10.1097/AOG.0000000000003889.
    • Young onset breast cancer in Southern China - a 5-year clinico-pathological study from a multi-centre database.
    • Co M, Kwong A.
    • Cancer Treat Res Commun. 2020 May 30;24:100182. doi: 10.1016/j.ctarc.2020.100182. Epub ahead of print.
    • Diagnosing hereditary cancer predisposition in men with prostate cancer.
    • Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, Jackson M, Dolinsky JS, LaDuca H, Xu J, Black MH, Helfand BT.
    • Genet Med. 2020 May 22. doi: 10.1038/s41436-020-0830-5. Epub ahead of print.
    • Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
    • Tennen RI, Laskey SB, Koelsch BL, McIntyre MH, Tung JY.
    • Sci Rep. 2020 May 6;10(1):7669. doi: 10.1038/s41598-020-63466-x.
    • Combined associations of a polygenic risk score and classical risk factors with breast cancer risk.
    • Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, Michailidou K, Dennis J, Bolla MK, Wang Q, Jung A, Abu-Ful Z, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Freeman LEB, Becher H, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bernstein L, Bojesen SE, Brauch H, Brenner H, Brüning T, Cai Q, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chanock SJ, Chatterjee N, Chenevix-Trench G, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Dai JY, Earp HS, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fritschi L, Gabrielson M, Gago-Dominguez M, Gao C, Gapstur SM, Gaudet MM, Giles GG, González-Neira A, Guénel P, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Hatse S, Heyworth J, Holleczek B, Hoover RN, Hopper JL, Howell A, Hunter DJ; ABCTB Investigators; kConFab/AOCS Investigators, John EM, Jones ME, Kaaks R, Keeman R, Kitahara CM, Ko YD, Koutros S, Kurian AW, Lambrechts D, Marchand LL, Lee E, Lejbkowicz F, Linet M, Lissowska J, Llaneza A, MacInnis RJ, Martinez ME, Maurer T, McLean C, Neuhausen SL, Newman WG, Norman A, O'Brien KM, Olshan AF, Olson JE, Olsson H, Orr N, Perou CM, Pita G, Polley EC, Prentice RL, Rennert G, Rennert HS, Ruddy KJ, Sandler DP, Saunders C, Schoemaker MJ, Schöttker B, Schumacher F, Scott C, Scott RJ, Shu XO, Smeets A, Southey MC, Spinelli JJ, Stone J, Swerdlow AJ, Tamimi RM, Taylor JA, Troester MA, Vachon CM, van Veen EM, Wang X, Weinberg CR, Weltens C, Willett W, Winham SJ, Wolk A, Yang XR, Zheng W, Ziogas A, Dunning AM, Pharoah PDP, Schmidt MK, Kraft P, Easton DF, Milne RL, García-Closas M, Chang-Claude J.
    • J Natl Cancer Inst. 2020 May 2. pii: djaa056. doi: 10.1093/jnci/djaa056. [Epub ahead of print]
    • Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    • Demir S, Tozkir H, Gurkan H, Atli EI, Yalcintepe S, Atli E, Sezer YA, Eker D, Tuncbilek N, Tastekin E, Ozen Y, Cicin I.
    • J BUON. 2020 May-Jun;25(3):1337-1347.
    • Comparison of breast cancer incidence, clinicopathologic features, and risk factor prevalence in women aged 20-29 at diagnosis to those aged 30-39.
    • Limbach KE, Leon E, Pommier RF, Pommier SJ.
    • Breast J. 2020 May;26(5):1069-1070. doi: 10.1111/tbj.13783. Epub 2020 Feb 14.
    • National Minority Cancer Awareness Month: Is the Cancer in Your Family Hereditary?
    • Wu J.
    • FORCE Blog. 2020 Apr 22.
    • Blog post

    Blog post: Luck Is More Than Just A Rainbow: A Previvor’s Story. (FORCE Blog)

    • Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
    • Zeng C, Guo X, Wen W, Shi J, Long J, Cai Q, Shu XO, Xiang Y, Zheng W.
    • Breast Cancer Res Treat. 2020 Apr 21. doi: 10.1007/s10549-020-05643-0. [Epub ahead of print]
    • Comparison of mammography behaviors, health beliefs, and fear levels of women with and without familial breast cancer history.
    • Erdogan E, Tuzcu A.
    • Women Health. 2020 Apr 6:1-16. doi: 10.1080/03630242.2020.1746949. [Epub ahead of print]
    • Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History.
    • Patel AP, Wang M, Fahed AC, Mason-Suares H, Brockman D, Pelletier R, Amr S, Machini K, Hawley M, Witkowski L, Koch C, Philippakis A, Cassa CA, Ellinor PT, Kathiresan S, Ng K, Lebo M, Khera AV.
    • JAMA Netw Open. 2020 Apr 1;3(4):e203959. doi: 10.1001/jamanetworkopen.2020.3959.

    Press: Family History Insufficient to Determine High Risk of Gene-Linked CVD or Cancer. (Clinical OMICs)

    • Ethnic disparities in the frequency of cancer reported in family histories.
    • Maves H, Flodman P, Nathan D, Smith M.
    • J Genet Couns. 2020 Mar 28. doi: 10.1002/jgc4.1264. [Epub ahead of print]
    • Future Research Suggestions for Multigene Testing in Unselected Populations.
    • Jun I, Berger AL, Yaghjyan L.
    • JAMA Oncol. 2020 Mar 26. doi: 10.1001/jamaoncol.2020.0128. [Epub ahead of print]
    • Letter, Comment

    Original research:

    A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.

    Letter, Reply:

    Future Research Suggestions for Multigene Testing in Unselected Populations-Reply.

    • Evaluating Family History Links between Breast Cancer and Prostate Cancer Among PLCO Trial Participants.
    • Abdel-Rahman O.
    • Clin Breast Cancer. 2020 Mar 20. pii: S1526-8209(20)30061-6. doi: 10.1016/j.clbc.2020.03.005. [Epub ahead of print]
    • Factors shaping at-risk individuals' decisions to undergo genetic testing for cancer in Asia.
    • Sun S, Li ST, Ngeow J.
    • Health Soc Care Community. 2020 Mar 20. doi: 10.1111/hsc.12981. [Epub ahead of print]
    • Familial risk of breast cancer by dynamic, accumulative, and static definitions of family history.
    • Mukama T, Kharazmi E, Sundquist K, Sundquist J, Brenner H, Fallah M.
    • Cancer. 2020 Mar 10. doi: 10.1002/cncr.32815. [Epub ahead of print]
    • Breast cancer risk assessment in patients who test negative for a hereditary cancer syndrome.
    • Breit C, Ablah E, Ward M, Okut H, Tenofsky PL.
    • Am J Surg. 2020 Mar;219(3):430-433. doi: 10.1016/j.amjsurg.2019.10.015. Epub 2019 Oct 11.

    Commentary, Presentation:

    Discussion on: Breast cancer risk assessment in patients who test negative for a hereditary cancer syndrome.

    • A retrospective study on breast cancer presentation, risk factors, and protective factors in patients with a positive family history of breast cancer.
    • Liaw YY, Loong FS, Tan S, On SY, Khaw E, Chiew Y, Nordin R, Mat TN, Arulanantham S, Gandhi A.
    • Breast J. 2020 Mar;26(3):469-473. doi: 10.1111/tbj.13520. Epub 2019 Sep 4.
    • Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    • Su L, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32918. [Epub ahead of print]
    • Breast cancer suspected to originate from familial hereditary tumors: A case report.
    • Yamamoto S, Chishima T, Sugae S, Shibata Y, Yamada A.
    • Clin Case Rep. 2020 Feb 8;8(4):648-652. doi: 10.1002/ccr3.2698. eCollection 2020 Apr.
    • Transmission of X-linked Ovarian Cancer: Characterization and Implications.
    • Etter JL, Moysich K, Kohli S, Lele S, Odunsi K, Eng KH.
    • Diagnostics (Basel). 2020 Feb 7;10(2). pii: E90. doi: 10.3390/diagnostics10020090.
    • Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
    • Conz L, Mota BS, Bahamondes L, Dória MT, Derchain SFM, Rieira R, Sarian LO.
    • Acta Obstet Gynecol Scand. 2020 Jan 28. doi: 10.1111/aogs.13817. [Epub ahead of print]
    • Review
    • Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
    • Weidner AE, Liggin ME, Zuniga BI, Tezak AL, Wiesner GL, Pal T.
    • Cancer. 2020 Jan 22. doi: 10.1002/cncr.32715. [Epub ahead of print]
    • Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care.
    • Lee SI, Qureshi N, Dutton B, Kai J, Weng S.
    • J Community Genet. 2020 Jan 22. doi: 10.1007/s12687-020-00452-w. [Epub ahead of print]
    • Germline Variants in Driver Genes of Breast Cancer and Their Association with Familial and Early-Onset Breast Cancer Risk in a Chilean Population.
    • Fernandez-Moya A, Morales S, Arancibia T, Gonzalez-Hormazabal P, Tapia JC, Godoy-Herrera R, Reyes JM, Gomez F, Waugh E, Jara L.
    • Cancers (Basel). 2020 Jan 20;12(1). pii: E249. doi: 10.3390/cancers12010249.
    • Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
    • Ryu JM, Nam SJ, Kim SW, Lee JE, Chae BJ, Lee SK, Yu J.
    • Jpn J Clin Oncol. 2020 Jan 11. pii: hyz147. doi: 10.1093/jjco/hyz147. [Epub ahead of print]
    • Comparison of clinical features and oncologic outcomes between familial (non-hereditary) and hereditary breast cancer in Korean female patients.
    • Park CS, Park HY, Jung JH, Kim WW, Chae YS, Lee SJ, Park JY, Park JY, Lee J.
    • Asian J Surg. 2020 Jan 7. pii: S1015-9584(19)30880-2. doi: 10.1016/j.asjsur.2019.12.001. [Epub ahead of print]
    • Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation.
    • Teoh V, Tasoulis MK, Gui G.
    • Cancers (Basel). 2020 Jan 6;12(1). pii: E140. doi: 10.3390/cancers12010140.
    • Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk.
    • Kehm RD, Genkinger JM, MacInnis RJ, John EM, Phillips KA, Dite GS, Milne RL, Zeinomar N, Liao Y, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Whitaker KD, Friedlander M, Weideman PC, Glendon G, Nesci S, Investigators K, Andrulis IL, Buys SS, Daly MB, Hopper JL, Terry MB.
    • Cancer Res. 2020 Jan 1;80(1):116-125. doi: 10.1158/0008-5472.CAN-19-1847. Epub 2019 Oct 2.

    Commentary:

    Physical Activity and Breast Cancer: Focusing on High-Risk Subgroups and Putting Recommendations in Context.

    Research news: Study: Women who exercise have lower breast cancer risk whether or not they have a family history of breast cancer. (FORCE. XRAYS.)

    • Importance of family history and indications for genetic testing.
    • Wood ME, Rehman HT, Bedrosian I.
    • Breast J. 2020 Jan;26(1):100-104. doi: 10.1111/tbj.13722. Epub 2019 Dec 22.
    • Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    • Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, Ahmed M, Barwell J, Brady AF, Brewer C, Cook J, Davidson R, Donaldson A, Eason J, Gregory H, Henderson A, Izatt L, Kennedy MJ, Miller C, Morrison PJ, Murray A, Ong KR, Porteous M, Pottinger C, Rogers MT, Side L, Snape K, Walker L, Tischkowitz M, Eeles R, Easton DF, Antoniou AC.
    • Eur Urol. 2020 Jan;77(1):24-35. doi: 10.1016/j.eururo.2019.08.025. Epub 2019 Sep 6.

    Editorial:

    How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?

    Comment:

    Re: Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

    Editorial:

    The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?

    • Prediction and clinical utility of a contralateral breast cancer risk model.
    • Giardiello D, Steyerberg EW, Hauptmann M, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, Czene K, Devilee P, Dunning AM, Easton DF, Eccles DM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Haeberle L, Haiman CA, Hall P, Hamann U, Hopper JL, Jager A, Jakubowska A, Jung A, Keeman R, Kramer I, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Manoochehri M, Mariani L, Nevanlinna H, Oldenburg HSA, Pelders S, Pharoah PDP, Shah M, Siesling S, Smit VTHBM, Southey MC, Tapper WJ, Tollenaar RAEM, van den Broek AJ, van Deurzen CHM, van Leeuwen FE, van Ongeval C, Van't Veer LJ, Wang Q, Wendt C, Westenend PJ, Hooning MJ, Schmidt MK.
    • Breast Cancer Res. 2019 Dec 17;21(1):144. doi: 10.1186/s13058-019-1221-1.
    • Tea consumption and breast cancer risk in a cohort of women with family history of breast cancer.
    • Zhang D, Nichols HB, Troester M, Cai J, Bensen JT, Sandler DP.
    • Int J Cancer. 2019 Dec 13. doi: 10.1002/ijc.32824. [Epub ahead of print]
    • Study: Women who exercise have lower breast cancer risk whether or not they have a family history of breast cancer.
    • [No author given.]
    • FORCE. XRAYS. 2019 Dec 6.

    Original research:

    Recreational physical activity is associated with reduced breast cancer risk in adult women at high risk for breast cancer: a cohort study of women selected for familial and genetic risk.

    • Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing.
    • Dominguez-Valentin M, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Holth A, Capella G, Davidson B, Evans DG, Martins A, Møller P, Hovig E.
    • Sci Rep. 2019 Dec 6;9(1):18555. doi: 10.1038/s41598-019-54517-z.

    Press: Gene Panel Finds Pathogenic Variants Missed by Standard Tests in 5 Percent of Familial Cancer Cases. (GenomeWeb)

    • Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.
    • Jones T, Trivedi MS, Jiang X, Silverman T, Underhill M, Chung WK, Kukafka R, Crew KD.
    • J Cancer Educ. 2019 Dec 4. doi: 10.1007/s13187-019-01646-8. [Epub ahead of print]

    Research news: Study: Racial and ethnic differences in genetic testing among young breast cancer survivors. (FORCE. XRAYS.)

    • Paraben Content in Adjacent Normal-malignant Breast Tissues from Women with Breast Cancer.
    • Amin MM, Tabatabaeian M, Chavoshani A, Amjadi E, Hashemi M, Ebrahimpour K, Klishadi R, Khazaei S, Mansourian M.
    • Biomed Environ Sci. 2019 Dec;32(12):893-904. doi: 10.3967/bes2019.112.
    • Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.
    • [No authors listed]
    • Obstet Gynecol. 2019 Dec;134(6):e143-e149. doi: 10.1097/AOG.0000000000003562.

    Summary:

    Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793.

    • Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC).
    • Zeinomar N, Knight JA, Genkinger JM, Phillips KA, Daly MB, Milne RL, Dite GS, Kehm RD, Liao Y, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators, Andrulis IL, Buys SS, John EM, MacInnis RJ, Hopper JL, Terry MB.
    • Breast Cancer Res. 2019 Nov 28;21(1):128. doi: 10.1186/s13058-019-1213-1.
    • Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    • Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu Y, Xie Y.
    • Breast Cancer Res Treat. 2019 Nov 25. doi: 10.1007/s10549-019-05483-7. [Epub ahead of print]
    • Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication.
    • Evans DG, Edwards M, Duffy SW; Cancer Genetics Group clinical leads, Tischkowitz M.
    • Br J Cancer. 2019 Nov 25. doi: 10.1038/s41416-019-0631-2. [Epub ahead of print]
    • Germline mutations in Thai patients with nonmucinous epithelial ovarian cancer.
    • Manchana T, Phowthongkum P, Teerapakpinyo C.
    • World J Clin Oncol. 2019 Nov 24;10(11):358-368. doi: 10.5306/wjco.v10.i11.358.
    • Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study.
    • Abildgaard J, Ahlström MG, Nielsen DL, Daugaard G, Lindegaard B, Obel N, Lidegaard Ø.
    • Psychooncology. 2019 Nov 16. doi: 10.1002/pon.5290. [Epub ahead of print]
    • Synergistic Effect Between Full-Term Pregnancy/Breastfeeding And Familial Susceptibility On Breast Cancer Risk.
    • Lin H, Wen J, Hong L, Chen Y, Wu Y, Zhong S.
    • Cancer Manag Res. 2019 Nov 15;11:9743-9748. doi: 10.2147/CMAR.S231426. eCollection 2019.
    • Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer.
    • Mukama T, Kharazmi E, Xing X, Sundquist K, Sundquist J, Brenner H, Fallah M.
    • JAMA Oncol. 2019 Nov 14. doi: 10.1001/jamaoncol.2019.3876. [Epub ahead of print]

    Editorial:

    Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines.

    Editorial:

    Breast cancer screening programs: does one risk fit all?

    Letter, Comment:

    Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer.

    Letter, Reply:

    Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer-Reply.

    • 2019 exceptional surveillance of familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (NICE guideline CG164) [Internet].
    • NICE Surveillance programme project team: Nolan K, Allaby M, McFarlane E, Haynes C.
    • London: National Institute for Health and Care Excellence (UK); 2019 Nov.
    • Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer.
    • Glentis S, Dimopoulos AC, Rouskas K, Ntritsos G, Evangelou E, Narod SA, Mes-Masson AM, Foulkes WD, Rivera B, Tonin PN, Ragoussis J, Dimas AS.
    • Front Genet. 2019 Oct 18;10:1005. doi: 10.3389/fgene.2019.01005. eCollection 2019.
    • Interval Breast Cancer Risk Associations with Breast Density, Family History, and Breast Tissue Ageing.
    • Nguyen TL, Li S, Dite GS, Aung YK, Evans CF, Trinh HN, Baglietto L, Stone J, Song YM, Sung J, English DR, Jenkins MA, Dugué PA, Milne RL, Southey MC, Giles GG, Pike MC, Hopper JL.
    • Int J Cancer. 2019 Oct 14. doi: 10.1002/ijc.32731. [Epub ahead of print]
    • Mammographic Breast Density Assessed with Fully Automated Method and its Risk for Breast Cancer.
    • J Clin Imaging Sci. 2019 Oct 11;9:43. doi: 10.25259/JCIS_70_2019. eCollection 2019.
    • Patterns and Predictors of Genetic Referral among Ovarian Cancer Patients at a National Cancer Institute Comprehensive Cancer Center.
    • Mallen AR, Conley CC, Townsend MK, Wells A, Boac BM, Todd S, Gandhi A, Kuznicki M, Augusto BM, McIntyre M, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Clin Genet. 2019 Oct 10. doi: 10.1111/cge.13654. [Epub ahead of print]
    • Considerations when using breast cancer risk models for women with negative BRCA1/BRCA2 mutation results.
    • MacInnis RJ, Liao Y, Knight JA, Milne RL, Whittemore AS, Chung WK, Leoce N, Buchsbaum R, Zeinomar N, Dite GS, Southey MC, Goldgar D, Giles GG, McLachlan SA, Weideman PC, Nesci S, Friedlander ML, Glendon G; kConFab Investigators, Andrulis IL, John EM, Daly MB, Buys SS, Phillips KA, Hopper JL, Terry MB.
    • J Natl Cancer Inst. 2019 Oct 4. pii: djz194. doi: 10.1093/jnci/djz194. [Epub ahead of print]
    • A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    • Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3323. [Epub ahead of print]

    CME Audio Interview: Cost-effectiveness of Multigene Testing for All Patients With Breast Cancer. (JN Learning : JAMA Oncology)

    Press: Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients. (GenomeWeb)

    Letter, Comment:

    Future Research Suggestions for Multigene Testing in Unselected Populations.

    Letter, Reply:

    Future Research Suggestions for Multigene Testing in Unselected Populations—Reply.

    • The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS.
    • Valero MG, Zabor EC, Park A, Gilbert E, Newman A, King TA, Pilewskie ML.
    • Ann Surg Oncol. 2019 Sep 26. doi: 10.1245/s10434-019-07814-w. [Epub ahead of print]
    • Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing.
    • Greenberg S, Buys SS, Edwards SL, Espinel W, Fraser A, Gammon A, Hafen B, Herget KA, Kohlmann W, Roundy C, Sweeney C.
    • Cancer Med. 2019 Sep 18. doi: 10.1002/cam4.2534. [Epub ahead of print]
    • Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes.
    • Gao Y, Goldberg JE, Young TK, Babb JS, Moy L, Heller SL.
    • Radiology. 2019 Sep 17:190971. doi: 10.1148/radiol.2019190971. [Epub ahead of print]

    Press: Men at High Risk for Breast Cancer May Benefit From Screening. (Medscape Oncology)

    • Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study.
    • Rashid MU, Muhammad N, Naeemi H, Khan FA, Hassan M, Faisal S, Gull S, Amin A, Loya A, Hamann U.
    • Hered Cancer Clin Pract. 2019 Sep 11;17:27. doi: 10.1186/s13053-019-0125-5. eCollection 2019.
    • A germline alteration of ERBB2 increases the risk of breast cancer in Chinese Han women with a familial history of malignant tumors.
    • Ju Y, Wang L, Ta S, Shu R, Yang S, Gao X, Song H, Liu L.
    • Oncol Lett. 2019 Sep;18(3):2885-2890. doi: 10.3892/ol.2019.10646. Epub 2019 Jul 22.
    • Risk factors for triple negative breast cancer among Latina women.
    • Rey-Vargas L, Sanabria Salas MC, Fejerman L, Serrano-Gómez SJ.
    • Cancer Epidemiol Biomarkers Prev. 2019 Aug 27. pii: cebp.0035.2019. doi: 10.1158/1055-9965.EPI-19-0035. [Epub ahead of print]
    • Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.
    • Terkelsen T, Rønning H, Skytte AB.
    • Acta Oncol. 2019 Aug 5:1-6. doi: 10.1080/0284186X.2019.1648860. [Epub ahead of print]
    • Does multilocus inherited neoplasia alleles syndrome have severe clinical expression?
    • Stradella A, Del Valle J, Rofes P, Feliubadaló L, Grau Garces È, Velasco À, González S, Vargas G, Izquierdo Á, Campos O, Tornero E, Navarro M, Balmaña-Gelpi J, Capellá G, Pineda M, Brunet J, Lázaro C.
    • J Med Genet. 2019 Aug;56(8):521-525. doi: 10.1136/jmedgenet-2018-105700. Epub 2018 Dec 22.
    • Response to Lee et al 2019: Essential to frame study implications within the context of prior findings from enriched cohorts for underlying familial risk of breast cancer.
    • Terry MB, Zeinomar N.
    • Occup Environ Med. 2019 Aug;76(8):592. doi: 10.1136/oemed-2019-105936.
    • Letter, Comment

    Original research:

    Women's occupational exposure to polycyclic aromatic hydrocarbons and risk of breast cancer.

    • Combined hormonal contraceptives in BRCA gene mutation carriers: why not?
    • Grandi G, Sammarini M, Chiara Del Savio M, Toss A, Facchinetti F.
    • Eur J Contracept Reprod Health Care. 2019 Jul 30:1-3. doi: 10.1080/13625187.2019.1647335. [Epub ahead of print]
    • Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.
    • Zeinomar N, Phillips KA, Daly MB, Milne RL, Dite GS, MacInnis RJ, Liao Y, Kehm RD, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators, Andrulis IL, Buys SS, John EM, Hopper JL, Terry MB.
    • Int J Cancer. 2019 Jul 15;145(2):370-379. doi: 10.1002/ijc.32112. Epub 2019 Feb 20.
    • Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria.
    • Xicola RM, Li S, Rodriguez N, Reinecke P, Karam R, Speare V, Black MH, LaDuca H, Llor X.
    • J Med Genet. 2019 Jul 11. pii: jmedgenet-2019-105991. doi: 10.1136/jmedgenet-2019-105991. [Epub ahead of print]
    • Mammographic screening in male patients at high risk for breast cancer: is it worth it?
    • Marino MA, Gucalp A, Leithner D, Keating D, Avendano D, Bernard-Davila B, Morris EA, Pinker K, Jochelson MS.
    • Breast Cancer Res Treat. 2019 Jul 6. doi: 10.1007/s10549-019-05338-1. [Epub ahead of print]
    • Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.
    • Fortner RT, Poole EM, Wentzensen NA, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Clendenen TV, Fournier A, Fraser G, Gapstur SM, Gaudet MM, Giles GG, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Kaaks R, Kirsh VA, Knutsen S, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Milne RL, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sánchez MJ, Schairer C, Schouten LJ, Tjonneland A, Townsend MK, Travis RC, Trichopoulou A, van den Brandt PA, Vineis P, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS.
    • Int J Cancer. 2019 Jul 1;145(1):58-69. doi: 10.1002/ijc.32075. Epub 2019 Jan 14.
    • Developing a community-based breast cancer risk prediction tool for resource-poor settings.
    • Pillai D, Hossain SS, Chattu VK.
    • J Educ Health Promot. 2019 Jun 27;8:106. doi: 10.4103/jehp.jehp_384_18. eCollection 2019.
    • Predictors of mammographic density among women with a strong family history of breast cancer.
    • Moran O, Eisen A, Demsky R, Blackmore K, Knight JA, Panchal S, Ginsburg O, Zbuk K, Yaffe M, Metcalfe KA, Narod SA, Kotsopoulos J.
    • BMC Cancer. 2019 Jun 26;19(1):631. doi: 10.1186/s12885-019-5855-2.
    • Annual versus biennial screening: diagnostic accuracy among concurrent cohorts within the Ontario Breast Screening Program.
    • Chiarelli AM, Blackmore KM, Mirea L, Done SJ, Majpruz V, Weerasinghe A, Rabeneck L, Muradali D.
    • J Natl Cancer Inst. 2019 Jun 24. pii: djz131. doi: 10.1093/jnci/djz131. [Epub ahead of print]
    • Rate of BRCA mutation in patients tested under NCCN genetic testing criteria.
    • Beck AC, Yuan H, Liao J, Imperiale P, Shipley K, Erdahl LM, Sugg SL, Weigel RJ, Lizarraga IM.
    • Am J Surg. 2019 Jun 19. pii: S0002-9610(19)30247-8. doi: 10.1016/j.amjsurg.2019.06.012. [Epub ahead of print]
    • Familial aggregation of early-onset cancers.
    • Heikkinen SM, Madanat-Harjuoja LM, Seppä KJ, Rantanen ME, Hirvonen EM, Malila NK, Pitkäniemi JM.
    • Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32512. [Epub ahead of print]
    • Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines.
    • Neben CL, Zimmer AD, Stedden W, van den Akker J, O'Connor R, Chan RC, Chen E, Tan Z, Leon A, Ji J, Topper S, Zhou AY.
    • J Mol Diagn. 2019 Jun 10. pii: S1525-1578(18)30334-9. doi: 10.1016/j.jmoldx.2019.03.001. [Epub ahead of print]

    Press: Multi-Gene Panel Testing Finds Pathogenic Variant Carriers Missed Under Current Testing Guidelines. (GenomeWeb)

    • High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.
    • Chen J, Haanpää MK, Gruber JJ, Jäger N, Ford JM, Snyder MP.
    • Clin Cancer Res. 2019 Jun 7. pii: clincanres.2423.2018. doi: 10.1158/1078-0432.CCR-18-2423. [Epub ahead of print]
    • Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach.
    • Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD.
    • Public Health Genomics. 2019 Jun 4:1-11. doi: 10.1159/000499852. [Epub ahead of print]
    • Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients.
    • Fernandes GC, Felicio PS, Michelli RAD, Coelho AS, Scapulatempo-Neto C, Palmero EI.
    • Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1655-1660. doi: 10.31557/APJCP.2019.20.6.1655.
    • Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
    • Ozanne EM, Howe R, Mallinson D, Esserman L, Van't Veer LJ, Kaplan CP.
    • J Genet Couns. 2019 Jun;28(3):507-515. doi: 10.1002/jgc4.1051. Epub 2019 Jan 21.
    • Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.
    • André S, Pereira T, Silva F, Machado P, Vaz F, Aparício M, Silva GL, Pinto AE.
    • Mol Clin Oncol. 2019 Jun;10(6):644-654. doi: 10.3892/mco.2019.1841. Epub 2019 Apr 8.
    • Breast Density in a Contemporary Cohort of Women With Ductal Carcinoma In Situ (DCIS).
    • Gooch JC, Chun J, Kaplowitz E, Kurz E, Guth A, Lee J, Schnabel F.
    • Ann Surg Oncol. 2019 May 30. doi: 10.1245/s10434-019-07479-5. [Epub ahead of print]
    • Breast cancer histologic subtypes show excess familial clustering.
    • Henry NL, Cannon-Albright LA.
    • Cancer. 2019 May 23. doi: 10.1002/cncr.32198. [Epub ahead of print]
    • Copy number alterations associated with clinical features in an underrepresented population with breast cancer.
    • Rodrigues-Peres RM, de S Carvalho B, Anurag M, Lei JT, Conz L, Gonçalves R, Cardoso Filho C, Ramalho S, de Paiva GR, Derchain SFM, Lopes-Cendes I, Ellis MJ, Sarian LO.
    • Mol Genet Genomic Med. 2019 May 16:e750. doi: 10.1002/mgg3.750. [Epub ahead of print]
    • Associations between XRCC3 Thr241Met polymorphisms and breast cancer risk: systematic-review and meta-analysis of 55 case-control studies.
    • Dashti S, Taherian-Esfahani Z, Keshtkar A, Ghafouri-Fard S.
    • BMC Med Genet. 2019 May 10;20(1):79. doi: 10.1186/s12881-019-0809-8.
    • Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey.
    • Allen CG, Roberts M, Guan Y.
    • J Pers Med. 2019 May 10;9(2). pii: E26. doi: 10.3390/jpm9020026.
    • Performance of Screening Breast MRI across Women with Different Elevated Breast Cancer Risk Indications.
    • Sippo DA, Burk KS, Mercaldo SF, Rutledge GM, Edmonds C, Guan Z, Hughes KS, Lehman CD.
    • Radiology. 2019 May 7:181136. doi: 10.1148/radiol.2019181136. [Epub ahead of print]
    • Nutrition knowledge, attitudes, and practice towards breast cancer prevention among the female population of Iran University of medical science students.
    • Raji Lahiji M, Dehdari T, Shokouhi Shoormasti R, Hosseini AF, Navaei M, Zarrati M.
    • Nutr Cancer. 2019 May 6:1-10. doi: 10.1080/01635581.2019.1607410. [Epub ahead of print]
    • Interaction between genetic ancestry and common breast cancer susceptibility variants in Colombian women.
    • Torres D, Lorenzo Bermejo J, Garcia Mesa K, Gilbert M, Briceño I, Pohl-Zeidler S, González Silos R, Boekstegers F, Plass C, Hamann U.
    • Int J Cancer. 2019 May 1;144(9):2181-2191. doi: 10.1002/ijc.32023. Epub 2019 Jan 5.
    • Effect of Diets, Familial History, and Alternative Therapies on Genomic Instability of Breast Cancer Patients.
    • Paz MFCJ, Gomes Júnior AL, de Alencar MVOB, Tabrez S, Islam MT, Jabir NR, Oves M, Alam MZ, Asghar MN, Ali ES, da Conceição Machado K, da Conceição Machado K, da Silva FCC, Sobral ALP, de Castro E Sousa JM, de Moraes GP, Mishra SK, da Silva J, de Carvalho Melo-Cavalcante AA.
    • Appl Biochem Biotechnol. 2019 May;188(1):282-296. doi: 10.1007/s12010-018-2918-9. Epub 2018 Nov 15.
    • Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk.
    • Weiss A, Grossmith S, Cutts D, Mikami SA, Suskin JA, Graichen MK, Rojas NA, Pace LE, Joyce E, Rhei E, Scheib R, Bychkovsky B, Garber JE, Morganstern D, King TA.
    • Breast Cancer Res Treat. 2019 May;175(1):229-237. doi: 10.1007/s10549-018-05116-5. Epub 2019 Jan 21.
    • Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J, Mitchell CL, Schlecht H, Woodward ER, Lallo FI, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR.
    • J Med Genet. 2019 May;56(5):301-307. doi: 10.1136/jmedgenet-2018-105792. Epub 2019 Jan 25.
    • Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
    • McGuinness JE, Trivedi MS, Silverman T, Marte A, Mata J, Kukafka R, Crew KD.
    • Cancer Genet. 2019 Apr 24. pii: S2210-7762(19)30059-6. doi: 10.1016/j.cancergen.2019.04.063. [Epub ahead of print]
    • Hereditary Breast Cancer Risk Analysis in Uninsured Mexican-Origin Women Living in the U.S.-Mexico Border Region.
    • Salinas JJ, Roy R, Dwivedi AK, Shokar NK.
    • Hisp Health Care Int. 2019 Apr 12:1540415319837850. doi: 10.1177/1540415319837850. [Epub ahead of print]
    • Epidemiological characteristics of and risk factors for breast cancer in the world.
    • Momenimovahed Z, Salehiniya H.
    • Breast Cancer (Dove Med Press). 2019 Apr 10;11:151-164. doi: 10.2147/BCTT.S176070. eCollection 2019.
    • Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    • Shahi RB, De Brakeleer S, Caljon B, Pauwels I, Bonduelle M, Joris S, Fontaine C, Vanhoeij M, Van Dooren S, Teugels E, De Grève J.
    • BMC Cancer. 2019 Apr 4;19(1):313. doi: 10.1186/s12885-019-5494-7.
    • Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The "Opt-Out" Process.
    • McGee J, Peart TM, Foley N, Bertrand M, Prefontaine M, Sugimoto A, Ettler H, Welch S, Panabaker K.
    • J Oncol. 2019 Apr 2;2019:6029097. doi: 10.1155/2019/6029097. eCollection 2019.
    • Predictive Power of PEN-3 Model Constructs in Breast Cancer Screening Behaviors among Teachers: A Cross- Sectional Study in Central Iran.
    • Moghaddam ES, Shahnazi H, Hassanzadeh A.
    • Eur J Breast Health. 2019 Apr 1;15(2):105-110. doi: 10.5152/ejbh.2019.4417. eCollection 2019 Apr.
    • Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy.
    • Grobmyer SR, Pederson HJ, Valente SA, Al-Hilli Z, Radford D, Djohan R, Yetman R, Eng C, Crowe JP.
    • BJS Open. 2018 Nov 26;3(2):169-173. doi: 10.1002/bjs5.50117. eCollection 2019 Apr.
    • Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis.
    • Akdeniz D, Schmidt MK, Seynaeve CM, McCool D, Giardiello D, van den Broek AJ, Hauptmann M, Steyerberg EW, Hooning MJ.
    • Breast. 2019 Apr;44:1-14. doi: 10.1016/j.breast.2018.11.005. Epub 2018 Dec 6.
    • Review/Meta-Analysis
    • Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    • Yang Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Zhang J, Xie Y.
    • Breast Cancer Res Treat. 2019 Apr;174(3):639-647. doi: 10.1007/s10549-018-05124-5. Epub 2019 Jan 3.
    • Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk.
    • Hamada T, Yuan C, Yurgelun MB, Perez K, Khalaf N, Morales-Oyarvide V, Babic A, Nowak JA, Rubinson DA, Giannakis M, Ng K, Kraft P, Stampfer MJ, Giovannucci EL, Fuchs CS, Ogino S, Wolpin BM.
    • Br J Cancer. 2019 Apr;120(8):848-854. doi: 10.1038/s41416-019-0426-5. Epub 2019 Mar 14.
    • Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    • Singer CF, Tan YY, Muhr D, Rappaport C, Gschwantler-Kaulich D, Grimm C, Polterauer S, Pfeiler G, Berger A, Tea MM.
    • Cancer Med. 2019 Apr;8(4):1875-1881. doi: 10.1002/cam4.2000. Epub 2019 Mar 1.
    • 10-year performance of four models of breast cancer risk: a validation study.
    • Terry MB, Liao Y, Whittemore AS, Leoce N, Buchsbaum R, Zeinomar N, Dite GS, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, John EM, Phillips KA, Daly MB, Buys SS, Hopper JL, MacInnis RJ.
    • Lancet Oncol. 2019 Apr;20(4):504-517. doi: 10.1016/S1470-2045(18)30902-1. Epub 2019 Feb 21.

    Commentary:

    Assessment of breast cancer risk: which tools to use?

    • Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
    • Feng L, Jin F.
    • Oncol Lett. 2019 Apr;17(4):3687-3700. doi: 10.3892/ol.2019.10046. Epub 2019 Feb 18.
    • Effect of Background Parenchymal Enhancement on Cancer Risk Across Different High-Risk Patient Populations Undergoing Screening Breast MRI.
    • Sippo DA, Rutledge GM, Burk KS, Mercaldo SF, Dontchos BN, Edmonds CE, Lehman CD.
    • AJR Am J Roentgenol. 2019 Mar 19:1-7. doi: 10.2214/AJR.18.20566. [Epub ahead of print]
    • Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result.
    • Stafford L, Flehr A, Judd F, Lindeman GJ, Gibson P, Komiti A, Mann GB, Kentwell M.
    • J Community Genet. 2019 Mar 27. doi: 10.1007/s12687-019-00415-w. [Epub ahead of print]
    • Performance of Screening Ultrasonography as an Adjunct to Screening Mammography in Women Across the Spectrum of Breast Cancer Risk.
    • Lee JM, Arao RF, Sprague BL, Kerlikowske K, Lehman CD, Smith RA, Henderson LM, Rauscher GH, Miglioretti DL.
    • JAMA Intern Med. 2019 Mar 18. doi: 10.1001/jamainternmed.2018.8372. [Epub ahead of print]
    • BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    • Kwon JS, Tinker AV, Hanley GE, Pansegrau G, Sun S, Carey MS, Schrader I.
    • Gynecol Oncol. 2019 Mar;152(3):459-464. doi: 10.1016/j.ygyno.2018.10.014.
    • Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing.
    • Fulk K, Milam MR, Li S, Yussuf A, Black MH, Chao EC, LaDuca H, Stany MP.
    • Gynecol Oncol. 2019 Mar;152(3):612-617. doi: 10.1016/j.ygyno.2018.12.021. Epub 2019 Jan 3.
    • BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    • Liu Y, Ide Y, Inuzuka M, Tazawa S, Kanada Y, Matsunaga Y, Kuwayama T, Sawada T, Akashi-Tanaka S, Nakamura S.
    • Mol Genet Genomic Med. 2019 Mar;7(3):e493. doi: 10.1002/mgg3.493. Epub 2019 Jan 16.
    • The influence of BRCA variants of unknown significance on cancer risk management decision-making.
    • Chern JY, Lee SS, Frey MK, Lee J, Blank SV.
    • J Gynecol Oncol. 2019 Feb 27. doi: 10.3802/jgo.2019.30.e60. [Epub ahead of print]

    Editorial:

    Clinical significance of variants of unknown significances in BRCA genes.

    • Association between hereditary predisposition to common cancers and congenital multimalformations.
    • Kwiatkowski F, Perthus I, Uhrhammer N, Francannet C, Arbre M, Bidet Y, Bignon YJ.
    • Congenit Anom (Kyoto). 2019 Feb 20. doi: 10.1111/cga.12329. [Epub ahead of print]
    • Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015.
    • Knerr S, Bowles EJA, Leppig KA, Buist DSM, Gao H, Wernli KJ.
    • J Natl Cancer Inst. 2019 Feb 8. doi: 10.1093/jnci/djz008. [Epub ahead of print]

    Editorial:

    Persistent underutilization of BRCA1/2 testing suggest the need for new approaches to genetic testing delivery.

    • Heterogeneity in risk factors for ductal and lobular breast carcinomas: A case-control study.
    • Dianatinasab M, Fararouei M, Daneshi N, Rezaian S, Mohammadianpanah M, Chaman R, Ghiasvand R.
    • Int J Cancer. 2019 Feb 4. doi: 10.1002/ijc.32182. [Epub ahead of print]
    • Association of Prepubertal and Adolescent Androgen Concentrations With Timing of Breast Development and Family History of Breast Cancer.
    • Houghton LC, Knight JA, Wei Y, Romeo RD, Goldberg M, Andrulis IL, Bradbury AR, Buys SS, Daly MB, John EM, Chung WK, Santella RM, Stanczyk FZ, Terry MB.
    • JAMA Netw Open. 2019 Feb 1;2(2):e190083. doi: 10.1001/jamanetworkopen.2019.0083.
    • Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer.
    • Wendt C, Margolin S.
    • Acta Oncol. 2019 Feb;58(2):135-146. doi: 10.1080/0284186X.2018.1529428. Epub 2019 Jan 3.
    • Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.
    • Yoon TI, Kwak BS, Yi OV, Kim S, Um E, Yun KW, Shin HN, Lee S, Sohn G, Chung IY, Kim J, Ko BS, Lee JW, Son BH, Ahn SH, Kim HJ.
    • Breast Cancer Res Treat. 2019 Feb;173(3):657-665. doi: 10.1007/s10549-018-5031-4. Epub 2018 Oct 30.
    • Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
    • Hanley GE, McAlpine JN, Cheifetz R, Schrader KA, McCullum M, Huntsman D.
    • Curr Oncol. 2019 Feb;26(1):e17-e23. doi: 10.3747/co.26.4068. Epub 2019 Feb 1.
    • Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    • Ohmoto A, Yachida S, Morizane C.
    • Int J Mol Sci. 2019 Jan 29;20(3). pii: E561. doi: 10.3390/ijms20030561.
    • Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    • Cotrim DP, Ribeiro ARG, Paixão D, de Queiroz Soares DC, Jbili R, Pandolfi NC, Cezana C, de Cássia Mauro C, Mantoan H, Bovolim G, de Brot L, Torrezan GT, Carraro DM, Baiocchi G, da Cruz Formiga MN, da Costa AABA.
    • BMC Cancer. 2019 Jan 3;19(1):4. doi: 10.1186/s12885-018-5235-3.
    • Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies.
    • Nichols HB, Schoemaker MJ, Cai J, Xu J, Wright LB, Brook MN, Jones ME, Adami HO, Baglietto L, Bertrand KA, Blot WJ, Boutron-Ruault MC, Dorronsoro M, Dossus L, Eliassen AH, Giles GG, Gram IT, Hankinson SE, Hoffman-Bolton J, Kaaks R, Key TJ, Kitahara CM, Larsson SC, Linet M, Merritt MA, Milne RL, Pala V, Palmer JR, Peeters PH, Riboli E, Sund M, Tamimi RM, Tjønneland A, Trichopoulou A, Ursin G, Vatten L, Visvanathan K, Weiderpass E, Wolk A, Zheng W, Weinberg CR, Swerdlow AJ, Sandler DP.
    • Ann Intern Med. 2019 Jan 1;170(1):22-30. doi: 10.7326/M18-1323. Epub 2018 Dec 11.

    Editorial, Comment:

    Learning From Temporal Relationships: Childbirth and Breast Cancer Risk.

    Research news: Breast cancer risk increases modestly after childbirth. (FORCE. XRAYS.)

    • Relationship between Background Parenchymal Enhancement on High-risk Screening MRI and Future Breast Cancer Risk.
    • Grimm LJ, Saha A, Ghate SV, Kim C, Soo MS, Yoon SC, Mazurowski MA.
    • Acad Radiol. 2019 Jan;26(1):69-75. doi: 10.1016/j.acra.2018.03.013. Epub 2018 Mar 27.
    • Adult Physical Activity and Breast Cancer Risk in Women with a Family History of Breast Cancer.
    • Niehoff NM, Nichols HB, Zhao S, White AJ, Sandler DP.
    • Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):51-58. doi: 10.1158/1055-9965.EPI-18-0674. Epub 2018 Oct 17.
    • Second primary cancer after female breast cancer: Familial risks and cause of death.
    • Zheng G, Hemminki A, Försti A, Sundquist J, Sundquist K, Hemminki K.
    • Cancer Med. 2019 Jan;8(1):400-407. doi: 10.1002/cam4.1899. Epub 2018 Nov 26.
    • Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
    • Lee EG, Kang HJ, Lim MC, Park B, Park SJ, Jung SY, Lee S, Kang HS, Park SY, Park B, Joo J, Han JH, Kong SY, Lee ES.
    • Cancer Res Treat. 2019 Jan;51(1):280-288. doi: 10.4143/crt.2018.079. Epub 2018 May 4.
    • Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer.
    • Evans DG, Thomas S, Caunt J, Burch A, Brentnall AR, Roberts L, Howell A, Wilson M, Fox R, Hillier S, Sibbering DM, Moss S, Wallis MG, Eccles DM; FH02 study group, Duffy S.
    • EClinicalMedicine. 2019 Jan;7:39-46. doi: 10.1016/j.eclinm.2019.01.005.
    • Preventative Health and Risk Behaviors Among Adolescent Girls With and Without Family Histories of Breast Cancer.
    • Schwartz LA, Henry-Moss D, Egleston B, Patrick-Miller L, Markman E, Daly M, Tuchman L, Moore C, Rauch PK, Karpink K, Sands CB, Domchek SM, Bradbury AR.
    • J Adolesc Health. 2019 Jan;64(1):116-123. doi: 10.1016/j.jadohealth.2018.07.011. Epub 2018 Oct 6.
    • Women's occupational exposure to polycyclic aromatic hydrocarbons and risk of breast cancer.
    • Lee DG, Burstyn I, Lai AS, Grundy A, Friesen MC, Aronson KJ, Spinelli JJ.
    • Occup Environ Med. 2019 Jan;76(1):22-29. doi: 10.1136/oemed-2018-105261.

    Letter, Comment:

    Response to Lee et al 2019: Essential to frame study implications within the context of prior findings from enriched cohorts for underlying familial risk of breast cancer.

    • Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report.
    • Sin M, McGuinness JE, Trivedi MS, Vanegas A, Silverman TB, Crew KD, Kukafka R.
    • AMIA Annu Symp Proc. 2018 Dec 5;2018:970-978. eCollection 2018.
    • [Genetic profiling in the diagnosis of hereditary prostate cancer: Where do we stand?]
    • Boehm K, Thomas C, Tsaur I.
    • Aktuelle Urol. 2018 Dec;49(6):525-529. doi: 10.1055/a-0755-7360. Epub 2018 Dec 6.
    • Review, [Article in German]
    • Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?
    • Hall ET, Parikh D, Caswell-Jin JL, Gupta T, Mills MA, Kingham KE, Koff R, Ford JM, Kurian AW.
    • JCO Precis Oncol. [2018 Nov 8];2:1-10. doi: 10.1200/PO.18.00167.
    • Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC).
    • Hopper JL, Dite GS, MacInnis RJ, Liao Y, Zeinomar N, Knight JA, Southey MC, Milne RL, Chung WK, Giles GG, Genkinger JM, McLachlan SA, Friedlander ML, Antoniou AC, Weideman PC, Glendon G, Nesci S; kConFab Investigators, Andrulis IL, Buys SS, Daly MB, John EM, Phillips KA, Terry MB.
    • Breast Cancer Res. 2018 Nov 3;20(1):132. doi: 10.1186/s13058-018-1056-1.
    • Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
    • Theobald KA, Susswein LR, Marshall ML, Roberts ME, Mester JL, Speyer D, Williams RNW, Knapke SC, Solomon SR, Murphy PD, Klein RT, Hruska KS, Solomon BD.
    • Ann Surg Oncol. 2018 Nov;25(12):3556-3562. doi: 10.1245/s10434-018-6581-8. Epub 2018 Aug 30.
    • Personal, reproductive, and familial characteristics associated with bilateral oophorectomy in premenopausal women: A population-based case-control study.
    • Rocca WA, Gazzuola Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, Stewart EA, Mielke MM, Kantarci K, Miller VM.
    • Maturitas. 2018 Nov;117:64-77. doi: 10.1016/j.maturitas.2018.09.002. Epub 2018 Sep 14.
    • Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.
    • van Nagell JR Jr, Burgess BT, Miller RW, Baldwin L, DeSimone CP, Ueland FR, Huang B, Chen Q, Kryscio RJ, Pavlik EJ.
    • Obstet Gynecol. 2018 Nov;132(5):1091-1100. doi: 10.1097/AOG.0000000000002921.

    Editorial, Research news:

    Ultrasound Screening for Ovarian Cancer: Are We There Yet?

    • A randomized controlled trial of a supportive expressive group intervention for women with a family history of breast cancer.
    • Esplen MJ, Leszcz M, Hunter J, Wong J, Leung YW, Toner B, Messner S, Glendon G, Stuckless N, Butler C.
    • Psychooncology. 2018 Nov;27(11):2645-2653. doi: 10.1002/pon.4822. Epub 2018 Jul 17.
    • BRCA1/BRCA2 Mutations Shaped by Ancient Consanguinity Practice in Southern Mediterranean Populations
    • Belaiba F, Medimegh I, Bidet Y, Boussetta S, Baroudi O, Mezlini A, Bignon YJ, Benammar El gaaied A.
    • Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2963-2972.
    • Familial risks of second primary cancers and mortality in ovarian cancer patients.
    • Zheng G, Chattopadhyay S, Försti A, Sundquist K, Hemminki K.
    • Clin Epidemiol. 2018 Oct 11;10:1457-1466. doi: 10.2147/CLEP.S174173. eCollection 2018.
    • An Estrogen-Related Dietary Pattern and Postmenopausal Breast Cancer Risk in a Cohort of Women with a Family History of Breast Cancer.
    • Guinter MA, Sandler DP, McLain AC, Merchant AT, Steck SE.
    • Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1223-1226. doi: 10.1158/1055-9965.EPI-18-0514. Epub 2018 Sep 19.
    • BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.
    • Mori H, Kubo M, Kai M, Velasquez VV, Kurata K, Yamada M, Okido M, Kuroki S, Oda Y, Nakamura M.
    • Clin Breast Cancer. 2018 Oct;18(5):e1217-e1227. doi: 10.1016/j.clbc.2018.05.008. Epub 2018 Jun 2.
    • Breast cancer in transgender patients: A systematic review. Part 1: Male to female.
    • Hartley RL, Stone JP, Temple-Oberle C.
    • Eur J Surg Oncol. 2018 Oct;44(10):1455-1462. doi: 10.1016/j.ejso.2018.06.035. Epub 2018 Jul 25.
    • Review
    • Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer.
    • Liu W, Wu J, Shi G, Yue X, Liu D, Zhang Q.
    • Oncol Lett. 2018 Oct;16(4):4462-4470. doi: 10.3892/ol.2018.9214. Epub 2018 Jul 25.
    • Factors associated with breast MRI use among women with a family history of breast cancer.
    • White MC, Soman A, Weinberg CR, Rodriguez JL, Sabatino SA, Peipins LA, DeRoo L, Nichols HB, Hodgson ME, Sandler DP.
    • Breast J. 2018 Sep;24(5):764-771. doi: 10.1111/tbj.13063. Epub 2018 May 20.
    • Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.
    • Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT.
    • Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17.
    • Imaging Phenotypes in Women at High Risk for Breast Cancer on Mammography, Ultrasound, and Magnetic Resonance Imaging Using the Fifth Edition of the Breast Imaging Reporting and Data System.
    • Marino MA, Riedl CC, Bernathova M, Bernhart C, A T Baltzer P, Helbich TH, Pinker K.
    • Eur J Radiol. 2018 Sep;106:150-159. doi: 10.1016/j.ejrad.2018.07.026. Epub 2018 Jul 30.
    • Family history of breast or prostate cancer and prostate cancer risk.
    • Barber LE, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn TU, Giovannucci EL, Parmigiani G, Mucci LA.
    • Clin Cancer Res. 2018 Aug 6. pii: clincanres.0370.2018. doi: 10.1158/1078-0432.CCR-18-0370. [Epub ahead of print]
    • Familial Ovarian Cancer Clusters with Other Cancers.
    • Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K.
    • Sci Rep. 2018 Aug 1;8(1):11561. doi: 10.1038/s41598-018-29888-4.
    • Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE Study.
    • Dash C, Taylor TR, Makambi KH, Hicks J, Hagberg JM, Adams-Campbell LL.
    • Cancer. 2018 Aug;124(16):3355-3363. doi: 10.1002/cncr.31569. Epub 2018 Jul 5.
    • Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women.
    • Ngene SO, Adedokun B, Adejumo P, Olopade O.
    • J Genet Couns. 2018 Aug;27(4):863-873. doi: 10.1007/s10897-017-0194-4. Epub 2017 Dec 19.
    • Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers.
    • Chan GHJ, Ong PY, Low JJH, Kong HL, Ow SGW, Tan DSP, Lim YW, Lim SE, Lee SC.
    • Oncotarget. 2018 Jul 17;9(55):30649-30660. doi: 10.18632/oncotarget.25769. eCollection 2018 Jul 17.
    • Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer.
    • Abildgaard J, Ahlström MG, Daugaard G, Nielsen DL, Tønnes Pedersen A, Lindegaard B, Obel N.
    • JNCI Cancer Spectrum. 2018 Jul 1;2(3):pky034. doi: 10.1093/jncics/pky034.
    • Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy.
    • Fagerholm R, Faltinova M, Aaltonen K, Aittomäki K, Heikkilä P, Halttunen-Nieminen M, Nevanlinna H, Blomqvist C.
    • Fam Cancer. 2018 Jul;17(3):321-331. doi: 10.1007/s10689-017-0046-2.
    • Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?
    • Evans DG, Woodward E, Harkness EF, Howell A, Plaskocinska I, Maher ER, Tischkowitz MD, Lalloo F.
    • J Med Genet. 2018 Jul;55(7):442-448. doi: 10.1136/jmedgenet-2017-105223. Epub 2018 Feb 26.
    • Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.
    • Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA.
    • J Natl Compr Canc Netw. 2018 Jul;16(7):829-837. doi: 10.6004/jnccn.2018.7024.
    • Health education models application by peer group for improving breast cancer screening among Iranian women with a family history of breast cancer: A randomized control trial.
    • Fathollahi-Dehkordi F, Farajzadegan Z.
    • Med J Islam Repub Iran. 2018 Jun 21;32:51. doi: 10.14196/mjiri.32.51. eCollection 2018.
    • Genetic alterations detected by comparative genomic hybridization in BRCAX breast and ovarian cancers of Brazilian population.
    • Felicio PS, Bidinotto LT, Melendez ME, Grasel RS, Campacci N, Galvão HCR, Scapulatempo-Neto C, Dufloth RM, Evangelista AF, Palmero EI.
    • Oncotarget. 2018 Jun 8;9(44):27525-27534. doi: 10.18632/oncotarget.25537. eCollection 2018 Jun 8.
    • The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
    • Teixeira N, van der Hout A, Oosterwijk JC, Vos JR; HEBON, Devilee P, van Engelen K, Meijers-Heijboer H, van der Luijt RB, Kriege M, Mensenkamp AR, Rookus MA, van Roozendaal KE, Mourits MJE, de Bock GH.
    • Eur J Hum Genet. 2018 Jun;26(6):848-857. doi: 10.1038/s41431-018-0111-9. Epub 2018 Feb 26.
    • Recommendations on prevention and screening for breast cancer in Hong Kong.
    • Lam TH, Wong KH, Chan KK, Chan MC, Chao DV, Cheung AN, Fan CY, Ho J, Hui EP, Lam KO, Law CK, Law WL, Loong HH, Ngan RK, Tsang TH, Wong MC, Yeung RM, Ying AC, Ching R.
    • Hong Kong Med J. 2018 Jun;24(3):298-306. doi: 10.12809/hkmj177037.
    • Leucocytes telomere length and breast cancer risk/ susceptibility: A case-control study.
    • Pavanello S, Varesco L, Gismondi V, Bruzzi P, Bolognesi C.
    • PLoS One. 2018 May 21;13(5):e0197522. doi: 10.1371/journal.pone.0197522. eCollection 2018.
    • Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
    • Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, Boice JD, Knight JA, Concannon P, Capanu M, Tischkowitz M, Robson M, Liang X, Woods M, Conti DV, Duggan D, Shore R, Stram DO, Thomas DC, Malone KE, Bernstein L; WECARE Study Collaborative Group, Bernstein JL.
    • J Clin Oncol. 2018 May 20;36(15):1513-1520. doi: 10.1200/JCO.2017.77.3424. Epub 2018 Apr 5.
    • Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study.
    • Lamy PJ, Trétarre B, Rebillard X, Sanchez M, Cénée S, Ménégaux F.
    • Oncotarget. 2018 May 4;9(34):23661-23669. doi: 10.18632/oncotarget.25320. eCollection 2018 May 4.
    • Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer.
    • Augustinsson A, Ellberg C, Kristoffersson U, Borg Å, Olsson H.
    • Acta Oncol. 2018 May;57(5):595-603. doi: 10.1080/0284186X.2017.1404635. Epub 2017 Nov 22.
    • Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    • Barrington DA, Champion ML, Boitano TKL, Walters-Haygood CL, Farmer MB, Alvarez RD, Estes JM, Leath CA 3rd.
    • Gynecol Oncol. 2018 May;149(2):337-340. doi: 10.1016/j.ygyno.2018.02.014. Epub 2018 Mar 2.
    • Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.
    • Barcenas CH, Shafaee MN, Sinha AK, Raghavendra A, Saigal B, Murthy RK, Woodson AH, Arun B.
    • J Natl Compr Canc Netw. 2018 May;16(5):518-524. doi: 10.6004/jnccn.2018.7002.
    • Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
    • Pande M, Joon A, Brewster AM, Chen WV, Hopper JL, Eng C, Shete S, Casey G, Schumacher F, Lin Y, Harrison TA, White E, Ahsan H, Andrulis IL, Whittemore AS, John EM, Ko Win A, Makalic E, Schmidt DF, Kapuscinski MK, Ochs-Balcom HM, Gallinger S, Jenkins MA, Newcomb PA, Lindor NM, Peters U, Amos CI, Lynch PM.
    • PLoS One. 2018 Apr 26;13(4):e0196245. doi: 10.1371/journal.pone.0196245. eCollection 2018.
    • Pathogenic Germline Variants in 10,389 Adult Cancers.
    • Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Hucthagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ; Cancer Genome Atlas Research Network, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L.
    • Cell. 2018 Apr 5;173(2):355-370.e14. doi: 10.1016/j.cell.2018.03.039.
    • Association of sporadic and familial Barrett's esophagus with breast cancer.
    • Chan MQ, Blum AE, Chandar AK, Emmons AMLK, Shindo Y, Brock W, Falk GW, Canto MI, Wang JS, Iyer PG, Shaheen NJ, Grady WM, Abrams JA, Thota PN, Guda KK, Chak A.
    • Dis Esophagus. 2018 Apr 1;31(4). doi: 10.1093/dote/doy007.
    • Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort.
    • Braithwaite D, Miglioretti DL, Zhu W, Demb J, Trentham-Dietz A, Sprague B, Tice JA, Onega T, Henderson LM, Buist DSM, Ziv E, Walter LC, Kerlikowske K; Breast Cancer Surveillance Consortium.
    • JAMA Intern Med. 2018 Apr 1;178(4):494-501. doi: 10.1001/jamainternmed.2017.8642.

    Research news:

    Older women with a family history of breast cancer face increased risk of the disease.

    • Down-regulation of microRNA-19b in hormone receptor-positive/HER2-negative breast cancer.
    • Maleki E, Ghaedi K, Shahanipoor K, Karimi Kurdistani Z.
    • APMIS. 2018 Apr;126(4):303-308. doi: 10.1111/apm.12820.
    • Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry.
    • Wang S, Qian F, Zheng Y, Ogundiran T, Ojengbede O, Zheng W, Blot W, Nathanson KL, Hennis A, Nemesure B, Ambs S, Olopade OI, Huo D.
    • Breast Cancer Res Treat. 2018 Apr;168(3):703-712. doi: 10.1007/s10549-017-4638-1. Epub 2018 Jan 4.
    • Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers.
    • Tanaka H, Phipps EA, Wei T, Wu X, Goswami C, Liu Y, Sledge GW Jr, Mina L, Herbert BS.
    • Mol Carcinog. 2018 Apr;57(4):567-575. doi: 10.1002/mc.22773. Epub 2018 Jan 5.
    • Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.
    • Gaceb H, Cherbal F, Bakour R, Ould-Rouis A, Mahfouf H.
    • Pathol Oncol Res. 2018 Apr;24(2):297-308. doi: 10.1007/s12253-017-0242-2. Epub 2017 May 6.
    • First DTC Test for Some BRCA Mutations Authorized by FDA.
    • Nelson R.
    • Medscape. Medscape Medical News. 2018 Mar 7.
    • Family History and Risk of Second Primary Breast Cancer after In Situ Breast Carcinoma.
    • Baglia ML, Tang MC, Malone KE, Porter P, Li CI.
    • Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):315-320. doi: 10.1158/1055-9965.EPI-17-0837. Epub 2018 Jan 16.
    • Molecular-genetic models for prognosis of development of tumors of reproductive system in women with family history of cancer.
    • Paliychuk OV, Polishchuk LZ, Rossokha ZI, Chekhun VF.
    • Exp Oncol. 2018 Mar;40(1):59-67.
    • Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland.
    • Kluz T, Jasiewicz A, Marczyk E, Jach R, Jakubowska A, Lubiński J, Narod SA, Gronwald J.
    • Hered Cancer Clin Pract. 2018 Feb 27;16:6. doi: 10.1186/s13053-018-0089-x. eCollection 2018.
    • Does Endometriosis Hinder Successful Ovarian Debulking Surgery?
    • Sananpanichkul P, Muangtan S, Suknikhom W, Bhamarapravatana K, Suwannarurk K.
    • Asian Pac J Cancer Prev. 2018 Feb 26;19(2):509-512.
    • Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study.
    • Eng KH, Szender JB, Etter JL, Kaur J, Poblete S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, Krolewski JJ, Zsiros E, Frederick PJ, Lele SB, Moysich KB, Odunsi KO.
    • PLoS Genet. 2018 Feb 15;14(2):e1007194. doi: 10.1371/journal.pgen.1007194. eCollection 2018 Feb.
    • Breast cancer risk factors and mammographic density among high-risk women in urban China.
    • Sung H, Ren J, Li J, Pfeiffer RM, Wang Y, Guida JL, Fang Y, Shi J, Zhang K, Li N, Wang S, Wei L, Hu N, Gierach GL, Dai M, Yang XR, He J.
    • NPJ Breast Cancer. 2018 Feb 6;4:3. doi: 10.1038/s41523-018-0055-9. eCollection 2018.
    • Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
    • Hull LE, Haas JS, Simon SR.
    • Am J Prev Med. 2018 Feb;54(2):221-228. doi: 10.1016/j.amepre.2017.10.015. Epub 2017 Dec 11.
    • The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.
    • Bernstein-Molho R, Laitman Y, Schayek H, Reish O, Lotan S, Haim S, Zidan J, Friedman E.
    • Breast Cancer Res Treat. 2018 Feb;167(3):697-702. doi: 10.1007/s10549-017-4551-7. Epub 2017 Oct 30.
    • Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History.
    • Grandi G, Toss A, Cagnacci A, Marcheselli L, Pavesi S, Facchinetti F, Cascinu S, Cortesi L.
    • Clin Breast Cancer. 2018 Feb;18(1):e15-e24. doi: 10.1016/j.clbc.2017.10.016. Epub 2017 Nov 14.
    • Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer.
    • Dou YD, Huang T, Wang Q, Shu X, Zhao SG, Li L, Liu T, Lu G, Chan WY, Liu HB.
    • Biochem Biophys Res Commun. 2018 Jan 29;496(1):191-198. doi: 10.1016/j.bbrc.2018.01.023. Epub 2018 Jan 4.
    • Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors.
    • Kırca N, Tuzcu A, Gözüm S.
    • Eur J Breast Health. 2018 Jan 1;14(1):23-28. doi: 10.5152/ejbh.2017.3272. eCollection 2018 Jan.
    • Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression.
    • Harris HR, Rice MS, Shafrir AL, Poole EM, Gupta M, Hecht JL, Terry KL, Tworoger SS.
    • Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):96-102. doi: 10.1158/1055-9965.EPI-17-0609. Epub 2017 Nov 13.
    • Surveillance report 2018 – Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (2013) NICE guideline CG164 [Internet].
    • NICE Surveillance programme project team: Nolan K, Allaby M, McFarlane E, Murray A.
    • London: National Institute for Health and Care Excellence (UK); 2018 Jan.

    • Breast Cancer Disparities: How Can We Leverage Genomics to Improve Outcomes?
    • Davis MB, Newman LA.
    • Surg Oncol Clin N Am. 2018 Jan;27(1):217-234. doi: 10.1016/j.soc.2017.07.009.
    • Review
    • Familial associations of male breast cancer with other cancers.
    • Zheng G, Yu H, Hemminki A, Försti A, Sundquist K, Hemminki K.
    • Breast Cancer Res Treat. 2017 Dec;166(3):897-902. doi: 10.1007/s10549-017-4468-1. Epub 2017 Aug 23.
    • Emerging Trends in Family History of Breast Cancer and Associated Risk.
    • Shiyanbola OO, Arao RF, Miglioretti DL, Sprague BL, Hampton JM, Stout NK, Kerlikowske K, Braithwaite D, Buist DSM, Egan KM, Newcomb PA, Trentham-Dietz A.
    • Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1753-1760. doi: 10.1158/1055-9965.EPI-17-0531. Epub 2017 Oct 6.
    • Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories.
    • Rosenthal ET, Bernhisel R, Brown K, Kidd J, Manley S.
    • Cancer Genet. 2017 Dec;218-219:58-68. doi: 10.1016/j.cancergen.2017.09.003. Epub 2017 Sep 25.
    • No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.
    • Guedaoura S, Pelletier S, Foulkes WD, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M.
    • Curr Oncol. 2017 Dec;24(6):352-359. doi: 10.3747/co.24.3759. Epub 2017 Dec 20.
    • Using family history forms in pediatric oncology to identify patients for genetic assessment.
    • Hamilton A, Smith E, Hamon J, Tomiak E, Bassal M, Sawyer SL.
    • Curr Oncol. 2017 Dec;24(6):e441-e445. doi: 10.3747/co.24.3710. Epub 2017 Dec 20.
    • Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.
    • Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, Wang Q, Aalfs CM; ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomäki K, Al-Ejeh F, Allen J, Ambrosone CB, Amos CI, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Auber B, Auer PL, Ausems MGEM, Azzollini J, Bacot F, Balmaña J, Barile M, Barjhoux L, Barkardottir RB, Barrdahl M, Barnes D, Barrowdale D, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Bernstein L, Bignon YJ, Blazer KR, Blok MJ, Blomqvist C, Blot W, Bobolis K, Boeckx B, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Børresen-Dale AL, Bozsik A, Bradbury AR, Brand JS, Brauch H, Brenner H, Bressac-de Paillerets B, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Brunet J, Brüning T, Burwinkel B, Buys SS, Byun J, Cai Q, Caldés T, Caligo MA, Campbell I, Canzian F, Caron O, Carracedo A, Carter BD, Castelao JE, Castera L, Caux-Moncoutier V, Chan SB, Chang-Claude J, Chanock SJ, Chen X, Cheng TD, Chiquette J, Christiansen H, Claes KBM, Clarke CL, Conner T, Conroy DM, Cook J, Cordina-Duverger E, Cornelissen S, Coupier I, Cox A, Cox DG, Cross SS, Cuk K, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, Davidson R, De Leeneer K, Devilee P, Dicks E, Diez O, Ding YC, Ditsch N, Doheny KF, Domchek SM, Dorfling CM, Dörk T, Dos-Santos-Silva I, Dubois S, Dugué PA, Dumont M, Dunning AM, Durcan L, Dwek M, Dworniczak B, Eccles D, Eeles R, Ehrencrona H, Eilber U, Ejlertsen B, Ekici AB, Eliassen AH; EMBRACE, Engel C, Eriksson M, Fachal L, Faivre L, Fasching PA, Faust U, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gaddam P, Gammon MD, Ganz PA, Gapstur SM, Garber J, Garcia-Barberan V, García-Sáenz JA, Gaudet MM, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Georgoulias V, Gerdes AM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goodfellow P, Greene MH, Alnæs GIG, Grip M, Gronwald J, Grundy A, Gschwantler-Kaulich D, Guénel P, Guo Q, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hallberg E, Hamann U, Hamel N, Hankinson S, Hansen TVO, Harrington P, Hart SN, Hartikainen JM, Healey CS; HEBON, Hein A, Helbig S, Henderson A, Heyworth J, Hicks B, Hillemanns P, Hodgson S, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover B, Hopper JL, Hu C, Huang G, Hulick PJ, Humphreys K, Hunter DJ, Imyanitov EN, Isaacs C, Iwasaki M, Izatt L, Jakubowska A, James P, Janavicius R, Janni W, Jensen UB, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kast K; kConFab/AOCS Investigators, Keeman R, Kerin MJ, Kets CM, Keupers M, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Konstantopoulou I, Kosma VM, Kristensen VN, Kruse TA, Kwong A, Lænkholm AV, Laitman Y, Lalloo F, Lambrechts D, Landsman K, Lasset C, Lazaro C, Le Marchand L, Lecarpentier J, Lee A, Lee E, Lee JW, Lee MH, Lejbkowicz F, Lesueur F, Li J, Lilyquist J, Lincoln A, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Loud JT, Lubinski J, Luccarini C, Lush M, MacInnis RJ, Maishman T, Makalic E, Kostovska IM, Malone KE, Manoukian S, Manson JE, Margolin S, Martens JWM, Martinez ME, Matsuo K, Mavroudis D, Mazoyer S, McLean C, Meijers-Heijboer H, Menéndez P, Meyer J, Miao H, Miller A, Miller N, Mitchell G, Montagna M, Muir K, Mulligan AM, Mulot C, Nadesan S, Nathanson KL; NBSC Collaborators, Neuhausen SL, Nevanlinna H, Nevelsteen I, Niederacher D, Nielsen SF, Nordestgaard BG, Norman A, Nussbaum RL, Olah E, Olopade OI, Olson JE, Olswold C, Ong KR, Oosterwijk JC, Orr N, Osorio A, Pankratz VS, Papi L, Park-Simon TW, Paulsson-Karlsson Y, Lloyd R, Pedersen IS, Peissel B, Peixoto A, Perez JIA, Peterlongo P, Peto J, Pfeiler G, Phelan CM, Pinchev M, Plaseska-Karanfilska D, Poppe B, Porteous ME, Prentice R, Presneau N, Prokofieva D, Pugh E, Pujana MA, Pylkäs K, Rack B, Radice P, Rahman N, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rennert HS, Rhenius V, Rhiem K, Richardson A, Rodriguez GC, Romero A, Romm J, Rookus MA, Rudolph A, Ruediger T, Saloustros E, Sanders J, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seal S, Senter L, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng X, Shimelis H, Shrubsole MJ, Shu XO, Side LE, Singer CF, Sohn C, Southey MC, Spinelli JJ, Spurdle AB, Stegmaier C, Stoppa-Lyonnet D, Sukiennicki G, Surowy H, Sutter C, Swerdlow A, Szabo CI, Tamimi RM, Tan YY, Taylor JA, Tejada MI, Tengström M, Teo SH, Terry MB, Tessier DC, Teulé A, Thöne K, Thull DL, Tibiletti MG, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Tranchant M, Truong T, Tucker K, Tung N, Tyrer J, Ulmer HU, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vega A, Viel A, Vijai J, Vincent D, Vollenweider J, Walker L, Wang Z, Wang-Gohrke S, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wesseling J, Whittemore AS, Wijnen JT, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yang XR, Yannoukakos D, Zaffaroni D, Zheng W, Zhu B, Ziogas A, Ziv E, Zorn KK, Gago-Dominguez M, Mannermaa A, Olsson H, Teixeira MR, Stone J, Offit K, Ottini L, Park SK, Thomassen M, Hall P, Meindl A, Schmutzler RK, Droit A, Bader GD, Pharoah PDP, Couch FJ, Easton DF, Kraft P, Chenevix-Trench G, García-Closas M, Schmidt MK, Antoniou AC, Simard J.
    • Nat Genet. 2017 Dec;49(12):1767-1778. doi: 10.1038/ng.3785. Epub 2017 Oct 23.

    Press: More Breast Cancer Risk Gene Variants Discovered. (Medscape/WebMD)

    Research News: No new high-risk breast cancer genes here. (FORCE)

    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Introduction. Risk Factors for Breast Cancer.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Introduction. Autosomal Dominant Inheritance of Breast and Gynecologic Cancer Predisposition.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Breast cancer cases of female patients under 35 years of age in Togo: A series of 158 cases.
    • Darré T, Tchaou M, Folligan K, Amadou A, N'Timon B, Sonhaye L, Aboubakari AS, Amégbor K, Akpadza K, Napo Koura G.
    • Mol Clin Oncol. 2017 Dec;7(6):1125-1129. doi: 10.3892/mco.2017.1461. Epub 2017 Oct 18.
    • Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers.
    • Park B, Hopper JL, Win AK, Dowty JG, Sung HK, Ahn C, Kim SW, Lee MH, Lee J, Lee JW, Kang E, Yu JH, Kim KS, Moon BI, Han W, Noh DY, Park SK; KOHBRA Study Group.
    • Oncotarget. 2017 Oct 31;8(60):102110-102118. doi: 10.18632/oncotarget.22193. eCollection 2017 Nov 24.
    • Clinicopathologic and prognostic features of breast cancer in young women: a series from North of Morocco.
    • Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, Fihri M, Hassani S, Barakat A, Ghailani Nourouti N, Bennani Mechita M.
    • BMC Womens Health. 2017 Nov 9;17(1):106. doi: 10.1186/s12905-017-0456-1.
    • VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.
    • Schirosi L, De Summa S, Tommasi S, Paradiso A, Gasparini G, Popescu O, Simone G, Mangia A.
    • Int J Cancer. 2017 Nov 1;141(9):1901-1911. doi: 10.1002/ijc.30868. Epub 2017 Jul 20.
    • Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.
    • Phi XA, Houssami N, Hooning MJ, Riedl CC, Leach MO, Sardanelli F, Warner E, Trop I, Saadatmand S, Tilanus-Linthorst MMA, Helbich TH, van den Heuvel ER, de Koning HJ, Obdeijn IM, de Bock GH.
    • Eur J Cancer. 2017 Nov;85:31-38. doi: 10.1016/j.ejca.2017.07.055.
    • Meta-Analysis, Review
    • Cancer Status Bests Family History for BRCA Testing.
    • Neil Osterweil.
    • Medscape. Conference News. 2017 Oct 19.
    • Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.
    • Márquez-Rodas I, Pollán M, Escudero MJ, Ruiz A, Martín M, Santaballa A, Martínez Del Prado P, Batista N, Andrés R, Antón A, Llombart A, Fernandez Aramburu A, Adrover E, González S, Seguí MA, Calvo L, Lizón J, Rodríguez Lescure Á, Ramón Y Cajal T, Llort G, Jara C, Carrasco E, López-Tarruella S.
    • PLoS One. 2017 Oct 6;12(10):e0184181. doi: 10.1371/journal.pone.0184181. eCollection 2017.
    • Expanding the spectrum of germline variants in cancer.
    • Siraj AK, Masoodi T, Bu R, Parvathareddy SK, Al-Badawi IA, Al-Sanea N, Ashari LH, Abduljabbar A, Alhomoud S, Al-Sobhi SS, Tulbah A, Ajarim D, Alzoman K, Aljuboury M, Yousef HB, Al-Dawish M, Al-Dayel F, Alkuraya FS, Al-Kuraya KS.
    • Hum Genet. 2017 Oct 3. doi: 10.1007/s00439-017-1845-0. [Epub ahead of print]
    • Contralateral Prophylactic Mastectomy.
    • Ramaswami R, Morrow M, Jagsi R.
    • N Engl J Med. 2017 Sep 28;377(13):1288-1291. doi: 10.1056/NEJMclde1708293.
    • Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    • Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.
    • JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137.

    Editorial:

    The Potential and Challenges of Expanded Germline Testing in Clinical Oncology.

    Press: Study Shows More Cancer Mutations Detected by Universal Sequencing. (Clinical Omics)

    Press: Expanding Germline Analyses to Prevent and Treat Cancers. (Medscape)

    • Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer.
    • Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K; Breast Cancer Surveillance Consortium.
    • JAMA Oncol. 2017 Sep 1;3(9):1228-1236. doi: 10.1001/jamaoncol.2016.6326.
    • Screening Mammography for Women in Their 40s: The Potential Impact of the American Cancer Society and U.S. Preventive Services Task Force Breast Cancer Screening Recommendations.
    • Pitman JA, McGinty GB, Soman RR, Drotman MB, Reichman MB, Arleo EK.
    • AJR Am J Roentgenol. 2017 Sep;209(3):697-702. doi: 10.2214/AJR.16.17759. Epub 2017 May 15.
    • Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.
    • Lolas Hamameh S, Renbaum P, Kamal L, Dweik D, Salahat M, Jaraysa T, Abu Rayyan A, Casadei S, Mandell JB, Gulsuner S, Lee MK, Walsh T, King MC, Levy-Lahad E, Kanaan M.
    • Int J Cancer. 2017 Aug 15;141(4):750-756. doi: 10.1002/ijc.30771. Epub 2017 May 19.
    • TGFbeta and miRNA regulation in familial and sporadic breast cancer.
    • Danza K, Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R, Tommasi S.
    • Oncotarget. 2017 Jan 30;8(31):50715-50723. doi: 10.18632/oncotarget.14899. eCollection 2017 Aug 1.
    • MRI surveillance for women with dense breasts and a previous breast cancer and/or high risk lesion.
    • Nadler M, Al-Attar H, Warner E, Martel AL, Balasingham S, Zhang L, Lipton JH, Curpen B.
    • Breast. 2017 Aug;34:77-82. doi: 10.1016/j.breast.2017.04.005. Epub 2017 May 18.
    • Family history and risk of breast cancer: an analysis accounting for family structure.
    • Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ.
    • Breast Cancer Res Treat. 2017 Aug;165(1):193-200. doi: 10.1007/s10549-017-4325-2. Epub 2017 Jun 3.
    • Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
    • Rummel SK, Lovejoy L, Shriver CD, Ellsworth RE.
    • Breast Cancer Res Treat. 2017 Aug;164(3):593-601. doi: 10.1007/s10549-017-4291-8. Epub 2017 May 13.
    • Tumor characteristics and family history in relation to mammographic density and breast cancer: The French E3N cohort.
    • Maskarinec G, Dartois L, Delaloge S, Hopper J, Clavel-Chapelon F, Baglietto L.
    • Cancer Epidemiol. 2017 Aug;49:156-160. doi: 10.1016/j.canep.2017.07.003. Epub 2017 Jul 8.
    • Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    • Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, Knight JA, Hsu L, Concannon P, Mellemkjær L, Tischkowitz M, Haile RW, Shen R, Malone KE, Woods M, Liang X, Morrow M, Bernstein JL; WECARE Study Collaborative Group.
    • Breast Cancer Res. 2017 Jul 19;19(1):83. doi: 10.1186/s13058-017-0874-x.
    • Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age.
    • Johnson KC, Houseman EA, King JE, Christensen BC.
    • Breast Cancer Res. 2017 Jul 10;19(1):81. doi: 10.1186/s13058-017-0873-y.
    • Assessment of Breast Cancer Risk Factors Reveals Subtype Heterogeneity.
    • Holm J, Eriksson L, Ploner A, Eriksson M, Rantalainen M, Li J, Hall P, Czene K.
    • Cancer Res. 2017 Jul 1;77(13):3708-3717. doi: 10.1158/0008-5472.CAN-16-2574. Epub 2017 May 16.
    • Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study.
    • Maishman T, Cutress RI, Hernandez A, Gerty S, Copson ER, Durcan L, Eccles DM.
    • Ann Surg. 2017 Jul;266(1):165-172. doi: 10.1097/SLA.0000000000001930.
    • Single-base LOH can be used as Specific Marker to Classify BRCAx Familial Breast Cancer into More Homogenous Subtypes.
    • Downs B, Xiao F, Kim YC, Chen PX, Huang D, Fleissner EA, Cowan K, Wang SM.
    • Breast J. 2017 Jul;23(4):479-481. doi: 10.1111/tbj.12777. Epub 2017 Jan 24.
    • The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis.
    • Song JL, Chen C, Yuan JP, Sun SR.
    • Fam Cancer. 2017 Jul;16(3):339-349. doi: 10.1007/s10689-017-9969-x.
    • Review
    • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
    • Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC; and the BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H./li>
    • JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.

    Research news:

    Family history is strong risk factor in BRCA1 and BRCA2 carriers, study finds.

    Research news:

    Genetics: BRCA-mutant breast/ovarian cancer revealed.

    Press: Breast and ovarian cancers: Large study improves estimates of genetic risk. (Medical News Today)

    Press: Most Precise Estimates Ever of Cancer Risks With BRCA. (Medscape)

    • Design considerations for identifying breast cancer risk factors in a population-based study in Africa.
    • Brinton LA, Awuah B, Clegg-Lamptey JN, Wiafe-Addai B, Ansong D, Nyarko KM, Wiafe S, Yarney J, Biritwum R, Brotzman M, Adjei AA, Adjei E, Aitpillah F, Edusei L, Dedey F, Nyante SJ, Oppong J, Osei-Bonsu E, Titiloye N, Vanderpuye V, Abaidoo EB, Arhin B, Boakye I, Frempong M, Ohene Oti N, Okyne V, Figueroa JD.
    • Int J Cancer. 2017 Jun 15;140(12):2667-2677. doi: 10.1002/ijc.30688. Epub 2017 Mar 28.
    • Pubertal development in girls by breast cancer family history: the LEGACY girls cohort.
    • Terry MB, Keegan THM, Houghton LC, Goldberg M, Andrulis IL, Daly MB, Buys SS, Wei Y, Whittemore AS, Protacio A, Bradbury AR, Chung WK, Knight JA, John EM.
    • Breast Cancer Res. 2017 Jun 8;19(1):69. doi: 10.1186/s13058-017-0849-y.
    • Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population.
    • Ahern TP, Sprague BL, Bissell MC, Miglioretti DL, Buist DS, Braithwaite D, Kerlikowske K.
    • Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):938-944. doi: 10.1158/1055-9965.EPI-16-0801. Epub 2017 Jan 17.
    • Investigation of Methylenetetrahydrofolate Reductase C677T Polymorphism and Human Papilloma Virus Genotypes in Iranian Breast Cancer.
    • Rezaei H, Rassi H, Nemati Mansur F.
    • Monoclon Antib Immunodiagn Immunother. 2017 Jun;36(3):124-128. doi: 10.1089/mab.2017.0011. Epub 2017 May 24.
    • Non-BRCA familial breast cancer: review of reported pathology and molecular findings.
    • Keeney MG, Couch FJ, Visscher DW, Lindor NM.
    • Pathology. 2017 Jun;49(4):363-370. doi: 10.1016/j.pathol.2017.03.002. Epub 2017 Apr 24.
    • Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening.
    • Román M, Quintana MJ, Ferrer J, Sala M, Castells X.
    • Br J Cancer. 2017 May 23;116(11):1480-1485. doi: 10.1038/bjc.2017.107. Epub 2017 Apr 20.
    • Incorporation of the time aspect into the liability-threshold model for case-control-family data.
    • Cederkvist L, Holst KK, Andersen KK, Glidden DV, Frederiksen K, Kjaer SK, Scheike TH.
    • Stat Med. 2017 May 10;36(10):1599-1618. doi: 10.1002/sim.7229. Epub 2017 Jan 23.
    • Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation.
    • Giri VN, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty SE, Montgomery S, Forman A, Bingler R, Kelly WK, Dicker AP, Winheld S, Trabulsi EJ, Chen DYT, Lallas CD, Allen BA, Daly MB, Gomella LG.
    • JCO Precis Oncol. 2017 May 4;1:PO.16.00039. doi: 10.1200/PO.16.00039.

    Commentary:

    Genetic Testing for Prostate Cancer in Clinical Practice.

    • High-risk epithelial ovarian cancer patients for hereditary ovarian cancer.
    • Chirasophon S, Manchana T, Teerapakpinyo C.
    • J Obstet Gynaecol Res. 2017 May;43(5):929-934. doi: 10.1111/jog.13287. Epub 2017 Feb 11.
    • Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer.
    • Shen J, Liao Y, Hopper JL, Goldberg M, Santella RM, Terry MB.
    • Br J Cancer. 2017 Apr 25;116(9):1229-1233. doi: 10.1038/bjc.2017.81. Epub 2017 Mar 28.
    • BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    • Domagala P, Hybiak J, Cybulski C, Lubinski J.
    • Int J Cancer. 2017 Apr 1;140(7):1545-1550. doi: 10.1002/ijc.30570. Epub 2017 Jan 24.
    • Preoperative Breast MRI: Surgeons' Patient Selection Patterns and Potential Bias in Outcomes Analyses.
    • Lee J, Tanaka E, Eby PR, Zhou S, Wei W, Eppelheimer C, Loving VA.
    • AJR Am J Roentgenol. 2017 Apr;208(4):923-932. doi: 10.2214/AJR.16.17038. Epub 2016 Dec 27.
    • Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.
    • Skandarajah AR, Thomas S, Shackleton K, Chin-Lenn L, Lindeman GJ, Mann GB.
    • Breast. 2017 Apr;32:93-97. doi: 10.1016/j.breast.2017.01.002. Epub 2017 Jan 18.
    • Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast Cancer.
    • Dite GS, MacInnis RJ, Bickerstaffe A, Dowty JG, Milne RL, Antoniou AC, Weideman P, Apicella C, Giles GG, Southey MC, Jenkins MA, Phillips KA, Win AK, Terry MB, Hopper JL.
    • Am J Epidemiol. 2017 Mar 15;185(6):487-500. doi: 10.1093/aje/kww241.
    • Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer.
    • Huzarski T, Górecka-Szyld B, Huzarska J, Psut-Muszyńska G, Wilk G, Sibilski R, Cybulski C, Kozak-Klonowska B, Siołek M, Kilar E, Czudowska D, Janiszewska H, Godlewski D, Mackiewicz A, Jarkiewicz-Tretyn J, Szabo-Moskal J, Gronwald J, Lubiński J, Narod SA; Polish Hereditary Breast Cancer Study Group.
    • Hered Cancer Clin Pract. 2017 Mar 1;15:4. doi: 10.1186/s13053-017-0064-y. eCollection 2017.
    • Parent of Origin and Prognosis in Familial Breast Cancer in Sweden.
    • Wendt C, Lindblom A, Arver B, VON Wachenfeldt A, Margolin S.
    • Anticancer Res. 2017 Mar;37(3):1257-1262.
    • MiR-16: A novel hereditary marker in breast cancer and their offspring.
    • Usmani A, Shoro AA, Shirazi B, Memon Z, Hussain M.
    • J Pak Med Assoc. 2017 Mar;67(3):446-450.
    • Differences in survival for patients with familial and sporadic cancer.
    • Lee M, Reilly M, Lindström LS, Czene K.
    • Int J Cancer. 2017 Feb 1;140(3):581-590. doi: 10.1002/ijc.30476. Epub 2016 Nov 3.
    • DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry.
    • Wu HC, Southey MC, Hibshoosh H, Santella RM, Terry MB.
    • Anticancer Res. 2017 Feb;37(2):659-664.
    • Familial Associations Between Prostate Cancer and Other Cancers.
    • Frank C, Sundquist J, Hemminki A, Hemminki K.
    • Eur Urol. 2017 Feb;71(2):162-165. doi: 10.1016/j.eururo.2016.07.031. Epub 2016 Aug 4.
    • Health Behaviors and their Relationship with Disease Control in People Attending Genetic Clinics with a Family History of Breast or Colorectal Cancer.
    • Anderson AS, Caswell S, Macleod M, Steele RJ, Berg J, Dunlop J, Stead M, Eadie D, O'Carroll RE.
    • J Genet Couns. 2017 Feb;26(1):40-51. doi: 10.1007/s10897-016-9977-2. Epub 2016 Jun 17.
    • The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
    • Evans DG, Brentnall A, Byers H, Harkness E, Stavrinos P, Howell A; FH-risk study Group, Newman WG, Cuzick J.
    • J Med Genet. 2017 Feb;54(2):111-113. doi: 10.1136/jmedgenet-2016-104125. Epub 2016 Oct 28.
    • Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda.
    • Al jarroudi O, Abda N, Brahmi S, Afqir S.
    • Asian Pac J Cancer Prev. 2017 Jan 1;18(1):195-200.
    • Assessing family history of chronic disease in primary care: Prevalence, documentation, and appropriate screening.
    • Carroll JC, Campbell-Scherer D, Permaul JA, Myers J, Manca DP, Meaney C, Moineddin R, Grunfeld E.
    • Can Fam Physician. 2017 Jan;63(1):e58-e67.
    • Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.
    • Hermel DJ, McKinnon WC, Wood ME, Greenblatt MS.
    • Fam Cancer. 2017 Jan;16(1):159-166. doi: 10.1007/s10689-016-9913-5.

    Letter:

    Patients with negative multi-gene panel testing: a back to the future paradox?

    Letter:

    Placing negative multi-gene panel results into clinical context.

    • Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
    • Egloff H, Jatoi A.
    • Cancer Invest. 2016 Nov 25;34(10):531-535. Epub 2016 Oct 28.
    • Non-Neoplastic Conditions of the Ovaries in Grossly Normal Adnexa: A Clinicopathologic Study of 403 Completely Embedded Cases.
    • Seidman JD, Krishnan J.
    • Int J Gynecol Pathol. 2016 Nov;35(6):544-548.
    • The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden.
    • Sackey H, Hui M, Czene K, Verkooijen H, Edgren G, Frisell J, Hartman M.
    • Breast Cancer Res. 2016 Oct 18;18(1):105. doi: 10.1186/s13058-016-0764-7.
    • Breast cancer risk prediction using a clinical risk model and polygenic risk score.
    • Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JW, Tice JA, Vachon CM, Cummings SR, Kerlikowske K, Ziv E.
    • Breast Cancer Res Treat. 2016 Oct;159(3):513-25. doi: 10.1007/s10549-016-3953-2. Epub 2016 Aug 26.
    • A model for patient-direct screening and referral for familial cancer risk.
    • Niendorf KB, Geller MA, Vogel RI, Church TR, Leininger A, Bakke A, Madoff RD.
    • Fam Cancer. 2016 Oct;15(4):707-16. doi: 10.1007/s10689-016-9912-6.
    • Predictors of Self-Reported Family Health History of Breast Cancer.
    • Ricks-Santi LJ, Thompson N, Ewing A, Harrison B, Higginbotham K, Spencer C, Laiyemo A, DeWitty R, Wilson L, Horton S, Dunmore-Griffith J, Williams C, Frederick W.
    • J Immigr Minor Health. 2016 Oct;18(5):1175-82. doi: 10.1007/s10903-015-0253-6.
    • Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).
    • Davies KR, Brewster AM, Bedrosian I, Parker PA, Crosby MA, Peterson SK, Shen Y, Volk RJ, Cantor SB.
    • Breast Cancer Res. 2016 Sep 20;18(1):93. doi: 10.1186/s13058-016-0752-y.
    • Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer.
    • Pensabene M, Condello C, Carlomagno C, De Placido S, Liccardo R, Duraturo F.
    • Hered Cancer Clin Pract. 2016 Sep 6;14(1):18. doi: 10.1186/s13053-016-0054-5. eCollection 2016.
    • Contribution of extended family history in assessment of risk for breast and colon cancer.
    • Solomon BL, Whitman T, Wood ME.
    • BMC Fam Pract. 2016 Sep 1;17(1):126. doi: 10.1186/s12875-016-0521-0.
    • Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.
    • Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjöholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS.
    • J Clin Oncol. 2016 Aug 20;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20.
    • Contralateral risk reducing mastectomy in Non-BRCA-Mutated patients.
    • Falco G, Rocco N, Bordoni D, Marano L, Accurso A, Buccelli C, Di Lorenzo P, Capasso E, Policino F, Niola M, Ferrari G.
    • Open Med (Wars). 2016 Aug 2;11(1):238-241. doi: 10.1515/med-2016-0047. eCollection 2016.
    • DNA Repair Gene Expression Levels as Indicators of Breast Cancer in the Breast Cancer Family Registry.
    • Kappil MA, Liao Y, Terry MB, Santella RM.
    • Anticancer Res. 2016 Aug;36(8):4039-44.
    • Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families.
    • Muranen TA, Mavaddat N, Khan S, Fagerholm R, Pelttari L, Lee A, Aittomäki K, Blomqvist C, Easton DF, Nevanlinna H.
    • Breast Cancer Res Treat. 2016 Aug;158(3):463-9. doi: 10.1007/s10549-016-3897-6. Epub 2016 Jul 20.
    • Risk and Protective Factors for Small Intestine Neuroendocrine Tumours: A Prospectivecase-Control Study.
    • Rinzivillo M, Capurso G, Campana D, Fazio N, Panzuto F, Spada F, Cicchese N, Partelli S, Tomassetti P, Falconi M, Delle Fave G.
    • Neuroendocrinology. [2016 Aug;]103(5):531-7. doi: 10.1159/000440884. Epub 2015 Sep 10.
    • Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study.
    • Evans DG, Astley S, Stavrinos P, Harkness E, Donnelly LS, Dawe S, Jacob I, Harvie M, Cuzick J, Brentnall A, Wilson M, Harrison F, Payne K, Howell A.
    • Southampton (UK): NIHR Journals Library; 2016 Aug.
    • A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
    • Rashid MU, Naeemi H, Muhammad N, Loya A, Yusuf MA, Lubiński J, Jakubowska A, Hamann U.
    • Hered Cancer Clin Pract. 2016 Jul 12;14:14. doi: 10.1186/s13053-016-0056-3. eCollection 2016.
    • Pregnancy history and risk of premenopausal breast cancer-a nested case-control study.
    • Hajiebrahimi M, Cnattingius S, Lambe M, Bahmanyar S.
    • Int J Epidemiol. 2016 Jun;45(3):816-24. doi: 10.1093/ije/dyv293. Epub 2015 Nov 11.
    • Family history of breast cancer and its association with disease severity and mortality.
    • Melvin JC, Wulaningsih W, Hana Z, Purushotham AD, Pinder SE, Fentiman I, Gillett C, Mera A, Holmberg L, Van Hemelrijck M.
    • Cancer Med. 2016 May;5(5):942-9. doi: 10.1002/cam4.648. Epub 2016 Jan 22.
    • The LEGACY Girls Study: Growth and Development in the Context of Breast Cancer Family History.
    • John EM, Terry MB, Keegan TH, Bradbury AR, Knight JA, Chung WK, Frost CJ, Lilge L, Patrick-Miller L, Schwartz LA, Whittemore AS, Buys SS, Daly MB, Andrulis IL.
    • Epidemiology. 2016 May;27(3):438-48. doi: 10.1097/EDE.0000000000000456.
    • Assessing biases of information contained in pedigrees for the classification of BRCA-genetic variants: a study arising from the ENIGMA analytical working group.
    • Kerkhofs CH, Spurdle AB, Lindsey PJ, Goldgar DE, Gómez-García EB.
    • Hered Cancer Clin Pract. 2016 Apr 30;14:10. doi: 10.1186/s13053-016-0050-9. eCollection 2016.
    • Towards personalized screening: Cumulative risk of breast cancer screening outcomes in women with and without a first-degree relative with a history of breast cancer.
    • Ripping TM, Hubbard RA, Otten JD, den Heeten GJ, Verbeek AL, Broeders MJ.
    • Int J Cancer. 2016 Apr 1;138(7):1619-25. doi: 10.1002/ijc.29912. Epub 2015 Nov 20.
    • Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer.
    • Jobsen JJ, van der Palen J, Brinkhuis M, Ong F, Struikmans H.
    • Acta Oncol. 2016 Apr;55(4):449-54. doi: 10.3109/0284186X.2015.1074281. Epub 2015 Sep 23.
    • Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
    • González-Rivera M, Lobo M, López-Tarruella S, Jerez Y, Del Monte-Millán M, Massarrah T, Ramos-Medina R, Ocaña I, Picornell A, Garzón SS, Pérez-Carbornero L, García-Saenz JA, Gómez H, Moreno F, Márquez-Rodas I, Fuentes H, Martin M.
    • Breast Cancer Res Treat. 2016 Apr;156(3):507-15. doi: 10.1007/s10549-016-3792-1. Epub 2016 Apr 15.
    • High use of complementary and alternative medicine among a large cohort of women with a family history of breast cancer: the Sister Study.
    • Greenlee H, Sardo Molmenti CL, Falci L, Ulmer R, Deming-Halverson S, DeRoo LA, Sandler DP.
    • Breast Cancer Res Treat. 2016 Apr;156(3):527-38. doi: 10.1007/s10549-016-3740-0. Epub 2016 Mar 26.
    • [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
    • Zhang J, Sun J, Ouyang T, Li JF, Wang TF, Fan ZQ, Fan T, Lin BY, Xie YT.
    • Zhonghua Zhong Liu Za Zhi. 2016 Mar 23;38(3):185-9. doi: 10.3760/cma.j.issn.0253-3766.2016.03.005.
    • Family history in breast cancer in São Luís, Maranhão, Brazil.
    • Ribeiro MH, da Silva MA, Muniz Filho WE, Nascimento AC, Souza RD, Machado CE, Silva DF, de Barros Bezerra GF, de Castro Viana GM, Soares Brandão Nascimento Mdo D.
    • BMC Res Notes. 2016 Mar 10;9(1):155. doi: 10.1186/s13104-015-1471-7.
    • No strong evidence for increased risk of breast cancer 8-26 years after multiple mammograms in their 30s in females at moderate and high familial risk.
    • Evans DG, Kotre CJ, Harkness E, Wilson M, Maxwell AJ, Howell A.
    • Br J Radiol. 2016 Mar;89(1059):20150960. doi: 10.1259/bjr.20150960. Epub 2016 Jan 21.
    • The risk of contralateral breast cancer in daughters of women with and without breast cancer.
    • Narod SA, Kharazmi E, Fallah M, Sundquist K, Hemminki K.
    • Clin Genet. 2016 Mar;89(3):332-5. doi: 10.1111/cge.12604. Epub 2015 May 21.
    • Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women.
    • Bethea TN, Rosenberg L, Castro-Webb N, Lunetta KL, Sucheston-Campbell LE, Ruiz-Narváez EA, Charlot M, Park SY, Bandera EV, Troester MA, Ambrosone CB, Palmer JR.
    • Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):366-73. doi: 10.1158/1055-9965.EPI-15-1068. Epub 2015 Dec 31.
    • Genetic characterization of early onset ovarian carcinoma.
    • Bernards SS, Norquist BM, Harrell MI, Agnew KJ, Lee MK, Walsh T, Swisher EM.
    • Gynecol Oncol. 2016 Feb;140(2):221-225. doi: 10.1016/j.ygyno.2015.12.017. Epub 2015 Dec 21.
    • Sweeping Up after the Kardashians: What We Wish had been Covered in Their Genetic Testing Episode.
    • [No author given]
    • My Gene Counsel. 2016 Jan 22.
    • The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer.
    • Möller S, Mucci LA, Harris JR, Scheike T, Holst K, Halekoh U, Adami HO, Czene K, Christensen K, Holm NV, Pukkala E, Skytthe A, Kaprio J, Hjelmborg JB.
    • Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):145-50. doi: 10.1158/1055-9965.EPI-15-0913. Epub 2015 Nov 10.
    • Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.
    • Hu C, Hart SN, Bamlet WR, Moore RM, Nandakumar K, Eckloff BW, Lee YK, Petersen GM, McWilliams RR, Couch FJ.
    • Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):207-11. doi: 10.1158/1055-9965.EPI-15-0455. Epub 2015 Oct 19.
    • Survival in familial and non-familial breast cancer by age and stage at diagnosis.
    • Kharazmi E, Försti A, Sundquist K, Hemminki K.
    • Eur J Cancer. 2016 Jan;52:10-8. doi: 10.1016/j.ejca.2015.09.015. Epub 2015 Nov 27.
    • Women's beliefs about breast cancer causation in a breast cancer case-control study.
    • Lizama N, Rogers P, Thomson A, Slevin T, Fritschi L, Saunders C, Heyworth J.
    • Psychooncology. 2016 Jan;25(1):36-42. doi: 10.1002/pon.3869. Epub 2015 Jun 18.
    • BRCA1 and TP53 Gene-Mutations: Family Predisposition and Radioecological Risk of Developing Breast Cancer.
    • Apsalikov B, Manambaeva Z, Ospanov E, Massabayeva M, Zhabagin K, Zhagiparova Z, Maximov V, Voropaeva E, Apsalikov K, Belikhina T, Abdrahmanov R, Cherepkova E, Tanatarov S, Massadykov A, Urazalina N.
    • Asian Pac J Cancer Prev. 2016;17(8):4059-62.
    • Evaluation of the Relationship Between Family History of Breast Cancer and Risk Perception and Impacts on Repetition of Mammography.
    • Khoshravesh S, Taymoori P, Roshani D.
    • Asian Pac J Cancer Prev. 2016;17 Spec No.:135-41.
    • Does familial breast cancer and thymoma suggest a cancer syndrome? A family perspective.
    • Zhang X, Wang T, Wang W, Ding Y, Zhou L, Chen Q, Gao X, Wu Y, Mei Y, Jin Y, Gao Q, Yi L.
    • Gene. 2015 Dec 1;573(2):333-7. doi: 10.1016/j.gene.2015.08.069. Epub 2015 Sep 4.
    • Case report
    • Internet-based physical activity intervention for women with a family history of breast cancer.
    • Hartman SJ, Dunsiger SI, Marinac CR, Marcus BH, Rosen RK, Gans KM.
    • Health Psychol. 2015 Dec;34 Suppl:1296-304. doi: 10.1037/hea0000307.
    • Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility.
    • Piccolo SR, Andrulis IL, Cohen AL, Conner T, Moos PJ, Spira AE, Buys SS, Johnson WE, Bild AH.
    • BMC Med Genomics. 2015 Nov 4;8(1):72. doi: 10.1186/s12920-015-0145-6.
    • Psychosocial Adjustment in School-age Girls With a Family History of Breast Cancer.
    • Bradbury AR, Patrick-Miller L, Schwartz L, Egleston B, Sands CB, Chung WK, Glendon G, McDonald JA, Moore C, Rauch P, Tuchman L, Andrulis IL, Buys SS, Frost CJ, Keegan TH, Knight JA, Terry MB, John EM, Daly MB.
    • Pediatrics. 2015 Nov;136(5):927-37. doi: 10.1542/peds.2015-0498. Epub 2015 Oct 19.

    Press: Are the kids all right? When breast cancer runs in the family (CBS News)

    • Should women at high risk for cancer use oral contraceptive pills?
    • Moorman PG.
    • Per Med. 2015 Nov;12(6):533-535. doi: 10.2217/pme.15.36. Epub 2015 Nov 3.
    • Editorial
    • Putting it off: family breast cancer history and women's retirement planning.
    • Zick CD, Mayer RN, Smith KR.
    • Psychooncology. 2015 Nov;24(11):1500-5. doi: 10.1002/pon.3759. Epub 2015 Jan 29.
    • Genetic Counselors Help Patients Assess and Address Risk for Cancer, Poor Recovery From Concussion.
    • Joy Larsen Haidle.
    • NSGC Blog. 2015 Oct 23.
    • Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.
    • Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman LJ.
    • Ann Surg Oncol. 2015 Oct;22(10):3338-45. doi: 10.1245/s10434-015-4745-3. Epub 2015 Jul 28.
    • Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk.
    • Teixeira N, Mourits MJ, Vos JR, Kolk DM, Jansen L, Oosterwijk JC, Bock GH.
    • Maturitas. 2015 Oct;82(2):197-202. doi: 10.1016/j.maturitas.2015.07.001. Epub 2015 Jul 9.
    • Patients Tested at a Laboratory for Hereditary Cancer Syndromes Show an Overlap for Multiple Syndromes in Their Personal and Familial Cancer Histories.
    • Saam J, Arnell C, Theisen A, Moyes K, Marino I, Roundy KM, Wenstrup RJ.
    • Oncology. [2015 Oct;]89(5):288-93. doi: 10.1159/000437307. Epub 2015 Aug 28.
    • Breast cancer risk factors.
    • Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E.
    • Prz Menopauzalny. 2015 Sep;14(3):196-202. doi: 10.5114/pm.2015.54346. Epub 2015 Sep 30.
    • Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer.
    • Gross AL, May BJ, Axilbund JE, Armstrong DK, Roden RB, Visvanathan K.
    • Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1262-9. doi: 10.1158/1055-9965.EPI-15-0212. Epub 2015 Jul 15.
    • Familial risk for lifestyle-related chronic diseases: can family health history be used as a motivational tool to promote health behaviour in young adults?
    • Prichard I, Lee A, Hutchinson AD, Wilson C.
    • Health Promot J Austr. 2015 Aug;26(2):122-8.
    • Family history and outcome of young patients with breast cancer in the UK (POSH study).
    • Eccles BK, Copson ER, Cutress RI, Maishman T, Altman DG, Simmonds P, Gerty SM, Durcan L, Stanton L, Eccles DM; POSH Study Steering Group.
    • Br J Surg. 2015 Jul;102(8):924-35. doi: 10.1002/bjs.9816. Epub 2015 May 20.
    • African Americans and Hispanics Remain at Lower Risk of Ovarian Cancer Than Non-Hispanic Whites after Considering Nongenetic Risk Factors and Oophorectomy Rates.
    • Wu AH, Pearce CL, Tseng CC, Pike MC.
    • Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1094-100. doi: 10.1158/1055-9965.EPI-15-0023. Epub 2015 Apr 14.
    • Breast cancer in women in their thirties (2007-2013): A retrospective review.
    • Arleo EK, Reichman M, Dashevsky BZ, Babagbemi K, Drotman M.
    • Breast Dis. 2015 Jun 1;35(2):87-93. doi: 10.3233/BD-150400.
    • Personal or first-degree family breast cancer history: which has higher impact on tumor detection and tumor size in breast cancer.
    • Schwab FD, Kilic N, Huang DJ, Schmid SM, Vetter M, Schötzau A, Güth U.
    • Arch Gynecol Obstet. 2015 Jun;291(6):1387-94. doi: 10.1007/s00404-014-3592-y. Epub 2014 Dec 17.
    • Breast cancer correlates in a cohort of breast screening program participants in Riyadh, KSA.
    • Al-Amri FA, Saeedi MY, Al-Tahan FM, Ali AM, Alomary SA, Arafa M, Ibrahim AK, Kassim KA.
    • J Egypt Natl Canc Inst. 2015 Jun;27(2):77-82. doi: 10.1016/j.jnci.2015.04.002. Epub 2015 Apr 29.
    • Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative.
    • Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK.
    • J Cancer. 2015 May 23;6(7):610-5. doi: 10.7150/jca.11710. eCollection 2015.
    • A case-control study to assess the impact of mammographic density on breast cancer risk in women aged 40-49 at intermediate familial risk.
    • Assi V, Massat NJ, Thomas S, MacKay J, Warwick J, Kataoka M, Warsi I, Brentnall A, Warren R, Duffy SW.
    • Int J Cancer. 2015 May 15;136(10):2378-87. doi: 10.1002/ijc.29275. Epub 2014 Nov 22.
    • Association of family risk and lifestyle/comorbidities in ovarian cancer patients.
    • Teixeira N, Folgueira MA, Maistro S, Encinas G, Bock GH, Diz Mdel P.
    • Rev Assoc Med Bras. 2015 May-Jun;61(3):234-9. doi: 10.1590/1806-9282.61.03.234.
    • Family history and risk of pregnancy-associated breast cancer (PABC).
    • Johansson AL, Andersson TM, Hsieh CC, Cnattingius S, Dickman PW, Lambe M.
    • Breast Cancer Res Treat. 2015 May;151(1):209-17. doi: 10.1007/s10549-015-3369-4. Epub 2015 Apr 19.
    • Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study.
    • Beebe-Dimmer JL, Yee C, Cote ML, Petrucelli N, Palmer N, Bock C, Lane D, Agalliu I, Stefanick ML, Simon MS.
    • Cancer. 2015 Apr 15;121(8):1265-72. doi: 10.1002/cncr.29075. Epub 2015 Mar 9.

    Press: Prostate Cancer Family History Linked to Breast Cancer Risk. (Medscape Oncology)

    • Patterns of changing cancer risks with time since diagnosis of a sibling.
    • Lee M, Czene K, Rebora P, Reilly M.
    • Int J Cancer. 2015 Apr 15;136(8):1948-56. doi: 10.1002/ijc.29239. Epub 2014 Oct 10.
    • Close-familial prostate cancer might increase risk of breast cancer.
    • [No author given]
    • Nurs Stand. 2015 Mar 18;29(29):14. doi: 10.7748/ns.29.29.14.s15.
    • News
    • Familial Risks and Estrogen Receptor-Positive Breast Cancer in Hong Kong Chinese Women.
    • Tse LA, Li M, Chan WC, Kwok CH, Leung SL, Wu C, Yu IT, Yu WC, Lao X, Wang X, Wong CK, Lee PM, Wang F, Yang XR.
    • PLoS One. 2015 Mar 10;10(3):e0120741. doi: 10.1371/journal.pone.0120741.
    • Contribution of shared environmental factors to familial aggregation of common cancers: an adoption study in Sweden.
    • Sundquist K, Sundquist J, Ji J.
    • Eur J Cancer Prev. 2015 Mar;24(2):162-4. doi: 10.1097/CEJ.0000000000000101.
    • Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.
    • Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, Petersen GM, Lerner-Ellis J, Holter S, Gallinger S.
    • Gastroenterology. 2015 Mar;148(3):556-64. doi: 10.1053/j.gastro.2014.11.042. Epub 2014 Dec 2.

    Comment:

    Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing.

    Introductory Journal Article

    Covering the Cover

    CME Activities: Exam 2: Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer (Gastroenterology)

    • Cognitive and affective influences on perceived risk of ovarian cancer.
    • Peipins LA, McCarty F, Hawkins NA, Rodriguez JL, Scholl LE, Leadbetter S.
    • Psychooncology. 2015 Mar;24(3):279-86. doi: 10.1002/pon.3593. Epub 2014 Jun 11.
    • Sister chromatid exchange: A possible approach to characterize familial breast cancer patients.
    • De Pascalis I, Pilato B, Mazzotta A, Dell'Endice TS, Rubini V, Simone G, Paradiso A, Aiello V, Mangia A.
    • Oncol Rep. 2015 Feb;33(2):930-4. doi: 10.3892/or.2014.3628. Epub 2014 Nov 26.
    • Survival outcome in endometrial cancer patients according to hereditary predisposition.
    • Yoo HJ, Lim MC, Son Y, Seo SS, Kang S, Kim SH, Yoo CW, Park SY.
    • Taiwan J Obstet Gynecol. 2015 Feb;54(1):24-8. doi: 10.1016/j.tjog.2014.11.003.
    • Beliefs about weight and breast cancer: an interview study with high risk women following a 12 month weight loss intervention.
    • Wright CE, Harvie M, Howell A, Evans DG, Hulbert-Williams N, Donnelly LS.
    • Hered Cancer Clin Pract. 2015 Jan 9;13(1):1. doi: 10.1186/s13053-014-0023-9. eCollection 2015.
    • A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
    • Vachon CM, Schaid DJ, Ingle JN, Wickerham DL, Kubo M, Mushiroda T, Goetz MP, Carlson EE, Paik S, Wolmark N, Nakamura Y, Wang L, Weinshilboum R, Couch FJ.
    • Breast Cancer Res Treat. 2015 Jan;149(2):517-23. doi: 10.1007/s10549-014-3175-4. Epub 2015 Jan 10.
    • Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.
    • Ellberg C, Jernström H, Broberg P, Borg Å, Olsson H.
    • Genes Chromosomes Cancer. 2015 Jan;54(1):39-50. doi: 10.1002/gcc.22217. Epub 2014 Sep 23.
    • Higher than expected frequencies of non-ovarian cancers within a large familial ovarian cancer registry.
    • Brightwell RM, Grzankowski KS, Kaur J, Poblete S, Miller A, Lele SB, Sucheston-Campbell L, Moysich K, Odunsi KO.
    • Am J Clin Exp Obstet Gynecol. 2015;2(1):39-44. Epub 2015 Feb 15.
    • Serous tubal intraepithelial carcinoma: an incidental finding at the time of prophylactic bilateral salpingo-oophorectomy.
    • Vaughan MH, Modesitt SC, Mo Y, Trowbridge ER.
    • Case Rep Obstet Gynecol. 2015;2015:760429. doi: 10.1155/2015/760429. Epub 2015 Feb 23.
    • Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women.
    • Anderson K, Thompson PA, Wertheim BC, Martin L, Komenaka IK, Bondy M, Daneri-Navarro A, Meza-Montenegro MM, Gutierrez-Millan LE, Brewster A, Madlensky L, Tobias M, Natarajan L, Martínez ME.
    • Springerplus. 2014 Dec 11;3:727. doi: 10.1186/2193-1801-3-727. eCollection 2014.
    • Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
    • Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, Ready KJ, Arun B.
    • Breast. 2014 Dec;23(6):770-4. doi: 10.1016/j.breast.2014.08.010. Epub 2014 Sep 16.
    • Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
    • Zugazagoitia J, Pérez-Segura P, Manzano A, Blanco I, Vega A, Custodio A, Teulé A, Fachal L, Martínez B, González-Sarmiento R, Cruz-Hernández JJ, Chirivella I, Garcés V, Garre P, Romero A, Caldés T, Díaz-Rubio E, de la Hoya M.
    • Breast Cancer Res Treat. 2014 Nov;148(2):415-21. doi: 10.1007/s10549-014-3167-4. Epub 2014 Oct 24.
    • Pedigree studies and evaluation of risk factors of breast cancer in Goa.
    • Fernandes NV, Pinto S, Dias P, Kolwalkar D, Chipkar T.
    • Indian J Cancer. 2014 Oct-Dec;51(4):600-3. doi: 10.4103/0019-509X.175300.
    • Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer.
    • Lindström LS, Li J, Lee M, Einbeigi Z, Hartman M, Hall P, Czene K.
    • Ann Oncol. 2014 Oct;25(10):1966-72. doi: 10.1093/annonc/mdu270. Epub 2014 Jul 23.
    • Completeness of pedigree and family cancer history for ovarian cancer patients.
    • Son Y, Lim MC, Seo SS, Kang S, Park SY.
    • J Gynecol Oncol. 2014 Oct;25(4):342-8. doi: 10.3802/jgo.2014.25.4.342. Epub 2014 Aug 5.
    • Risk of breast cancer and family history of other cancers in first-degree relatives in Chinese women: a case control study.
    • Zhou W, Ding Q, Pan H, Wu N, Liang M, Huang Y, Chen L, Zha X, Liu X, Wang S.
    • BMC Cancer. 2014 Sep 11;14:662. doi: 10.1186/1471-2407-14-662.
    • Familial transmission of prostate, breast and colorectal cancer in adoptees is related to cancer in biological but not in adoptive parents: A nationwide family study.
    • Zöller B, Li X, Sundquist J, Sundquist K.
    • Eur J Cancer. 2014 Sep;50(13):2319-27. doi: 10.1016/j.ejca.2014.05.018. Epub 2014 Jun 18.

    Press: Family history is 'a bigger risk factor than lifestyle' for some cancers. (Medical News Today)

    Press: Genetics is the dominant risk factor for familial breast, prostate, and colorectal cancers. (Oncology Nurse Advisor)

    • Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status.
    • Rosato V, Bosetti C, Negri E, Talamini R, Dal Maso L, Malvezzi M, Falcini F, Montella M, La Vecchia C.
    • Eur J Cancer Prev. 2014 Sep;23(5):412-7. doi: 10.1097/CEJ.0b013e3283639f7a.
    • Does perceived risk predict breast cancer screening use? Findings from a prospective cohort study of female relatives from the Ontario site of the breast cancer family registry.
    • Walker MJ, Mirea L, Glendon G, Ritvo P, Andrulis IL, Knight JA, Chiarelli AM.
    • Breast. 2014 Aug;23(4):482-8. doi: 10.1016/j.breast.2014.04.001. Epub 2014 May 10.
    • Family history of cancer associated with breast tumor clinicopathological features.
    • Ricks LJ, Ewing A, Thompson N, Harrison B, Wilson B, Richardson F, Carter-Nolan P, Spencer C, Laiyemo A, Williams C.
    • J Community Genet. 2014 Jul;5(3):233-40. doi: 10.1007/s12687-013-0180-y. Epub 2014 Jan 15.
    • Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer.
    • Meiser B, Price MA, Butow PN, Rahman B, Tucker K, Cheah B, Bickerstaffe A, Hopper J, Phillips KA.
    • Fam Cancer. 2014 Jun;13(2):153-62. doi: 10.1007/s10689-013-9687-y.
    • Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry.
    • Walker MJ, Mirea L, Cooper K, Nabavi M, Glendon G, Andrulis IL, Knight JA, O'Malley FP, Chiarelli AM.
    • Fam Cancer. 2014 Jun;13(2):163-72. doi: 10.1007/s10689-013-9689-9.
    • Expanding the genetic basis of copy number variation in familial breast cancer.
    • Masson AL, Talseth-Palmer BA, Evans TJ, Grice DM, Hannan GN, Scott RJ.
    • Hered Cancer Clin Pract. 2014 May 24;12(1):15. doi: 10.1186/1897-4287-12-15. eCollection 2014.
    • Testing for Familial BRCA1-2 Mutations: Implications for Genetic Counseling and Risk Assessment.
    • Travis T. Sims, Taya J. Fallen, Jeffrey S. Dungan, Lee P. Shulman.
    • Obstetrics & Gynecology. 123(Suppl 1):185S-186S, May 2014. doi: 10.1097/01.AOG.0000447208.37582.d4.
    • Conference abstract
    • Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study.
    • Daniels MS, Babb SA, King RH, Urbauer DL, Batte BA, Brandt AC, Amos CI, Buchanan AH, Mutch DG, Lu KH.
    • J Clin Oncol. 2014 Apr 20;32(12):1249-55. doi: 10.1200/JCO.2013.50.6055. Epub 2014 Mar 17.

    Comment/Letter:

    Misreported family histories and underestimation of risk.

    Comment/Letter:

    Reply to D. Braun et al.

    • Comparison of breast cancers diagnosed in screening patients in their 40s with and without family history of breast cancer in a community outpatient facility.
    • Destounis SV, Arieno AL, Morgan RC, Cavanaugh D, Seifert PJ, Murphy PF, Somerville PA.
    • AJR Am J Roentgenol. 2014 Apr;202(4):928-32. doi: 10.2214/AJR.13.11194.
    • The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation.
    • Møller P, Stormorken A, Holmen MM, Hagen AI, Vabø A, Mæhle L.
    • Breast Cancer Res Treat. 2014 Apr;144(3):607-14. doi: 10.1007/s10549-014-2902-1. Epub 2014 Mar 12.
    • Male Breast Cancer and Hyperestrogenemia: A Thirteen-Year Review.
    • Tariq KB, Al-Saffar F, Ibrahim S, Pham D, Farhangi A, Rana F, Zaiden R.
    • World J Oncol. 2014 Apr;5(2):55-61. doi: 10.14740/wjon803w. Epub 2014 May 6.
    • Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'.
    • Kotsopoulos J, Metcalfe K, Alston J, Nikitina D, Ginsburg O, Eisen A, Demsky R, Akbari M, Zbuk K, Narod SA.
    • BMC Cancer. 2014 Mar 25;14:221. doi: 10.1186/1471-2407-14-221.
    • Asymmetry in family history implicates nonstandard genetic mechanisms: application to the genetics of breast cancer.
    • Weinberg CR, Shi M, Deroo LA, Taylor JA, Sandler DP, Umbach DM.
    • PLoS Genet. 2014 Mar 20;10(3):e1004174. doi: 10.1371/journal.pgen.1004174. eCollection 2014.
    • Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer.
    • Schwab FD, Bürki N, Huang DJ, Heinzelmann-Schwarz V, Schmid SM, Vetter M, Schötzau A, Güth U.
    • Fam Cancer. 2014 Mar;13(1):99-107. doi: 10.1007/s10689-013-9682-3.
    • Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study.
    • Kharazmi E, Chen T, Narod S, Sundquist K, Hemminki K.
    • Breast Cancer Res Treat. 2014 Feb;144(1):185-92. doi: 10.1007/s10549-014-2848-3. Epub 2014 Feb 1.
    • Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.
    • Yiannakopoulou E.
    • Cell Oncol (Dordr). 2014 Feb;37(1):1-8. doi: 10.1007/s13402-013-0158-0. Epub 2013 Dec 4.
    • Differences in DNA methylation by extent of breast cancer family history in unaffected women.
    • Delgado-Cruzata L, Wu HC, Liao Y, Santella RM, Terry MB.
    • Epigenetics. 2014 Feb;9(2):243-8. doi: 10.4161/epi.26880. Epub 2013 Oct 29.
    • Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants.
    • Jervis S, Song H, Lee A, Dicks E, Tyrer J, Harrington P, Easton DF, Jacobs IJ, Pharoah PP, Antoniou AC.
    • J Med Genet. 2014 Feb;51(2):108-13. doi: 10.1136/jmedgenet-2013-102015. Epub 2013 Nov 25.
    • Risk of nonsyndromic cleft lip and palate in relatives of women with breast cancer.
    • Martelli DR, Vieira AR, Fonseca AT, Coletta RD, Soares PB, Martelli-Júnior H.
    • Am J Med Genet A. 2014 Jan;164(1):270-1. doi: 10.1002/ajmg.a.36186. Epub 2013 Nov 20.
    • Family history attributes and risk factors for breast cancer in Turkey.
    • Gokdemir-Yazar O, Yaprak S, Colak M, Yildirim E, Guldal D.
    • Asian Pac J Cancer Prev. 2014;15(6):2841-6.
    • Risk of malignancy associated with a maternal family history of cancer.
    • Liu J, Shu T, Chang S, Sun P, Zhu H, Li H.
    • Asian Pac J Cancer Prev. 2014;15(5):2039-44.
    • Factors associated with breast cancer in Puerto Rican women.
    • Morales L, Alvarez-Garriga C, Matta J, Ortiz C, Vergne Y, Vargas W, Acosta H, Ramírez J, Perez-Mayoral J, Bayona M.
    • J Epidemiol Glob Health. 2013 Dec;3(4):205-15. doi: 10.1016/j.jegh.2013.08.003. Epub 2013 Oct 12.
    • Do breast cancer risk factors differ among those who do and do not undertake mammography screening?
    • Beckmann KR, Roder DM, Hiller JE, Farshid G, Lynch JW.
    • J Med Screen. 2013 Dec;20(4):208-19. doi: 10.1177/0969141313510293. Epub 2013 Oct 23.
    • Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules.
    • Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H.
    • BMC Clin Pathol. 2013 Nov 4;13(1):28. doi: 10.1186/1472-6890-13-28.
    • Breast and Ovarian Cancer Family History and Genetic Counseling among Michigan Women.
    • Fussman C, Mange S.
    • Michigan BRFSS Surveillance Brief. Vol. 7, No. 5. Lansing, MI: Michigan Department of Community Health, Lifecourse Epidemiology and Genomics Division, Surveillance and Program Evaluation Section, Chronic Disease Epidemiology Unit. 2013 Nov.
    • Association between documented family history of cancer and screening for breast and colorectal cancer.
    • Carney PA, O'Malley JP, Gough A, Buckley DI, Wallace J, Fagnan LJ, Morris C, Mori M, Heintzman JD, Lieberman D.
    • Prev Med. 2013 Nov;57(5):679-84. doi: 10.1016/j.ypmed.2013.08.031. Epub 2013 Sep 9.
    • Retrospective analysis of clinicopathological characteristics and family history data of early-onset breast cancer: a single-institutional study of Hungarian patients.
    • Madaras L, Baranyák Z, Kulka J, Szász AM, Kovács A, Lan PH, Székely B, Dank M, Nagy T, Kiss O, Harsányi L, Barbai T, Kenessey I, Tőkés AM.
    • Pathol Oncol Res. 2013 Oct;19(4):723-9. doi: 10.1007/s12253-013-9635-z. Epub 2013 May 26.
    • Validation, calibration and refitting of a familial breast cancer model in sisterships: a case study in the Swedish sisters data.
    • van Houwelingen HC, Rebora P, Reilly M.
    • Stat Med. 2013 Sep 10;32(20):3486-500. doi: 10.1002/sim.5781. Epub 2013 Mar 18.
    • Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study.
    • Hou N, Ogundiran T, Ojengbede O, Morhason-Bello I, Zheng Y, Fackenthal J, Adebamowo C, Anetor I, Akinleye S, Olopade OI, Huo D.
    • Ann Epidemiol. 2013 Sep;23(9):551-7. doi: 10.1016/j.annepidem.2013.06.008. Epub 2013 Jul 20.
    • Can Unknown Predisposition in Familial Breast Cancer be Family-Specific?
    • Lynch H, Wen H, Kim YC, Snyder C, Kinarsky Y, Chen PX, Xiao F, Goldgar D, Cowan KH, Wang SM.
    • Breast J. 2013 Sep;19(5):520-8. doi: 10.1111/tbj.12145. Epub 2013 Jun 26.
    • Cytogenetic finding of breast cancer cases and in their first-degree relatives.
    • Celik DA, Koşar PA, Ozçelik N, Eroğlu E.
    • J Breast Cancer. 2013 Sep;16(3):285-90. doi: 10.4048/jbc.2013.16.3.285. Epub 2013 Sep 30.
    • Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial.
    • Wu RR, Orlando LA, Himmel TL, Buchanan AH, Powell KP, Hauser ER, Agbaje AB, Henrich VC, Ginsburg GS.
    • BMC Fam Pract. 2013 Aug 6;14:111. doi: 10.1186/1471-2296-14-111.
    • Accuracy of Self-Reported Screening Mammography Use: Examining Recall among Female Relatives from the Ontario Site of the Breast Cancer Family Registry.
    • Walker MJ, Chiarelli AM, Mirea L, Glendon G, Ritvo P, Andrulis IL, Knight JA.
    • ISRN Oncol. 2013 Aug 1;2013:810573. doi: 10.1155/2013/810573. eCollection 2013.
    • Comparison of the Screening Practices of Unaffected Noncarriers under 40 and between 40 and 49 in BRCA1/2 Families.
    • Duprez C, Christophe V, Milhabet I, Krzeminski A, Adenis C, Berthet P, Peyrat JP, Vennin P.
    • J Genet Couns. 2013 Aug;22(4):469-81. doi: 10.1007/s10897-012-9569-8. Epub 2013 Jan 25.
    • Improving the management of people with a family history of breast cancer in primary care: before and after study of audit-based education.
    • Rafi I, Chowdhury S, Chan T, Jubber I, Tahir M, de Lusignan S.
    • BMC Fam Pract. 2013 Jul 24;14:105. doi: 10.1186/1471-2296-14-105.
    • Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    • Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.
    • Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.
    • Relationship between family history of breast cancer and clinicopathological features in moroccan patients.
    • Tazzite A, Jouhadi H, Saiss K, Benider A, Nadifi S.
    • Ethiop J Health Sci. 2013 Jul;23(2):150-7.
    • A focus group study on breast cancer risk presentation: one format does not fit all.
    • Dorval M, Bouchard K, Chiquette J, Glendon G, Maugard CM, Dubuisson W, Panchal S, Simard J.
    • Eur J Hum Genet. 2013 Jul;21(7):719-24. doi: 10.1038/ejhg.2012.248. Epub 2012 Nov 21.
    • Simplifying clinical use of the genetic risk prediction model BRCAPRO.
    • Biswas S, Atienza P, Chipman J, Hughes K, Barrera AM, Amos CI, Arun B, Parmigiani G.
    • Breast Cancer Res Treat. 2013 Jun;139(2):571-9. doi: 10.1007/s10549-013-2564-4. Epub 2013 May 21.
    • Development and evaluation of a brief self-completed family history screening tool for common chronic disease prevention in primary care.
    • Walter FM, Prevost AT, Birt L, Grehan N, Restarick K, Morris HC, Sutton S, Rose P, Downing S, Emery JD.
    • Br J Gen Pract. 2013 Jun;63(611):e393-400. doi: 10.3399/bjgp13X668186.

    Comment:

    [Are questions better than the glucose tolerance test?].

    Comment/Letter:

    Misreported family histories and underestimation of risk.

    • Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.
    • Ingham SL, Warwick J, Buchan I, Sahin S, O'Hara C, Moran A, Howell A, Evans DG.
    • J Med Genet. 2013 Jun;50(6):368-72. doi: 10.1136/jmedgenet-2013-101607. Epub 2013 Mar 28.

    Research News:

    BRCA1/2 negative status predicts no extended risk of invasive ovarian cancer.

    • Mammographic density and breast cancer: a comparison of related and unrelated controls in the Breast Cancer Family Registry.
    • Linton L, Martin LJ, Li Q, Huszti E, Minkin S, John EM, Rommens J, Paterson AD, Boyd NF.
    • Breast Cancer Res. 2013 May 25;15(3):R43. doi: 10.1186/bcr3430.
    • Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    • Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O.
    • Am J Obstet Gynecol. 2013 Apr;208(4):329.e1-6. doi: 10.1016/j.ajog.2013.01.026. Epub 2013 Jan 17.
    • Prevalence and Healthcare Actions of Women in a Large Health System with a Family History Meeting the 2005 USPSTF Recommendation for BRCA Genetic Counseling Referral.
    • Bellcross CA, Leadbetter S, Alford SH, Peipins LA.
    • Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):728-35. doi: 10.1158/1055-9965.EPI-12-1280. Epub 2013 Jan 31.
    • Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
    • Duffy S, Mackay J, Thomas S, Anderson E, Chen T, Ellis I, Evans G, Fielder H, Fox R, Gui G, Macmillan D, Moss S, Rogers C, Sibbering M, Wallis M, Warren R, Watson E, Whynes D, Allgood P, Caunt J.
    • Health Technol Assess. 2013 Mar;17(11):1-95. doi: 10.3310/hta17110.
    • Breast cancer knowledge and screening behaviour among women with a positive family history: a cross sectional study.
    • Subramanian P, Oranye NO, Masri AM, Taib NA, Ahmad N.
    • Asian Pac J Cancer Prev. 2013;14(11):6783-90.
    • Evaluation of breast self-examination (BSE) application in first and second degree relatives of patients with breast cancer.
    • Bebis H, Altunkurek SZ, Acikel C, Akar I, Altunkurek SZ.
    • Asian Pac J Cancer Prev. 2013;14(8):4925-30.
    • Low level of consanguinity in moroccan families at high risk of breast cancer.
    • Elalaoui SC, Jaouad IC, Laarabi FZ, Elgueddari Bel K.
    • Asian Pac J Cancer Prev. 2013;14(2):723-6.
    • A multicenter matched case control study of breast cancer risk factors among women in Karachi, Pakistan.
    • Shamsi U, Khan S, Usman S, Soomro S, Azam I.
    • Asian Pac J Cancer Prev. 2013;14(1):183-8.
    • Family history of cancer and its association with breast cancer risk perception and repeat mammography.
    • Haber G, Ahmed NU, Pekovic V.
    • Am J Public Health. 2012 Dec;102(12):2322-9. doi: 10.2105/AJPH.2012.300786. Epub 2012 Oct 18.
    • The heritability of mammographic breast density and circulating sex-hormone levels: two independent breast cancer risk factors.
    • Varghese JS, Smith PL, Folkerd E, Brown J, Leyland J, Audley T, Warren RM, Dowsett M, Easton DF, Thompson DJ.
    • Cancer Epidemiol Biomarkers Prev. 2012 Dec;21(12):2167-75. doi: 10.1158/1055-9965.EPI-12-0789. Epub 2012 Oct 16.
    • Low penetrance alleles as risk modifiers in familial and sporadic breast cancer.
    • Esteban Cardeñosa E, de Juan Jiménez I, Palanca Suela S, Chirivella González I, Segura Huerta A, Santaballa Beltran A, Casals El Busto M, Barragán González E, Fuster Lluch O, Bermúdez Edo J, Bolufer Gilabert P.
    • Fam Cancer. 2012 Dec;11(4):629-36. doi: 10.1007/s10689-012-9563-1.
    • Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.
    • Saadatmand S, Rutgers EJ, Tollenaar RA, Zonderland HM, Ausems MG, Keymeulen KB, Schlooz-Vries MS, Koppert LB, Heijnsdijk EA, Seynaeve C, Verhoef C, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MM.
    • BMC Cancer. 2012 Oct 2;12:440. doi: 10.1186/1471-2407-12-440.
    • Family Health History: Use It to Inform Preventive Services for Your Patients.
    • Katherine Kolor.
    • Medscape Oncology. CDC Expert Commentary. 2012 Sep 9.
    • Family history and breast cancer.
    • Carroll JC, Heisey R, Warner E.
    • CMAJ. 2012 Sep 4;184(12):1391. doi: 10.1503/cmaj.111670. Epub 2012 Jan 30.
    • Adequacy of family history taking in ovarian cancer patients: a population-based study.
    • van Altena AM, van Aarle S, Kiemeney LA, Hoogerbrugge N, Massuger LF, de Hullu JA.
    • Fam Cancer. 2012 Sep;11(3):343-9. doi: 10.1007/s10689-012-9518-6.
    • Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.
    • Brozek I, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Rachtan J, Steffen J, Limon J.
    • Fam Cancer. 2012 Sep;11(3):351-4. doi: 10.1007/s10689-012-9519-5.
    • Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
    • Dite GS, Makalic E, Schmidt DF, Giles GG, Hopper JL, Southey MC.
    • Breast Cancer Res. 2012 Aug 28;14(4):R122. doi: 10.1186/bcr3248.
    • Grace Rock's consent.
    • Ross TS.
    • Endocr Relat Cancer. 2012 Jul 22;19(4):C29-31. doi: 10.1530/ERC-12-0186. Print 2012 Aug.
    • Inference about causation from examination of familial confounding: application to longitudinal twin data on mammographic density measures that predict breast cancer risk.
    • Stone J, Dite GS, Giles GG, Cawson J, English DR, Hopper JL.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1149-55. doi: 10.1158/1055-9965.EPI-12-0051. Epub 2012 Apr 26.
    • Young women with family history of breast cancer and their risk factors for benign breast disease.
    • Berkey CS, Tamimi RM, Rosner B, Frazier AL, Colditz GA.
    • Cancer. 2012 Jun 1;118(11):2796-803. doi: 10.1002/cncr.26519. Epub 2011 Nov 14.

    Press: Family History, Alcohol Affect Risk for Benign Breast Disease (Medscape)

    • Family history and risk of breast cancer: nurses' health study.
    • Colditz GA, Kaphingst KA, Hankinson SE, Rosner B.
    • Breast Cancer Res Treat. 2012 Jun;133(3):1097-104. doi: 10.1007/s10549-012-1985-9. Epub 2012 Feb 19.
    • Implementation and outcomes of a multidisciplinary high-risk breast cancer program: the William Beaumont Hospital experience.
    • Shah C, Berry S, Dekhne N, Lanni T, Lowry H, Vicini F.
    • Clin Breast Cancer. 2012 Jun;12(3):215-8. doi: 10.1016/j.clbc.2012.03.002. Epub 2012 Apr 14.
    • Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis.
    • Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, Miglioretti DL.
    • Ann Intern Med. 2012 May 1;156(9):635-48. doi: 10.7326/0003-4819-156-9-201205010-00006.

    Comment, Editorial:

    Risk-based mammography screening: an effort to maximize the benefits and minimize the harms.

    News:

    Studies support risk-based mammography screening.

    • The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility.
    • Keimling M, Deniz M, Varga D, Stahl A, Schrezenmeier H, Kreienberg R, Hoffmann I, König J, Wiesmüller L.
    • FASEB J. 2012 May;26(5):2094-104. doi: 10.1096/fj.11-200790. Epub 2012 Jan 25.
    • Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases.
    • Martinez-Delgado B, Yanowsky K, Inglada-Perez L, de la Hoya M, Caldes T, Vega A, Blanco A, Martin T, Gonzalez-Sarmiento R, Blasco M, Robledo M, Urioste M, Song H, Pharoah P, Benitez J.
    • J Med Genet. 2012 May;49(5):341-4. Epub 2012 Apr 6.

    Free Full Text: Shorter Telomere Length Is Associated With Increased Ovarian Cancer Risk in Both Familial and Sporadic Cases. (Medscape Oncology)

    • Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    • Alford SH, Toy K, Merajver SD, Kleer CG.
    • Breast Cancer Res Treat. 2012 Apr;132(2):429-37. doi: 10.1007/s10549-011-1591-2. Epub 2011 May 26.
    • Risk of breast cancer in families of multiple affected women and men.
    • Bevier M, Sundquist K, Hemminki K.
    • Breast Cancer Res Treat. 2012 Apr;132(2):723-8. doi: 10.1007/s10549-011-1915-2. Epub 2011 Dec 17.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Relative risks for male breast cancer

    • Disparities in cancer screening in individuals with a family history of breast or colorectal cancer.
    • Ponce NA, Tsui J, Knight SJ, Afable-Munsuz A, Ladabaum U, Hiatt RA, Haas JS.
    • Cancer. 2012 Mar 15;118(6):1656-63. doi: 10.1002/cncr.26480. Epub 2011 Aug 25.

    Press: Cancer Screening Lags in Latinos With Family History. (Medscape/Reuters)

    • Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London.
    • Kohut K, D'Mello L, Bancroft EK, Thomas S, Young MA, Myhill K, Shanley S, Briggs BH, Newman M, Saraf IM, Cox P, Scambler S, Wagman L, Wyndham MT, Eeles RA, Ferris M.
    • Fam Cancer. 2012 Mar;11(1):107-13. doi: 10.1007/s10689-011-9482-6.
    • Breast cancer risk factors in Queensland women attending population-based mammography screening.
    • Protani M, Page A, Taylor R, Glazebrook R, Lahmann PH, Branch E, Muller J.
    • Maturitas. 2012 Mar;71(3):279-86. doi: 10.1016/j.maturitas.2011.12.008. Epub 2012 Jan 4.
    • Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis.
    • Cardinale F, Bruzzi P, Bolognesi C.
    • Br J Cancer. 2012 Feb 14;106(4):780-90. doi: 10.1038/bjc.2011.567. Epub 2011 Dec 20.
    • Germline DNA copy number variation in familial and early-onset breast cancer.
    • Krepischi AC, Achatz MI, Santos EM, Costa SS, Lisboa BC, Brentani H, Santos TM, Gonçalves A, Nóbrega AF, Pearson PL, Vianna-Morgante AM, Carraro DM, Brentani RR, Rosenberg C.
    • Breast Cancer Res. 2012 Feb 7;14(1):R24.
    • Family History and Women With Ovarian Cancer: Is it Asked and Does it Matter?: An Observational Study.
    • Lanceley A, Eagle Z, Ogden G, Gessler S, Razvi K, Ledermann JA, Side L.
    • Int J Gynecol Cancer. 2012 Feb;22(2):254-9. doi: 10.1097/IGC.0b013e3182392714.
    • Are genetic and environmental components of variance in mammographic density measures that predict breast cancer risk independent of within-twin pair differences in body mass index?
    • Dite GS, Stone J, Chiarelli AM, Giles GG, English DR, Cawson JC, Hopper JL.
    • Breast Cancer Res Treat. 2012 Jan;131(2):553-9. doi: 10.1007/s10549-011-1739-0. Epub 2011 Aug 27.
    • Familial breast cancer registry program in patients referred to the cancer institute of iran.
    • Sabokbar T, Khajeh E, Taghdiri F, Peyghambari V, Shirkoohi R.
    • Asian Pac J Cancer Prev. 2012;13(6):2675-9.
    • Risk factors for premenopausal breast cancer: a case-control study in Uruguay.
    • Ronco AL, De Stefani E, Deneo-Pellegrini H.
    • Asian Pac J Cancer Prev. 2012;13(6):2879-86.
    • Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
    • Cazzaniga M, Varricchio C, Montefrancesco C, Feroce I, Guerrieri-Gonzaga A.
    • J Biomed Biotechnol. 2012;2012:172897. doi: 10.1155/2012/172897. Epub 2012 Mar 5.